The Regulatory Role Of Matrix Metalloproteinases In T Cell Activation by Benson, Heather Lynette
  
 
 
THE REGULATORY ROLE OF MATRIX 
METALLOPROTEINASES IN T CELL ACTIVATION 
 
 
Heather Lynette Benson 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School  
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Biochemistry and Molecular Biology 
Indiana University  
 
October 2009 
 
 ii 
Accepted by the Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
 
 
_____________________________________ 
David S. Wilkes, M.D., Chair 
 
 
 
 
 
 
_____________________________________ 
Janice S. Blum, Ph.D. 
 
 
Doctoral Committee 
 
 
 
_____________________________________ 
Mark G. Goebl, Ph.D. 
 
July 28, 2009 
 
 
 
_____________________________________ 
Maureen A. Harrington, Ph.D. 
 
 
 
 
 
_____________________________________ 
Gerald N. Smith, Ph.D. 
 
iii 
 
DEDICATION 
 
This thesis is dedicated to my husband, Eric “Bunny-bear” Benson, for his love, 
support and encouragement during the pursuit of my Ph.D. and continually throughout 
our marriage. I’m an orange moon and I shine so bright cause I reflect the light of my 
sun.; and to my wonderful parents, Robin and Stan Rayford, for giving me life, always 
believing in me and imparting strength and wisdom from which I draw from daily. Thank 
you for getting me off to a great start so that I can fly beautifully, just like Jemima 
Puddle-Duck. 
 
 iv 
ACKNOWLEDGEMENTS 
 
 I would like to thank “my P.I.” and mentor, Dr. David Wilkes, for his unique 
ability to always bring out the best in me. Dr. Wilkes, thank you for pushing me to think 
critically and outside the box, for believing in my abilities, for entertaining my ideas and 
giving me freedom to explore, for writing grants to fund my projects, for the knowledge 
that you have imparted and for really investing in me. Thank you for teaching me how to 
be a scientist.  
I would also like to thank the other members of my “All-star Dream Team” 
research committee: Dr. Janice Blum, Dr. Mark Goebl, Dr. Maureen Harrington and Dr. 
Gerald Smith. Thank you all for your time, energy, patience, advice, guidance and 
support. I would not have been able to complete this dissertation project without you. 
Additionally, I would like to thank Dr. Matthias Clauss and Dr. Alexander Obukhov for 
lending their advice and expertise in calcium signaling to support the progress of my 
project.  
To the Wilkes lab, thanks for helping out when needed and for always making 
sure we have fun no matter how hard we’re working. Jeremy “J-Lott” Lott, thanks for 
being a great friend, lab-mate and  lunch-buddy; it’s been fun. Elizabeth “Liz” Mickler, 
thanks for being a great friend, for always being willing to go everywhere, whether it’s to 
the gym, riding bikes or just out for a good time. Dr. Ann Kimble-Hill, thanks for being 
my BFF and for always being willing to talk science. To all of my other school/science 
friends, you know who you are; thanks for always being willing to sit through my 
v 
 
practice talks, for talking through experiments and other great science with me and for 
always being supportive. 
I thank Dr. Bruce Uhal and Dr. William Martin for sparking my interest in lung 
research as an undergraduate, allowing me to explore different areas of lung research and 
for serving as excellent mentors. I am grateful to my life-long mentor Sis. Marion Jeffers, 
for always being there for me, helping me develop into a great student and for believing 
in me.  
Mom and Dad, thank you for giving me all of the tools I need to be a successful 
contributor to society. You’ve taught me to be steadfast, unmovable, always abounding in 
the work of the Lord. I love you very much!   To my husband, “Two are better than one, 
because they have a good reward for their labor. Two working together to fulfill their 
divine destiny in the Lord can be a powerful team” Ecclesiastes 4:9. Thank you for being 
my teammate, I look forward to fulfilling our divine destiny together. Throughout this 
process, I have come into a deeper understanding that I can do all things through Christ 
who strengthens me. Thank you God for your divine favor and for all that you’ve allowed 
me to accomplish in my life. 
 vi 
ABSTRACT 
Heather Lynette Benson 
 
THE REGULATORY ROLE OF MATRIX METALLOPROTENASES IN T CELL 
ACTIVATION 
Introduction: Matrix metalloproteinases (MMPs) are known for their role in 
extracellular matrix remodeling, but their role in regulating intracellular immune cell 
function is unknown. We reported that MMP inhibition down regulated T cell 
proliferation in response to alloantigens and autoantigens; but the direct role of MMP 
involvement in T cell activation has not been reported.  
Methods: MMP deficient or MMP sufficient wild-type CD4+ or CD8+ T cells from 
C57BL/6 mice were treated with SB-3CT, a specific inhibitor of MMP2 and MMP9, 
stimulated with anti-CD3 Ab, alone, or with IL-2 or CD28. Cellular activation and 
cytokine profiles were examined. A mouse model of antigen specific T cell mediated 
lung injury was used to examine MMP inhibition in antigen-specific T cell mediated lung 
injury.  
Results: SB-3CT (1-25μM) induced dose-dependent reductions in anti-CD3 Ab-induced 
proliferation (p<0.0001). Compared to wild-type, MMP9-/- CD4+ and CD8+ T cells 
proliferated 80-85% less (p<0.001) in response to anti-CD3 Ab. Compared to untreated 
or wild-type cells, anti-CD3 Ab-induced calcium flux was enhanced in SB-3CT-treated 
or MMP9-/- CD4+ and CD8+ T cells. Cytokine transcripts for IL-2, TNF-α and IFN-γ 
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were reduced in both CD4+ and CD8+ MMP9-/- T cells, as well as in SB3CT treated 
CD4+ T cells. MMP inhibition dampened antigen-specific T cell mediated lung injury.  
Conclusions: Although known to be functional extracellularly, the current data suggest 
that MMPs function inside the cell to regulate intracellular signaling events involved in T 
cell activation. T cell targeted MMP inhibition may provide a novel approach of immune 
regulation in the treatment of T cell-mediated diseases. 
David S. Wilkes, M.D., Chair 
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I. INTRODUCTION 
 
A. The immune response 
 The immune response consists of a concerted action of both innate and adaptive 
immunity that serve to protect the body from infection, disease and foreign antigens. The 
innate immune system is comprised of a variety of cells and processes that serve in a non-
specific manner as the body’s first line of defense against invading pathogens. The innate 
system does not confer long-lasting or protective immunity, therefore the immune system 
is able to adapt accordingly and activate a second response known as adaptive immunity. 
It is through the adaptive immune response that the immune system gains the ability to 
recognize a specific pathogen, and to mount an even stronger attack each time the 
pathogen is encountered. The basis of adaptive immunity lies in its ability to distinguish 
between the body's own cells, and those that are foreign. In the adaptive immune system 
B cells and T cells (CD4+ and CD8+) are the major cell types present. B cells are involved 
in the humoral immune response, whereas T-cells are involved in cell-mediated immune 
responses. Cell-mediated immunity involves direct interactions between T cells and 
antigen presenting cells (APC) that can present antigens that the T cells recognize. 
CD8+ T cells, also known as cytotoxic T cells (CTLs), are activated when their T-cell 
receptor (TCR) strongly interacts with a peptide-bound MHC class I molecule. Since all 
nucleated cells express MHC class I, CTLs have the ability to respond to any virally 
infected cell. Once activated, the CTL undergoes clonal expansion, in which it gains 
functionality and rapidly divides to produce an army of “armed” effector cells. When 
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exposed to these infected cells, effector CTLs release perforin which form pores in the 
infected cell's plasma membrane and granzyme B, a serine protease,’ to cause cell lysis 
and death. 
 In contrast, CD4+ T cells, also known as helper T cells, are immune response 
mediators that play an important role in establishing and maximizing the capabilities of 
the adaptive immune response. CD4+ T cells express TCRs that recognize antigen bound 
class II MHC molecules on the cell surface antigen presenting cells (APCs). APCs, which 
include dendritic cells, tissue macrophages, and B cells, provide a key contact point for 
the generation of the appropriate adaptive immune response. Dendritic cells have potent 
antigen-processing capabilities, express abundant class II MHC molecules, and are 
present at sites that facilitate naïve T cell encounters. Recent studies have suggested that 
dendritic cells may be the primary, and perhaps exclusive, type of APC involved in 
presenting alloantigen peptides to naïve T cells (1). Once activated, the CD4+ T cells 
undergo clonal expansion to produce T helper cells, which release cytokines that 
influence the activity of many cell types in the local environment. 
 Three types of helper CD4+ T cell responses can be induced by APCs, designated 
Th1, Th2 and Th17 [figure 1] (2). The Th1 response is characterized by the production of 
interferon-gamma (IFN-γ) and interleukin 2 (IL-2). The Th2 response is characterized by 
the release of interleukin 4 (IL-4), IL-5, IL-6, IL-10 and IL-13. The recently identified 
Th17 response is characterized by the release of IL-17 (isoforms IL-17A and IL-17F), IL-
21 and IL-22. Generally, Th1 responses are more effective against intracellular pathogens 
(viruses and bacteria that are inside the host cells), while Th2 responses are more 
3 
effective against extracellular pathogens (bacteria, parasites and toxins). Th17 cells play a 
role in play a key role in autoimmunity and cell-mediated tissue injury (2). 
 
Figure 1. T cell subsets 
General diagram of T cells involved in the adaptive immune response. Naïve T cells can differentiate 
into T cell subsets in response to the cytokine signals received.      
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B. T cell activation 
 Ligation of the T-cell antigen receptor (TCR) initiates a complex signaling 
cascade that involves three signals: 1) Recognition of the alloantigen peptide:MHC 
complex by the TCR on the T cell surface; 2) Interaction of co-stimulatory molecules 
(CD28 on T cells interacting with its ligands, CD80 and CD86, expressed on APCs 
(DCs); 3) Cytokine/chemokine production, leading to clonal expansion and 
differentiation. Activation of essential downstream signaling pathways, including the 
phosphatidylinositol-4,5-bisphosphate (PIP2), Ras-mitogen-activated protein kinase 
(MAPK), and phosphatidylinositol-3-kinase (PI3K) pathways, is dependent upon the 
activity of protein tyrosine kinases (3, 4).  
 The T cell receptor exists as a complex of several proteins. Structurally, the T cell 
receptor is composed of two separate peptide chains, the alpha and beta (TCRα and 
TCRβ) chains [figure 2]. The other proteins in the complex are the CD3 proteins, which 
consist of the CD3εγ and CD3εδ heterodimers and a CD3ζ homodimer, which has a total 
of six ITAM motifs (5). The earliest step in intracellular signaling following TCR ligation 
is the activation of Src family (p56Lck (Lck) and p59Fyn (Fyn) protein tyrosine kinases 
(PTKs), leading to phosphorylation of the CD3ζ ITAMs. Recruitment of zeta-chain-
associated protein kinase 70 (ZAP-70) follows, leading to a cascade of phosphorylation 
events. To demonstrate the importance of Src PTKs, a study by Rapecki et al. reported 
that Src kinase inhibitors, which inhibit Lck and Fyn, attenuated anti-CD3 Ab-induced T 
cell proliferation and block interleukin (IL)-2, IL-4, and interferon-γ production, and IL-
2Rα (CD25) expression in anti-CD3 Ab-activated T cells (6).   
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 Among the most important of the ZAP-70 targets are the transmembrane 
adapterprotein linker for the activation of T cells (7) and the cytosolic adapter protein Src 
homology 2 (SH2) domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76) (7, 
8). These two adapters form the backbone of a complex that organizes effector molecules 
in the correct spatiotemporal manner to allow for the activation of multiple signaling 
pathways. The importance of these adapters is highlighted by studies showing that the 
loss of either LAT or SLP-76 results in a near complete loss of TCR signal transduction. 
Similar results were seen in Syk/ZAP-70 or Lck/Fyn double-deficient T cells (7, 9, 10).  
 LAT, which localizes to lipid rafts, contains nine tyrosines that are 
phosphorylated following TCR engagement, which bind the C-terminal SH2 domain of 
phospholipase C γ (PLCγ1), the p85 subunit of phosphoinositide 3-kinase (PI3K), and the 
adapters growth factor receptor-bound protein 2 (GRB2) and GRB2-related adapter 
downstream of Shc (Gads) (9). SLP-76 is then recruited to phosphorylated LAT via their 
mutual binding partner Gads (11). SLP-76 itself contains three modular domains: 1) an 
N-terminal acidic domain with three phosphorylatable tyrosines that interact with the 
SH2 domains of the adaptor proteins Vav1, Nck, and IL-2-induced tyrosine kinase (Itk); 
2) a proline-rich region that binds constitutively Gads and PLCγ1; and 3) a C-terminal 
SH2 region that can bind adhesion and degranulation-promoting adapter protein (ADAP) 
and hematopoietic progenitor kinase 1 (HPK1) (7). Activated PLCγ1 and PI3K then 
hydrolyze the membrane lipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) on the 
inner leaflet of the membrane producing the second messengers inositol-1,4,5 
triphosphate (IP3) and diacylglycerol (DAG). These two messengers are essential for T 
cell function.
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 DAG results in the activation of two major pathways involving Ras and protein 
kinase C (PKCθ). Ras is a GTPase, or a guanine-nucleotide-hydrolase required for the 
activation of the serine-threonine kinase Raf-1. Raf-1 initiates mitogen-associated protein 
kinase (MAPK) phosphorylation and an activation cascade. Raf-1 is a MAPK kinase 
kinase (MAPKKK) that phosphorylates and activates MAPK kinases (MEK1/2), which 
in turn phosphorylate and activate the MAPK's extracellular signal-regulated kinase 1 
(Erk1) and Erk2. Erk kinase activity results in the activation of the transcription factor 
Elk1, which contributes to the activation of the activator protein-1 (AP-1) (Jun/Fos) 
transcription complex (12). PKCθ, a member of the PKC family, contains a lipid-binding 
domain specific for DAG, which is important for recruiting PKCθ to the plasma 
membrane. PKCθ is involved in the activation of the transcription factor nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB).  
 In conjunction with DAG, IP3 is released from the membrane by PLCγ1 and 
diffuses rapidly to activate calcium permeable ion channel receptors (IP3Rs) on the 
endoplasmic reticulum (ER) membrane leading to the release of ER calcium (Ca2+) 
stores into the cytoplasm. Depletion of ER calcium triggers a sustained influx of 
exogenous calcium through the activation of plasma membrane calcium release-activated 
calcium (CRAC) channels in a process known as store-operated calcium entry (SOCE). 
This calcium influx activates the phosphatase, calcineurin (13). Activated calcineurin 
dephosphorylates members of the nuclear factor of activated T cells (NFAT) family, 
leading to their translocation to the nucleus. In the nucleus, NFAT isoforms (NFAT1-4) 
can form cooperative complexes with a variety of other transcription factors, thereby 
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integrating signaling pathways, resulting in differential gene expression patterns and 
functional outcomes, depending on the context of the TCR signal.  
 One of the most-well-studied interaction is, NFAT/AP-1, which integrates Ca2+ 
and Ras signals and results in the expression of genes important for T cell activation 
including the production of IL-2. In contrast, NFAT activity in the absence of AP-1 
activation induces a pattern of gene expression that ultimately results in T cell anergy and 
a characteristic lack of IL-2 production (14). The regulatory T cell lineage–specific 
transcription factor forkhead box protein 3 (FOXP3) also cooperates with NFAT and 
antagonizes NFAT/AP-1 gene transcription, resulting in regulatory T cell (Treg) 
functional gene expression and a lack of IL-2 production (15). Finally, NFAT family 
members can also cooperate with signal transducers and activator of transcription 
(STAT) proteins to induce either Th1 or Th2 differentiation through expression of T box 
expressed in T cells (T-bet) or GATA binding protein 3 (GATA3), respectively (13) or 
Th17 differentiation through RORγt (16, 17).   
 It is important to note that although T cell activation is often discussed and 
diagramed as a linear pathway starting at the receptor and ending in the nucleus, there 
appears to be complex feedback and feed-forward regulation at each step. Many of the 
proteins interact closely and function as docking sites and adaptor proteins which exert 
their actions in sync. Following TCR ligation, there are many events that occur within the 
cell that are necessary for proper T cell function.  
 
C. Matrix metalloproteinases                                                                                                 
 Matrix Metalloproteinases (MMPs) were first described by Jerome Gross and 
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Charles Lapiere in 1962, who observed enzymatic cleavage of collagen triple helix 
during tadpole tail metamorphosis. Since then the MMP family has grown to consist of 
over 25 secreted and cell surface zinc-dependent endopeptidases. The members within 
this family share structural similarities but differ in their substrate specificity and 
expression profiles. MMPs are responsible for the turnover of the extracellular matrix 
(ECM) and basement membranes (BMs). The ECM is a complex network composed of 
protein constituents including collagens and elastin, glycoproteins such as laminin, 
fibronectin, as well as various proteoglycans and glycosaminoglycans. Because they are 
tightly apposed and highly cross-linked triple helical fibrils, collagens I, II, and III are 
known to be extremely resistant to cleavage by most proteinases. Collagenases (MMP-1, 
-8, -13) cleave fibrillar collagens at unique sites in the triple helix near the N-terminal 
end, generating collagen fragments. Due to thermal degradation and loss of stability, 
these collagen fragments unfold their triple helix and fall apart into fragmented single α-
chains, the so-called gelatins (MMP2 and MMP9 substrates) (18). They all initially 
cleave at a specific Gly-Leu/Ile bond to generate characteristic 1/4 and 3/4 fragments that 
are then degraded further by the collagenase itself as well as by gelatinolytic enzymes, 
such as gelatinases A and B (MMP2 and MMP9, respectively), neutrophil elastase (NE) 
and plasmin. 
 The ECM is not only a mechanical support for cells, but also acts as a reservoir 
for cytokines and growth factors. The integrity of the ECM is controlled by a dynamic 
equilibrium between synthesis and local degradation of its different components. MMPs 
are the main physiological mediators of ECM degradation. MMPs have a broad range of 
substrate specificity and participate in a plethora of biological processes, such as cellular 
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proliferation, embryonic development, morphogenesis, bone remodeling, angiogenesis, 
wound healing and inflammation.  
 
D. Matrix metalloproteinase structure 
 MMPs are classified by their conserved protein domains: a pro-domain, and a 
catalytic domain, which contains a Zn2+ binding domain [figure 3]. All MMPs, with the 
exception of MMP-7 and -26, contain an additional carboxyterminal hemopexin domain. 
Due to differences in substrate specificity and structural characteristics, the MMPs are 
divided into several subclasses: collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), 
stromelysins (MMP-3, -10, -11), matrylysin (MMP-7), elastase (MMP-12), enamelysin 
(MMP-20) and membrane type-MMPs (MMP-14, -15, -16, -17) (19). In general, the pro-
domain is ~80 amino acids with a hydrophobic residue at the N-terminus, and contains a 
cysteine residue in the conserved sequence PRCXXPD. The cysteine within this 
conserved sequence is termed the “cysteine switch” due to its interaction with a Zn2+ ion 
in the catalytic site. The catalytic domain contains the active site, is ~160 residues and 
contains a Zn2+ binding motif of the conserved sequence HEXXHXXGXXH. The three 
conserved histidine residues within the catalytic site are responsible for the coordination 
of the catalytic Zn2+ ion. The catalytic domain also includes a conserved methionine, 
which forms a unique “met-turn” structure, structural binding sites for 2-3 Ca2+ ions, 
which are important for stability. The C-terminal hemopexin-like domain is ~ 200 
residues and is thought to modulate substrate specificity and the binding of Tissue 
Inhibitors of MMPs (TIMPs).  
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Figure 3. General structure and classification of matrix metalloproteinases  
Diagram showing the structural domains of matrix metalloproteinases. Adapted from (20). 
 12 
 Within the context of this dissertation, the gelatinases MMP-2 (Gelatinase A) and 
MMP-9 (Gelatinase B), are of particular interest because they have been clinically shown 
to be key enzymes in several pulmonary diseases including emphysema, pulmonary 
fibrosis, bronchial asthma and pulmonary infection (21, 22). These two MMPs have an 
additional gelatin binding fibronectin domain composed of 3 fibronectin type II repeats. 
These repeats are within the catalytic domain, and are responsible for binding gelatin, 
laminin and collagens type I and IV. MMP-9 also contains an additional Ser/Thr/Pro-rich 
collagen type V domain situated in the hinge region which is ~75 amino acid residues in 
length (23-26). It is of interest to point out that in the gelatinases, collagen binding is 
conferred by the fibronectin type II-repeats and the Ser/Thr/Pro-rich collagen type V 
domain, whereas in collagenases, collagen binding is conferred by the hemopexin domain 
(27, 28). The hemopexin-like domain of MMP-2 is also required for the cell surface 
activation of pro-MMP-2 by MT-MMP1 (29).  
 
E. Matrix metalloproteinases and cytokine modulation 
 Apart from digesting the ECM, the gelatinases modulate the activity of other 
proteases and cytokines and chemokines that are important in lung diseases. MMP-2 and 
MMP-9 have certain chemokines and cytokines as their substrates. As such, the 
gelatinases have the ability to have varying affects on the biological properties of 
cytokines and chemokines, ranging from potentiation to inactivation to antagonistic 
formation. Both MMP-2 and MMP-9 can release TGF-β from an inactive extracellular 
complex that consists of TGF-β latent-associated protein, and latent TGF-β-binding 
protein (30). MMP-2 cleaves the proinflammatory molecule monocyte chemoattractant 
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protein (MCP-3) into a truncated anti-inflammatory molecule which helps in the 
dampening of the inflammatory processes. MMP-9 cleaves IL-8 at its N-terminal 
increasing its chemotactic activity for neutrophils 10-fold. But it also inactivates other 
neutrophil chemokines (31). IL-1β and TNF-α have been reported to be increased in lung 
allograft BAL fluid. MMP-9 is also able to cleave the membrane-bound forms of tumor 
necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) into their 
active forms. Both gelatinases are able to generate the active form of interleukin-1 beta 
(IL-1β) from its inactive pro-form. MMP-9 degrades α1-antitrypsin, protecting neutrophil 
elastase activity (32), and potentiates the collagenolytic activity of MMP-13 (33).  
 Thus, cleavage of cytokines and chemokines by gelatinases can have varying 
effects on their biological properties, ranging from potentiation to inactivation to 
antagonist formation thereby affecting different physiological and pathological processes. 
All of these processes occur by MMPs acting extracellularly. New evidence, however, is 
suggesting the presence of intracellular MMP substrates that may indirectly regulate 
cytokine and chemokine activity. The plethora of potential substrates and the diversity of 
cell types that express these enzymes suggest the possibility of the involvement in 
multiple events occurring simultaneously in different microenvironments.   
 
F. Matrix metalloproteinase substrates 
 MMPs function can be regulated at many levels. In addition to transcriptional and 
translational regulation, MMPs can be regulated at the levels of secretion, intracellular 
trafficking, subcellular or extracellular localization, activation of the zymogen form, 
expression of their endogenous protein inhibitors (TIMPS) and protease degradation. 
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Also, substrate availability and accessibility determine the degree to which MMP activity 
is used. Within the lung, multiple factors are involved in MMP regulation including: a 
large list of growth factors, cytokines, cell adhesion molecules, ECM proteins and their 
bioactive fragments, intracellular signaling factors, and agents that cause actin 
cytoskeletal reorganization, all of which can directly or indirectly regulate the expression 
of MMPs (34). Interestingly, most of the same factors that regulate the expression of 
MMPs in the lung can also act as their substrates, providing a built-in and, most likely, 
essential component of the regulatory cascades. This coordination between MMP and 
substrate ensures efficient activation and control of MMPs (35).  
 Recently, using a proteomics approach analyzing bronchoalveolar lavage fluid 
(BALF) from the lungs of wild-type and MMP2/9 double deficient mice following 
allergen-challenge, Kheradmand et al. reported three new in vivo substrates for MMP2 
and MMP9; Ym1, S100A8 and S100A9, all of which are involved in chemotaxis (36). 
Ym1 is synthesized and secreted as an enzymatically inactive member of the chitinase 
family of proteins and has been identified in macrophages and airway epithelium of 
airway challenged mice (36). Intracellular and extracellular crystalline material 
corresponding to Ym1 has been identified in macrophages of NADPH deficient mice, 
which leads to the development of progressive crystalline macrophage pneumonia (37). 
S100A8 and S100A9 are small calcium-binding proteins of the S100 protein family that 
are  highly expressed in neutrophil and monocyte cytosol and are found at high levels in 
the extracellular milieu during inflammatory conditions (38). Intracellular S100A8/A9 
complexes play an important role in cell trafficking (39). To identify these proteins in 
vivo, BALF from wild-type and MMP2/9 double deficient (MMP2/9-/-) mice were 
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analyzed using two-dimensional differential in gel electrophoresis (2D-DIGE) followed 
by mass spectrometry. Western blot analysis revealed an increase in Ym1 protein 
fragments in the BALF of wild-type allergen-challenged mice as compared to MMP2/9-/- 
allergen-challenged mice, in which the Ym1 protein fragments were absent.  
 Furthermore, probing with a polyclonal Ym1 Ab that only detects the full-length 
Ym1 protein revealed increased levels of Ym1 in the BALF of MMP2/9-/- mice and not 
in wild-type allergen-challenged mice. These results demonstrate that MMP2 and or 
MMP9 are needed to process Ym1. To verify that Ym1 is cleaved by MMP2 or MMP9, 
silver staining studies were performed on purified Ym1 after incubation with 
recombinant MMP2 and MMP9. The results demonstrated that Ym1 is in fact a substrate 
of MMP2 and MMP9. Due to the size of the S100 proteins, in vitro cleavage assays were 
performed which revealed that S100A8 and S100A9 are substrates of MMP2. In an in 
vivo model of asthma, it was found that inhibition of S100 proteins by function-blocking 
Abs to S100A8 and S100A9, altered migration of allergic inflammatory cells in the 
alveolar space (36). These proteins have been identified in adult and juvenile rheumatoid 
arthritis, chronic bronchitis, cystic fibrosis, systemic lupus erythematosus, langerhans cell 
histiocytosis (40) and granulomatous conditions, such as tuberculosis and sarcoidosis 
(38). The identification of these new in vivo intracellular substrates, suggest a potential 
intracellular role for MMP2 and MMP9. 
 
G. Matrix metalloproteinase activation                                                                                           
 MMPs are present on the cell surface or secreted as latent, stable, pro-peptides 
known as zymogens. MMP2 is secreted as a 72kDa pro-form and MMP9 as a 92kDa pro-
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form. These enzymes are in an inactive state due to the thiol (SH-) group of the cysteine 
residue within the pro-domain interacting with the Zn2+ ion in the catalytic domain. 
Disruption of this cysteine-zinc interaction, by proteolysis for example, causes a 
conformational change thereby allowing the zinc to interact with the hydroxyl group 
(OH-) of a hydrolytic water molecule resulting in the activation of the enzyme. This 
mechanism is termed the cysteine-switch mechanism (41, 42). In most cases, the pro-
domain is cleaved to yield the truncated active forms of MMP-2 and -9, 64kDa and 
83kDa, respectively. MMPs may also be activated by other MMPs.  
 
H. Tissue inhibitors of matrix metalloproteinases (TIMPs) 
 The major physiologic inhibitors of the MMPs in vivo, are a group of specific 
tissue inhibitors of MMPs (TIMPS). These naturally occurring inhibitors are comprised 
of a family of four structurally related members, TIMP-1, -2, -3, and -4. TIMPs have an 
N- and C- terminal domain, each of which contains three conserved disulfide bonds. 
TIMPs bind to MMPs in a 1:1 stoichiometry. TIMP expression is regulated during 
development and tissue remodeling. These secreted proteins bind to the catalytic site of 
active MMPs resulting in their loss of proteolytic activity. Of the four TIMPs, TIMP-1 
and -2 have been shown to have key roles in the pathogenesis of lung disease. The 
balance between TIMPs and MMPs is believed to be important in regulating protease 
activity, suggesting that disruption of this balance can lead to serious pathological 
conditions (43, 44). Although TIMPs play an important role in MMP regulation, they are 
beyond the scope of this report, and therefore will not be discussed.  
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I. Matrix metalloproteinase inhibitors 
 Thus far, the known pharmacological inhibitors of MMPs are broad-spectrum 
molecules, which are designed to chelate the active-site zinc ions. Two broad spectrum 
inhibitors were tested, COL-3, a chemically modified tetracycline and 1,10 
Phenanthroline, a heterocyclic broad spectrum inhibitor of MMP activity. COL-3 is a 
synthetic inhibitor that lacks antibiotic activity but retain anti-MMP activity. 1,10 
Phenanthroline, is commonly used as a chelating agent for divalent metals such as Zinc 
and Ca2+ thereby inhibiting MMPs stability and potential activation (45). These two 
inhibitors were shown to be challenging due to their lack of specificity and their effects 
on other non-related signaling events. CMT-3 has been shown to interact with PKC 
which can effect cell growth and differentiation. 1,10 Phenanthroline chelates Zn2+ and 
Ca2+ ions which can lead to cell dysfunction.  
 Although there is a plethora of evidence confirming MMP involvement in lung 
injury, it is difficult to selectively pinpoint which of the up-regulated MMP activities are 
responsible for the tissue injury seen in various pulmonary diseases. This has largely been 
due to the lack of selective inhibitors. Mobeshery et al. has synthesized a selective 
gelatinase inhibitor (SB-3CT) [figure 4] to selectively inhibit MMP-2 and MMP-9 (46, 
47). This inhibitor is unique in that it works through a mechanism-based approach with 
the presence of a thiirane-containing inhibitor. The thiirane sulfur first coordinates with 
the active-site zinc ion. The coordinated thiirane predisposes it to nucleophilic attack by 
the active site glutamate, which leads to covalent modification of the MMP and attendant 
loss of activity. Through a series of reactions, the MMP2 and MMP9 are irreversibly 
inhibited by permanently blocking the cysteine switch interaction. 
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Figure 4. Schematic diagram of MMP activation and inhibition by SB3CT  
Diagram showing the mechanism based inhibitor SB3CT binding to the catalytic site of a matrix 
metalloproteinase (MMP2 or MMP9). Adapted from (48). 
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J. Matrix metalloproteinases in the normal lung 
 Under normal physiological conditions, cells in the lung do not normally express 
MMP2 and MMP9, with the exception of the constitutive expression of MMP2 in the 
endothelium. During infection and inflammatory disease, bronchial epithelial cells, Clara 
cells, alveolar type II cells, smooth muscle cells and fibroblasts are all capable of 
producing MMP9. Infiltrating leukocytes are another major source of MMP2 and MMP9, 
as neutrophils and eosinophils constitutively produce MMP9, whereas macrophages, 
mast cells and lymphocytes release MMP9 under inflammatory conditions (49). The 
gelatinases are able to modulate the process of tissue remodeling and therefore abnormal 
activation or inhibition of these enzymes is associated with many pulmonary pathologies. 
In the lung, MMP-2 and MMP-9 are implicated in the migration of epithelial cells 
following injury, by degrading components of the basement membrane allowing 
migration (50). In MMP-9 knock-out mice, there are reduced numbers of T lymphocytes 
and dendritic cells in the BAL fluid following antigen challenge (51). Infiltration of 
neutrophils, lymphocytes and dendritic cells into the lung further confirms a role for the 
gelatinases under normal and pathological conditions. 
 
K. Matrix metalloproteinases in cancer 
 MMPs, specifically the gelatinases, have been linked to a myriad of disease states. 
From a cancer perspective, MMP2 and MMP9 have been shown to be required for tumor 
cell invasion and angiogenesis (52). For example, in an experimental model for 
spontaneous metastasis of rat mammary carcinoma, increased serum and plasma levels of 
MMP-9 were associated with the development and extent of metastases in the lung and 
 20 
lymph nodes (53). MMP2 and MMP9 have been reported in human prostate cancer 
tissue, with the increase in MMP2 correlating to the degree of disease progression (54). 
Additionally, studies have reported an increase in MMP2 and MMP9 in expression and 
activity in the parenchyma of lung cancer patients (55). Thus, MMP2 and MMP9 
participate in migration, tumor cell invasion, angiogenesis and inflammation-induced 
tissue remodeling, and have been clinically shown to be key enzymes in the regulation of 
lung immunobiology. 
 
L. Matrix metalloproteinases in pulmonary disease 
 The mechanisms that initiate lung inflammation are important to understanding 
the immunobiology of pulmonary diseases such as asthma, chronic obstructive  
pulmonary disease (COPD), cystic fibrosis and idiopathic pulmonary fibrosis (IPF) (56). 
It is also important to understand the factors that are involved in resolution of the 
inflammation. This is a poorly understood topic that is of great importance because 
failure to resolve the inflammation results in irreversible airway remodeling and 
obstruction. We briefly discuss these diseases below and what is known of MMP2 and 
MMP9s involvement in each, and suggest a potential role for T cell-derived MMPs in 
these diseases. 
 1. Asthma 
 In the case of asthma, this disease is one that occurs when exposure to respiratory 
allergens triggers a systemic response, characterized by activation of the adaptive 
immune cells that are drive by Th2 cell-mediated airway inflammation (57). IL-4 and IL-
13 induce up-regulation of chemokines and cytokines that allow for homing of activated 
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Th2 cells to the site of inflammation (58). MMP2 and MMP9 have been shown to act 
downstream of Th2 cytokine signaling, but their presence is not required for the 
development of allergic and obstructive lung phenotype (59, 60). Interestingly, there has 
been a correlation between asthma severity and the expression of MMP9. MMP9 levels 
in the sputum, BAL and serum are higher in patients with severe asthma, as compared 
with milder asthmatics (61).  
 In murine models of allergen-induced asthma, the absence of MMP9 is 
responsible for a decrease of infiltration of airways and BAL by inflammatory cells. 
MMP9 deficient mice failed to develop allergen-induced airway hyperresponsiveness, 
suggesting a role for MMP9 in facilitating the egression of inflammatory cells into the 
airway lumen (62). With regard to allergen-induced asthma in MMP2 deficient mice, the 
absence of MMP2 causes inflammatory cell infiltration of alveolae and a decrease of 
inflammatory cells recovered in the BAL despite a strong peribronchovascular cell 
accumulation (63). These results suggest that MMP2 may play a role in the luminal 
clearance of inflammatory cells. MMP9 gene deletion reduces allergen-induced 
inflammatory process by decreasing dendritic cell (DC) trafficking, one of the key events 
during initiation of allergic immune responses, including asthma (51). Although asthma 
is known to be a Th2 driven disease and MMP2 and MMP9 are up-regulated, the 
potential connection between CD4+ T cells and MMPs in the regulation of this disease 
has not been studied.   
 2. Chronic obstructive pulmonary disease (COPD)                                                    
 Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive 
airway disorders, but differing types of inflammation are involved in the pathogenesis of 
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these distinct lung diseases. COPD is a disease that encompasses chronic bronchitis, 
small airway disease, and emphysema (64). It is characterized by a progressive chronic 
obstruction to airflow with a persistent inflammatory process. Among the cells involved 
in the inflammation reaction, alveolar macrophages are the predominant cell population 
identified by BAL with the addition of increased numbers neutrophils, and T 
lymphocytes (65). The development of COPD is characterized by an excess of 
extracellular matrix deposition in bronchial walls, sputum production and destruction of 
alveolar septa, resulting in reduced functional lung parenchyma and reduced elasticity 
due to elastolytic enzymes, such as neutrophil elastase and MMP9 (66). Within this 
disease, there are excess numbers of CD8+ T cytotoxic cells in the airways (67). This 
increase in CD8+ T cells may be due to the fact that these cells are known for their 
potential to eradicate infected cells. It is well known that COPD patients suffer from 
frequent exacerbations triggered by virus or bacteria, leading to an accelerated decline in 
lung function. It has been reported that CD4+ and CD8+ T cells are increased with the 
increasing number of CD8+ cells in both lung parenchyma and pulmonary arteries of 
COPD patients significantly correlates with the degree of airflow limitation, therefore 
suggesting an important role for T cells in COPD (68).   
 Elastin is important to lung integrity, and in emphysema elastin degradation 
occurs, leading to airway obstruction and disease severity. A study by Lee et al., 
highlighted the importance of T cells in mediating emphysema (69). They reported that 
activated T cells in emphysematous lungs exhibit a predominantly Th1 effector 
phenotype. They found a significant correlation between peripheral blood Th1 responses 
to elastin peptides, and severity of lung disease and airway obstruction, with an increase 
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in Th1 infiltration leading to severity of lung disease. They went on to propose that 
exposure to cigarette smoke (as is seen in emphysema patients) induces secretion of 
proteolytic enzymes (likely MMPs) from cells of the innate immune system that liberate 
lung elastin fragments, which in susceptible individuals could initiate T- and B- cell-
mediated immunity against elastin, leading to exacerbation of the disease (69). This study 
again links the potential relationship between MMPs and T cells. 
 MMPs have been suggested as the major proteolytic enzymes involved in the 
pathogenesis of this disease. Patients with COPD exhibit significantly elevated levels of 
MMP2 and MMP9 expression and activity in their lung parenchyma, as well as increased 
gelatinolytic activity in their sputum (21, 70). A report by Segura-Valdez et al. found 
increased MMP-2 and MMP-9 in the airway and lung parenchyma of COPD patients 
(71). Patients with stable chronic asthma or emphysema also showed increased levels of 
MMP-2 and MMP-9 in the sputum and BAL fluid (72, 73). The study of MMPs 
involvement in these diseases has largely focused on matrix degradation and remodeling, 
causing immunological changes and progression of the disease. However, there may be 
another important idea that has been overlooked. COPD and asthma are both diseases that 
involve T cell infiltration and have elevated levels of MMPs. These characteristics 
suggest that T cells could be involved in the elevated MMP expression within these 
diseases, since T cells are capable of expressing MMPs. These data suggest a potential 
link between T cells and MMP2 and MMP9 in COPD and asthma.  
 3. Cystic fibrosis 
 Cystic fibrosis (CF) is a genetic disorder in which abnormal ion transport 
predisposes patients to infection and neutrophilic inflammation (74). A predominant 
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feature of CF is the dynamic structural changes in the airway, such as the widening of 
airways and loss of normal mucociliary clearance mechanisms. These structural changes 
can lead to bronchiectasis and pulmonary hypertension and are a direct cause of the 
pulmonary morbidity and mortality seen in the majority of CF patients, due to the 
insistent airway inflammation in the disease (75).  
 A few studies have examined MMP9 in CF and have reported an increase in 
MMP-9 activity in CF sputum (76). A report from Ratjen et al. examined bronchoalveolar 
lavage fluid from CF patients and found increased MMP-9 in children with CF compared 
with healthy controls (77). It has been reported by Sagel et al. that MMP-9 expression is 
dramatically increased in the lower airway secretions of CF patients, and a negative 
correlation exists between MMP-9 levels and lung function [forced expiratory volume in 
1s (FEV1)] (77). 
 4. Pulmonary fibrosis 
 Pulmonary fibrosis is a severe chronic disease characterized by a loss of lung 
epithelial cells, replaced by interstitial myofibroblasts and deposition of extracellular 
matrix proteins in the lung interstitium leading to pulmonary structural remodeling (78). 
Idiopathic pulmonary fibrosis is a chronic disorder characterized by excessive matrix 
degradation and interstitial and intraalveolar fibrosis, which leads to dyspnea, impaired 
oxygen transfer and alveolar collapse (79). The defects in the alveolar epithelium and 
basement membrane allow the migration of mesenchymal cells from the interstitium into 
the intraluminal compartment. This is a major characteristic of IPF and is associated with 
the recruitment of inflammatory cells, including lymphocytes into the airways leading to 
an imbalance between synthesis and degradation of extracellular matrix molecules in the 
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local environment (80). The pathogenesis of idiopathic pulmonary fibrosis, however, is 
not completely understood. Its main features include epithelial injury, fibroblastic 
proliferation, inflammation, and increased matrix production (78). The ultimate feature is 
the progressive fibrosis, resulting from expansion of the extracellular matrix (ECM), and 
extensive remodeling of the lung parenchyma, where matrix metalloproteinases (MMPs) 
are believed to play important roles.  
 In lung fibrosis, studies have reported a temporal difference observed in 
expression and localization of MMPs (81, 82). In the earlier stages of the disease, MMP9 
seems to be predominant, likely contributing to disruption of alveolar epithelial basement 
membrane, and enhances fibroblast invasion to alveolar spaces. In the later stages of the 
disease, MMP2 seems to become predominant and is localized in structural cells like 
regenerated alveolar epithelial cells (83, 84). The expression of MMP2 and MMP9 at 
different stages of pulmonary fibrosis suggest, MMP9s involvement in inflammation-
induced tissue remodeling, while MMP2 may be associated with an impairment of tissue 
remodeling, leading to the exacerbation of fibrosis by increased collagen deposition and 
interstitial fibrosis. 
 In many cases, these chronic and often end-stage pulmonary diseases have limited 
therapeutic options. For many of these patients, lung transplantation is the only 
therapeutic option. Despite significant medical improvements, patient survival rates 5-
years after transplantation is estimated to be 50 percent (85). The major cause of 
mortality and morbidity among these patients following transplantation is chronic 
rejection (86), clinically manifested as obliterans bronchiolitis (OB) (87, 88). OB is 
characterized by accumulation of granulation tissue in the lumen of the bronchioles 
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which may be accompanied by the accumulation of monocytes, neutrophils, eosinophils 
and lymphocytes (89, 90). The mechanism by which chronic lung rejection leads to OB is 
poorly understood. It is thought however, that airway inflammation and aberrant tissue 
remodeling play a major role in the pathogenesis (91). Rejection is mediated by host T 
cells that have been activated by host or donor-derived dendritic cells (DCs), antigen 
presenting cells. Alloreactive T cells infiltrate the graft resulting in varying degrees of 
perivascular and peribronchiolar infiltrates characteristic of the rejection response. DC-
induced T cell activation is a complex process involving bidirectional signaling between 
these cells mediated by cell surface molecules, soluble extracellular mediators and 
intracellular pathways.  
 
M. Matrix metalloproteinases in transplant biology 
 Recent studies have revealed interesting roles for MMPs in transplant biology. 
There have been reports suggesting a link between MMP activity, specifically MMP-9 
and the onset of OB (43, 44). Other studies show that ischemia-reperfusion injury 
associated with lung transplantation, is sufficient to cause a significant up-regulation of 
MMP-9 and/or MMP-2 in lung grafts, and that MMP inhibition attenuates this process 
(92, 93). A report by Trello et al. demonstrated that MMP-2 and MMP-9 are increased in 
BAL fluid in stable lung transplant recipients, indicating that up-regulated proteolytic 
activity in clinically stable lung transplant recipients may have a role in chronic rejection 
after transplantation (94). Data from our laboratory showed that acute lung allograft 
rejection in rat transplant recipients was associated with up-regulated MMP-2 expression. 
Additionally, we reported that MMP inhibition by a broad spectrum MMP inhibitor 
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(COL-3), inhibited MMP activity, decreased TNF-α and IL-1β and abrogated T cell 
proliferation (93).  
 Another study by Campbell et al. showed that MMP-2 and MMP-9 play different 
roles in the process of mononuclear cellular influx into the allograft, as well as in the 
process of activation and expansion of alloreactive T cells during cardiac allograft 
rejection (95). BALB/c cardiac allografts were transplanted into MMP2 deficient and 
MMP9 deficient mice. MMP2 deficiency significantly prolonged allograft survival time 
and functioning allografts harvested from MMP2 deficient mice showed lower cellular 
infiltration than rejected allografts harvested from wild-type mice. In contrast, MMP9 
deficiency significantly decreased allograft survival time and functioning allografts 
harvested from MMP9 deficient mice showed higher cellular infiltration than rejected 
allografts harvested from wild-type mice. Additionally, MMP2 deficient recipients 
showed a decrease in T cell alloreactivity, whereas, MMP9 deficient recipients showed 
an increase in T cell alloreactivity (95).  
 Ischemia-reperfusion injury associated with lung transplantation can cause a 
significant up-regulation of MMP-2 and MMP-9 in lung allografts, which is attenuated 
by non-selective MMP inhibition (92, 96). In a report by Hubner et al. it was shown that 
the MMP-9 to TIMP-1 ratio is significantly increased in patients with BOS (bronchiolitis 
obliterans syndrome), known as chronic rejection, following lung transplantation (44). 
Data from our laboratory confirm that MMP-9 is strongly up-regulated in transplanted 
lungs (96). Taken together these data suggest that MMP-2 and MMP-9 play an important 
role in transplant rejection. Further investigation is required to delineate the functional 
roles of these MMPs in the process of T cell mediated pulmonary disease and transplant 
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rejection. Reports from other investigators show that bulk splenocytes isolated from mice 
genetically deficient in either MMP-2 or MMP-9 have diminished ability to stimulate 
proliferation in allogeneic T cells (95, 97), suggesting a role of MMPs in T cell  
proliferation. 
 These data support the notion that MMPs have some regulatory role in T cells and 
pose a question as to whether they function extracellularly or intracellularly. Recent 
publications have identified the presence of MMPs in the nucleus. A report by Luo and 
colleagues found a variant of MMP-11 that is expressed as an intracellular active form 
(98). Another group identified the nuclear localization of MMP2 in cardiac myocytes and 
rat liver (99). An intriguing study by Si-Tayeb et al. elucidated a mechanism for nuclear 
localization of an MMP by identifying a nuclear localization signal and showed that 
nuclear MMP3 can induce apoptosis via its catalytic activity (100). Since MMPs are 
generally thought to be secreted or transmembrane proteins, studies showing their 
intracellular presence or regulation are of great importance and suggest a potentially new 
path of MMP regulation and activity.  
 With much of the focus of MMPs being on their extracellular regulation and with 
studies highlighting the role of MMPs, specifically MMP2 and MMP9, in the 
pathogenesis of many T cell mediated lung diseases, it is of interest to understand the 
interconnection between MMPs and T cells. The new identification of intracellular MMP 
activity, offers a new potential mechanism of action for MMPs. Although studies have 
demonstrated the presence of MMPs within T cells, the role that MMPs may play in 
regulating T cell activation remains unknown. More importantly, no reports have 
identified potential intracellular MMP substrates that may be involved in regulating T cell 
29 
signaling events. This understanding would shed light on the potential mechanism of 
action that MMPs may be exerting in T cells to regulate their activation. The objective of 
the studies in this dissertation is to provide experimental evidence evaluating the 
regulatory role of matrix metalloproteinases, MMP2 and MMP9 in T cell activation at the 
functional level, intracellularly and in the context of T cell mediated lung injury in vivo.  
 The initial studies examined the expression levels of MMP9 in T cells, followed 
by the T cell functional response, as measured by T cell activation, in the presence of 
broad spectrum MMP inhibitors (1,10 phenanthroline and COL-3). Further studies more 
closely examined T cell in the presence of an MMP2 and MMP9 specific inhibitor 
(SB3CT) or in T cells that were deficient in MMP2 or MMP9, to determine if MMPs are 
important in T cell activation. Next, the intracellular signaling pathways in T cells were 
evaluated to determine if MMPs regulate intracellular signaling events important for T 
cell activation, such as the calcium and NFAT signaling pathways. Cell phenotypic 
studies were performed to analyze the expression of T cell surface activation markers 
following MMP inhibition or absence. Finally, MMP inhibition is evaluated in vivo to 
determine MMPs involvement in antigen-specific CD8+ T cell mediated lung injury.  
 
N. Hypothesis 
Matrix Metalloproteinases, specifically MMP2 and MMP9 regulate T cell activation. 
 30 
II. MATERIALS AND METHODS 
 
A. Animals 
 Female Balb/c and C57BL/6 mice 6-10 weeks old, were purchased from Harlan 
(Indianapolis, IN) or bred in the Laboratory Animal Resource Center at Indiana 
University School of Medicine (Indianapolis, IN). MMP2 null, MMP9 null and 
MMP2/MMP9 double null mice (C57BL/6 background) were a generous gift from Dr. 
Farrah Kheradmand (Baylor College of Medicine, Houston, TX) (59). CC10-OVA mice 
(C57BL/6 background) and OT-1 TCR transgenic mice (C57BL/6-Thy1.1 background) 
were a generous gift from Dr. Rebecca Shilling (University of Chicago Medical Center, 
Chicago, IL) (101). All mouse studies were conducted in accordance with institutional 
animal care and usage guidelines.   
 
B. Formulation of buffers and media 
MACS buffer  
 In a 2L beaker, 50ml of 10X PBS is added to 448ml of ddH20. To that 2ml of 
0.5M EDTA is added followed by 2.5g of BSA (Fisher Scientific, Pittsburgh, PA). Buffer 
is then filter sterilized and degassed. 
Cell lysis buffer 
 In a 2L beaker, 8.29g of NH4Cl, 1g of KHCO3, 0.372g of Na EDTA 
(C10H12N2Na4O8) are added to approximately 1L of ddH20 adjusted to a final volume of 
1L and then the buffer is then filter sterilized. 
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Complete RPMI (cRPMI) 
 RPMI, 400 mM l-glutamine, 100 U penicillin streptomycin (Gibco, Carlsbad, 
CA), 10% FCS (Hyclone, Logan, UT), and 5 x105 M 2-mercaptoethanol (Sigma, St. 
Louis, MO). 
 
C. Isolation of murine T cells from the spleen  
 Single cell suspensions were prepared from the spleens of five to seven mice. Red 
blood cells were lysed with an NH4Cl lysis buffer. Cell suspensions were then 
centrifuged at 300 x g for 10 minutes. Supernates were aspirated and cells were 
resuspended in 900μl of MACS buffer per 108 total cells. 100μl of either CD4 (L3T4) or 
CD8 (CD8a-Ly2) Microbeads (Miltenyi Biotech, Auburn CA) were then added per 108 
total cells. Cells containing the CD4 Microbeads or CD8 Microbeads were mixed well 
and incubated at 4 degrees C for 15 minutes. 5-10ml of MACs buffer was added to the 
cell suspension followed by centrifugation at 300 x g for 10 minutes. Supernates were 
aspirated and cell pellets were resuspended in 500μl MACs buffer per 108 total cells. 
CD4+ or CD8+ T cells were then isolated from the splenocytes through positive magnetic 
selection steps using the autoMACS Seperator run on the “posseld” program. The purity 
of CD4+ and CD8+ T cells determined by staining cells with anti-CD4 FITC labeled Ab 
and anti-CD8 PE labeled Ab, respectively. Stained cells were then analyzed by flow 
cytometry and purity ranged from 97 to 99%. This isolation protocol was used to isolate 
T cells from C57BL/6 wild-type mice, MMP2 deficient, MMP9 deficient, MMP2/9 
deficient, OT-I transgenic and OT-II transgenic mice.  
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D. Isolation of murine dendritic cells from the spleen 
 Single cell suspensions were prepared from the spleens of five to seven mice. Red 
blood cells were lysed with an NH4Cl lysis buffer. Cells were collected by centrifugation 
(200 x g, 10 minutes). Supernates were aspirated and cell pellets were resuspended in 
400μl of MACS buffer per 108 total cells. 100μl of cD11c Microbeads (Miltenyi Biotech, 
Auburn CA) were then added per 108 total cells. Cells were mixed well and incubated at 
4 degrees C for 15 minutes. 5-10ml of MACs buffer was added to the cell suspension, 
and suspensions were centrifuged at 200 x g for 10 minutes. Supernates were aspirated 
and cell pellets were resuspended in 500μl MACs buffer per 108 total cells. CD11c+ 
dendritic cells were then isolated from the splenocytes through positive magnetic 
selection steps using the autoMACS Seperator run on the “posseld” program. The purity 
of cD11c+ dendritic cells determined by staining cells with anti-CD11c FITC labeled Ab. 
Stained cells were then analyzed by flow cytometry flow cytometry, ranged >90%.   
 
E. Isolation of murine regulatory T cells from the spleen 
 Tregs were isolated from splenocytes through a series of magnetic selection steps 
using the mouse CD4+CD25+ Isolation Kit (Miltenyi Biotech, Auburn, CA). Single cell 
suspensions were prepared from the spleens of ten to twenty mice. Red blood cells were 
lysed with an NH4Cl lysis buffer. Cells were collected by centrifugation (300 x g, 10 
minutes). Supernates were aspirated and cell pellets were resuspended in 400μl of MACS 
buffer per 108 total cells. 100μl of Biotin-Antibody Cocktail, which consists of biotin-
conjugated monoclonal anti-mouse antibodies against: CD8a (Ly-2; isotype: rat IgG2a), 
CD11b (Mac-1; isotype: rat IgG2b), CD45R (B220; isotype: rat IgG2a), CD49b (DX5; 
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isotype: rat IgM) and Ter-119 (isotype: rat IgG2b (Miltenyi Biotech, Auburn CA) was 
then added per 108 total cells. Cells were mixed well and incubated at 4 degrees C for 10 
minutes. 300μl of MACS buffer, 200μl of Anti-Biotin MicroBeads and 100μl of CD25-
PE antibody were added per 108 total cells. Cells were mixed well and incubated at 4 
degrees C for 15 minutes in the dark. 5-10ml of MACs buffer was added to the cell 
suspension, and suspensions were centrifuged at 300 x g for 10 minutes. Supernates were 
aspirated and cell pellets were resuspended in 500μl MACs buffer per 108 total cells. The 
CD4+ cell fraction was then isolated from the splenocytes through negative magnetic 
selection steps using the autoMACS Seperator run on the “Depl025” program. The 
negative fraction consisted of the CD4+ cell population. The CD4+ cells were centrifuged 
at 300 x g for 10 minutes, supernatant was completely aspirated and cells were 
resuspended in 900μl of MACS buffer and 100μl of Anti-PE MicroBeads. Cells were 
mixed well and incubated at 4 degrees C for 10 minutes. Cells were mixed well and 
incubated at 4 degrees C for 15 minutes in the dark. Cells were then washed by addition 
of 5-10ml of MACs buffer and centrifuged at 300 x g for 10 minutes. Supernatant was 
completely aspirated and cells were resuspended in 500μl MACs buffer per 108 total 
cells. The CD4+25+ cell fraction was then isolated from the splenocytes through double 
positive magnetic selection steps using the autoMACS Seperator run on the “Posseld2” 
program. Treg cell purity determined by flow cytometry, ranged from >93%. Where 
indicated, the CD4- fraction was γ-irradiated (2000 rads) and used as APCs. The 
CD4+CD25- cell fraction was also retained and used as fresh T cells. The purity of Tregs 
and Th cells, determined by flow cytometry, ranged from 93-97% and 93-99%, 
respectively.   
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F. Preparation of matrix metalloproteinase inhibitors (MMPIs)  
 Broad spectrum MMPIs, 1,10 Phenanthroline and COL-3, or MMP2/9 specific 
MMPI, SB3CT,were used in the following experiments. 1,10 Phenanthroline (Sigma, St. 
Louis, MO) was reconstituted in tissue culture grade dimethyl sulfoxide (DMSO) to a 1M 
solution then diluted to concentrations ranging from 0.001-0.1uM in cRPMI. CMT-3, a 
chemically modified tetracycline, and generous gift from Dr. Brad Zerler (CollaGenex 
Pharmaceuticals, Inc., Newtown, PA) was reconstituted in carboxy-methylcellulose to a 
1M solution then diluted to concentrations ranging from 1-100uM in cRPMI. SB3CT, a 
specific mechanism-based MMP2/9 inhibitor, and generous gift from Dr. Shriar 
Mobashery (University of Notre Dame, Notre Dame, IN) was reconstituted in DMSO and 
polyethylene glycol (PEG) to a 1M solution then diluted to concentrations ranging from 
0.0001-1mM in cRPMI.  
 
G. Mixed leukocyte reactions 
 Purified CD4+ T cells from Balb/c mice (1x106/ml) were treated with the 
indicated concentrations of MMPIs. Cells were then co-culture with γ-irradiated CD11c+ 
dendritic cells (DC), purified based on CD11c expression from C57BL/6 mice. DCs and 
T cells were co-cultured at DC: T cell ratios of 0.01, 0.075 and 0.1, in the presence of 
anti-mouse CD3 (0.5μg/ml, BD Biosciences, San Jose, CA) in 200μl of cRPMI at 37°C 
for 72h. 18h prior to harvest, cultures were pulsed with 3[H]-thymidine (0.5 μCi/well). 
Plates were harvested using a Skatron Basic 96 Harvestor (Molecular Devices, 
Sunnyvale, CA). 3[H]-thymidine incorporation was measured using a liquid scintillation 
counter (Beckman, Fullerton, CA).  
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H. T cell proliferation assays 
 Purified CD4+ or CD8+ T cells from Balb/c or C57BL/6 mice (1x106/ml) were 
incubated with the indicated concentrations of MMPIs. Cells were then washed in RPMI 
and plated in the presence of anti-CD3 Ab (0.5μg/ml, BD Biosciences, San Jose, CA) in 
200μl of cRPMI at 37°C for 72h. 18h prior to harvest, cultures were pulsed with 3[H]-
thymidine (0.5 μCi/well). Plates were harvested using a Skatron Basic 96 Harvestor 
(Molecular Devices, Sunnyvale, CA). 3[H]-thymidine incorporation was measured using 
a liquid scintillation counter (Beckman, Fullerton, CA).  
 Purified CD4+ and CD8+ T cells from MMP2, MMP9 or MMP2/9 double knock 
out C57BL/6 mice (1x106/ml) were cultured in the presence of anti-CD3 Ab (0.5μg/ml) 
in 200μl of cRPMI at 37°C for 72h. CD4+ and CD8+ T cells were also incubated with the 
indicated concentrations of SB3CT for 6h and then washed three times with RPMI 1640. 
Drug or vehicle-treated T cells were cultured (1x106/ml) with anti-CD3 Ab (0.5μg/ml) in 
200μl of cRPMI at 37°C for 72h. Cells were harvested as indicated above. 
 
I. OT-I and OT-II Ag-specific T cell proliferation 
 Pure splenic CD4+ and CD8+ T cells from OT-II transgenic or OT-I transgenic 
C57BL/6 mice were incubated with the indicated concentrations of MMPIs. Cells were 
then washed in RPMI and plated at 1x105/well in a 96 well plate in the presence of OVA-
pulsed (OT-II:ova peptide and OT-I: SIINFEKL peptide) antigen presenting cells (APCs) 
for 72 hours. 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the 
culture. T cell proliferation was measured by the amount of 3H thymidine incorporation. 
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J. CD4+25- T cell suppressor assay 
 Purified CD4+25- T cells from C57BL/6 mice were incubated with the indicated 
concentrations of SB3CT or vehicle control for 6 hours. Cells were then washed in RPMI 
and added at varying ratios (1:1, 2:1, 4:1, 6:1 treated: untreated ) in co-culture with 
untreated CD4+25- T cells in the presence of irradiated antigen presenting cells (APCs) in 
200μl of cRPMI at 37°C for 72h. 18h prior to harvest, cultures were pulsed with 3[H]-
thymidine (0.5 μCi/well). Plates were harvested using a Skatron Basic 96 Harvestor 
(Molecular Devices, Sunnyvale, CA). 3[H]-thymidine incorporation was measured using 
a liquid scintillation counter (Beckman, Fullerton, CA). 
 
K. Regulatory T cell (Treg) suppressor assay 
 Purified CD4+25+ T cells from C57BL/6 mice were incubated with the indicated 
concentrations of SB3CT or vehicle control for 6 hours. Cells were then washed in RPMI 
and added at varying ratios (0.5:1 and 1:1 treated: untreated ) in co-culture with untreated 
CD4+25- T cells in the presence of irradiated antigen presenting cells (APCs) in 200μl of 
cRPMI at 37°C for 72h. 18h prior to harvest, cultures were pulsed with 3[H]-thymidine 
(0.5 μCi/well). Plates were harvested using a Skatron Basic 96 Harvestor (Molecular 
Devices, Sunnyvale, CA). 3[H]-thymidine incorporation was measured using a liquid 
scintillation counter (Beckman, Fullerton, CA). 
 
L. Gelatin zymography 
 Cell lysates and conditioned media supernatant were collected, concentrated to 
16X and centrifuged to remove any cell debris, and stored at -80°C prior to assay. The 
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concentrated samples were suspended in sodium dodecyl sulfate (SDS) electrophoresis 
sample buffer but not heated, and subjected to SDS-page under non-reducing conditions 
on 10% acrylamide gels containing 2 mg/ml gelatin. The gels were soaked in two 25-min 
changes of 0.05 M Tris-HCl, 5 mM CaCl2, 1 µM ZnSO4, 2.5% Triton X-100 to remove 
SDS, then washed for 5 min in the same buffer without Triton X-100. Then the gels were 
incubated overnight at 37°C in 0.05 M Tris-HCl, 5 mM CaCl2, 1 µM ZnSO4, 1% Triton 
X-100, pH 7.6, containing 1 mM aminophenylmercuric acetate (APMA) to activate the 
MMP within the gel. After incubation, the gels were stained with 1% Coomassie Blue. 
Gelatinolytic activity was identified as clear bands of lysis on a uniform blue background. 
To confirm that the observed gelatinolysis was due to MMP activity, gels were incubated 
in assay buffer containing 1mM 1,10 phenanthroline, a matrix metalloproteinase 
inhibitor. 
 
M. Cytokine profiling by quantitative real-time PCR 
 Purified CD4+ T cells were incubated with the indicated concentrations of SB3CT 
for 6h and then washed three times with RPMI 1640. Drug or vehicle-treated T cells were 
cultured (1x106/ml) with anti-CD3 Ab (0.5μg/ml) in cRPMI for 1-12h. Supernatants were 
collected and stored at -80°C. Cells were collected and total RNA was isolated using an 
RNeasy RNA extraction kit (Qiagen, Inc., Valencia, CA). Total RNA quantity and purity 
was assessed using a NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE). cDNA 
was synthesized using 1μg of RNA with qScript™ cDNA SuperMix (Quanta 
Biosciences, Gaithersburg, MD) according to the manufacturer's instructions. mRNA 
expression levels were measured by real-time quantitative PCR and detected with 
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PerfeCTa™ SYBR Green FastMix, Low ROX (Quanta Biosciences, Gaithersburg, MD) 
on a Applied Biosystems 7500 according to the manufacturer’s instructions. Briefly, 2μL 
of cDNA was amplified for 40 cycles at 95°C for 15 sec, 60°C for 1 min, and 72°C for 
30sec. Each sample was run in triplicate and normalized with murine β-actin. 
 
 
 
 
 
 
                                         
Table 1. Primer pairs used for qRT-PCR analysis. 
 
N. Cytokine profiling by cytometric bead array (CBA) 
 Purified MMP9 deficient or SB3CT treated (10μM) CD4+ T cells were incubated 
with 10μM of SB3CT for 6h and then washed three times with RPMI 1640. Drug or 
vehicle-treated T cells were cultured (1x106/ml) with anti-CD3 Ab (0.5μg/ml) in cRPMI 
for 1-12h. Supernatants were collected and cytokine protein levels were measured using 
the Mouse Inflammatory Cytokine Bead Array Kit (BD Biosciences, San Jose, CA) 
according to the manufacturer’s instructions. Briefly, Mouse Inflammation Capture Bead 
suspensions for each cytokine to be assayed were mixed together and 50μl aliquots were 
Primer Sequence 
β-actin F: CAATAGTGATGACCTGGCCGT       
R: AGAGGGAAATCGTGCGTGAC 
IL-2 F: TCCAGAACATGCCGCAGAG            
R: CCTGAGCAGGATGGAGAATTACA 
TNF-α F: TGGGAGTAGACAAGGTACAACCC 
R:CATCTTCTCAAAATTCGAGTGACAA 
IFN-γ F: TGGCTCTGCAGGATTTTCATG         
R: TCAAGTGGCATAGATGTGGAAGAA 
NFATc1 F: TGGAAGCAAAGACTGACCGG                                                    
R: CTGGTTGCGGAAAGGTGGTAT 
Foxp3 F: CTTACAGCTGAGAGGGGTGC                                                    
R: CCAGATGTTGTGGGTGAGTG 
CD25 F: TACAAGAACGGCACCATCCTAA       
R: TTGCTGCTCCAGGAGTTTCC   
IL-10 F: GGTTGCCAAGCCTTATCGGA          
R: ACCTGCTCCACTGCCTTGCT 
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added into FACS tubes (Falcon 12x75mm 5ml round-bottom polystyrene tubes) (BD 
Biosciences, San Jose, CA) containing PE detection reagent and sample supernatant. 
Samples were washed and analyzed on a Beckman Coulter Flow Cytometer using BD 
CBA Software. 
 
O. Intracellular calcium flux 
 Calcium flux was measured in CD4+ and CD8+ wild-type or MMP9 deficient or 
SB3CT treated (10μM) T cells using the Fluo-4 NW Calcium Assay kit (Molecular 
Probes, Carlsbad, CA) in accord with the provided instructions. In brief, 2.5 x 106 T cells 
were resuspended in 1.0 ml Assay Buffer (1x HBSS, 20mM HEPES), which contains 
calcium or calcium-free media (Invitrogen) then aliquoted in 50μl (1.25 x 105 cells) in a 
96-well plate and incubated for 1h at 37⁰C. The cells were then loaded with the 50μl of 
Fluo-4 dye diluted in Assay Buffer with 2.5mM probenecid acid for 30 minutes at 37°C, 
followed by a 30 minute incubation at room temperature. Cells were then stimulated and 
read in real time (0-300sec) on a Molecular Devices FlexStation I (Sunnyvale, CA) for 
300 seconds.   
 
P. Total and phosphorylated MEK1/2 colorimetric assay 
 CD8+ T cells were isolated from wild-type C57BL/6 mice. Cells were then treated 
with vehicle or SB3CT for 6 hours. A 96-well culture plate was treated with 10μg/ml 
poly-L-lysine for 30 minutes at 37°C. The plate was then washed twice for 5 minutes 
with PBS. Following the incubation with SB3CT, cells were then washed and plated in a 
96-well culture plate that had been treated with 10μg/ml poly-L-lysine. Cells were then 
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plated at 3x105 cells/well. Cells were then stimulated for varying times (0-60 minutes) 
with soluble anti-CD3 Ab (0.5μg/ml). Cells were then fixed by replacing the growth 
medium with 100μl of 8% formaldehyde in PBS. Cells were then incubated for 20 
minutes at room temperature, then washed 5 times. 100μl of quenching buffer was added 
to the cells and incubated for 20 minutes at room temperature. Cells were again washed 2 
times. 100μl of blocking buffer was added to the plate and incubate 1 hour at room 
temperature. The primary antibody (anti-MEK1/2 Ab) was then added and the cells were 
again incubated for 1 hour. Plates were again washed 3 times. 100μl diluted secondary 
antibody was added to the plate and the plate was covered and incubated at room 
temperature for 1 hour. The plate was then washed 2 times with 1X PBS. 100μl of 
developing solution was added to each well and incubated for 20 minutes at room 
temperature protected from direct light. 100μl of stop solution was added to each well 
and absorbance was read on a spectrophotometer at 450nm. 
 
Q. Activation of CD8+ Thy1.1+ T cells for adoptive transfer into CC10-OVA mice 
 Lymph node and spleen were isolated from OT-I transgenic mice and CD8+ T 
cells were isolated as stated above. OT-I cells were then treated with 10μM of SB3CT or 
the corresponding vehicle control (DMSO + PEG) for 6 hours, followed by three washes 
in culture media. Splenocytes were isolated from wild-type C57BL/6 mice and irradiated 
(2500 rad) to serve as the antigen presenting cells (APCs)/feeder cells in the activation 
co-culture. 5x107 irradiated splenocytes were cultured in 30ml of 10% DMEM 
supplemented with 0.7μg/ml of OVA peptide (SIINFEKL) for 5 min, followed by the 
addition of OT-1 T cells (5x106), anti-CD28 Ab (2μg/ml), IL-2 (132.02 U/ml) and IL-12 
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(10 ng/ml). On day 3, cells the cells were split and supplemented with more IL-2 
(25U/ml) in a final volume of 30mls. On day 5, cells were harvested and prepared for 
adoptive transfer into CC10-OVA mice. Cells were resuspended in PBS, and 7.5x105 
cells were then intratracheally instilled into the lungs of CC10-OVA mice.  
 
R. Isolation of lymphocytes from the lung of CC10-OVA mice in preparation for flow 
cytometry 
 The lungs of CC10-OVA mice were perfused and excised 10 days after adoptive 
transfer of SB3CT or vehicle treated OT-I Tg T cells. The lung was finely minced on ice, 
followed by a 60-90 minute digestion at 37°C with collagenase/dispase (0.2mg/ml of 
each) in RPMI medium with 5% fetal calf serum (FCS), in the presence of 25µg/ml 
DNase. To improve tissue disintegration, lungs were pipetted every 5 minutes using a 
pasteur pipet. Ethylenediaminetetraacetic acid was added to a final concentration of 5 
mM, followed by an additional 5 minute incubation at 37°C. Cells were passed through a 
70 µm cell strainer, washed, and lung lymphocytes were isolated by density 
centrifugation. Briefly, lung samples were resuspended in 5mL of a solution of 44% 
percoll in 1X PBS. Five mililiters of 66% percoll in 1X sterile PBS was gently added 
under the lung sample in 44% percoll. The samples were then centrifuged at 2000 rpm for 
20 min, no break, at room temperature. The top layer was carefully aspirated to the 
interface. The interface was transferred into a new tube and washed. The cells were then 
resuspended in 2ml of lysis buffer for 1 minute, then washed in cRPMI. Following 
isolation, cells were analyzed by flow cytometry for the presence of CD8+ Thy1.1+ T 
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cells, corresponding to OT-I Tg T cell migration into the lung. The percentage of 
macrophage and eosinophil populations present in the lung were also measured by flow  
cytometry. 
 
S. Flow Cytometry  
1. Cell phenotyping in MMP9 deficient mice 
 CD4+ and CD8+ T cells were isolated from wild-type and MMP9 deficient mice. 
In some studies, the wild-type mice were treated with SB3CT or the corresponding 
vehicle control, as stated above. Following the various treatment conditions, the cells 
were collected and washed in FACs buffer (10% BSA in PBS). Non-specific binding was 
blocked with FACs buffer supplemented with anti-CD16/anti-CD3 Ab2 Ab (0.5μg/well, 
eBioscience, San Diego, CA). Cells were then stained with anti-mouse CD4-FITC, CD8-
PE, CD25-PE, CD40L-PE, CD44-PE, CD45RO-FITC, CD62L-APC, CD69-FITC, and 
CTLA-4-PE Abs along with the corresponding isotype controls (all from eBioscience). 
After staining, cells were fixed in a 3% paraformaldehyde solution and read immediately 
on the flow cytometer. The data from 10,000 cells in the live gate were analyzed with a 
FACScan flow cytometer (Beckton Dickinson). FCS Express (DeNovo Software, Los 
Angeles, CA) was used for further analysis.  
 
2. Cell phenotyping of SB3CT treated T cells 
 CD4+ T cells were isolated from C57BL/6 wild-type mice and treated with 
SB3CT or the corresponding vehicle control. Following the various treatment conditions, 
the cells were collected and washed in FACs buffer (10% BSA in PBS). Non-specific 
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binding was blocked with FACs buffer supplemented with anti-CD16/anti-CD3 Ab2 Abs 
(0.5μg/well, eBioscience, San Diego, CA). Cells were then stained with anti-mouse 
CD25-PE and CD69-FITC Ab along with the corresponding isotype controls (all from 
eBioscience). After staining, cells were fixed in a 3% paraformaldehyde solution and read 
immediately on the flow cytometer. The data from 10,000 cells in the live gate were 
analyzed as stated above.  
 
3. Cell phenotyping of CD8+ Thy1.1+ T cells in the lung of CC10-OVA mice 
following adoptive transfer of SB3CT treated OT-I Tg T cells. 
 Total lung cells were isolated as stated above. Cells were then collected and 
washed in FACs buffer (10% BSA in PBS). Cells were then analyzed immediately on the 
flow cytometer. The data from 10,000 cells in the live gate were analyzed as stated 
above.  
 
4. Cell subset identification in BAL 
 Assessment of neutrophilic alveolitis in the animal model was determined by 
neutrophil accumulation in the BAL. BAL was collected from the lungs of wild-type and 
CC10 mice following adoptive transfer of vehicle or SB3CT treated OT-1 Tg T cells, by 
washing the mouse lung with 1.0ml of sterile 1X PBS. Collected fluid was then 
centrifuged for 10 minutes at 2000 rpm. Cell supernatant was then removed, and cell 
pellets were resuspended in 200μl of sterile 1XPBS. Cells were then stained with anti-
GR1 Ab, which was used as a marker of neutrophils, and analyzed immediately on the 
flow cytometer. To measure the percentages of other cell populations present within the 
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BAL, cells were collected and washed in FACs buffer (10% BSA in PBS). Non-specific 
binding was blocked with FACs buffer supplemented with anti-CD16/anti-CD3 Abs 
(0.5μg/well, eBioscience, San Diego, CA). Cells were then stained with anti-mouse CD9 
Ab, a surface marker for eosinophils and anti-CD11b Ab, a surface marker for 
macrophages. After staining, cells were fixed in a 3% paraformaldehyde solution and 
read immediately on the flow cytometer. The data from 10,000 cells in the live gate were 
analyzed with a FACScan flow cytometer (Beckton Dickinson). FCS Express (DeNovo 
Software, Los Angeles, CA) was used for further analysis.  
 
T. Total BAL cell counts 
 BAL was collected by washing the mouse lung with 1.0ml of sterile 1X PBS. 
Collected fluid was then centrifuged for 10 minutes at 2000 rpm. Cell supernatant was 
then removed. Cell pellets were resuspended in 200μl of sterile 1XPBS. Cells were then 
diluted 1:10 or 1:20 in trypan blue and counted at 20X using an Olympus microscope  
 
U. Histology 
 Lungs were perfused, inflated and fixed with neutral buffered formalin. The 
sections were then embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin (performed at University of Chicago Medical Center). Images were acquired at 20X 
using an Olympus microscope and DP12 digital camera (Olympus, Center Valley, PA).  
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V. Statistical analysis  
 Data were analyzed by either 2-way Analysis of Variance (ANOVA) with paired 
t-test or non-parametric t-test using Prism 4 (GraphPad Software for Windows, San 
Diego, CA) or Microsoft Office Excel 2007 (Microsoft, Seattle, WA) 
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III. RESULTS 
 
Chapter 1. The effects of matrix metalloproteinase inhibition on CD4+ and CD8+ T 
cell proliferative responses 
A. MMP9 expression in primary murine CD4+ and CD8+ T cells  
 Among the members of the MMP family, MMP2 and MMP9 have been shown to 
be important in inflammation due to their critical role in the process of cell infiltration 
into tissues and matrix remodeling (24, 102). As such, many reports have highlighted a 
role for MMP9 in a variety of pulmonary diseases such as bronchiolitis obliterans 
syndrome (103), which results from alloimmune-mediated injury following lung allograft 
rejection and in asthma, which is thought to be a T cell-mediated disease. Abnormalities 
in MMP9 production have been observed in bronchoalveolar lavage fluid, bronchial 
tissue and serum of BOS and asthmatic patients (44, 51). Additionally, previous studies 
have demonstrated that MMP9 is inducible in both CD4+ and CD8+ T cells, in response 
to various stimuli (104, 105). However, the role of MMP9 in regulating T cell activation 
remains unknown.  
 To begin to address the role of MMP9 in T cell activation, we first wanted to 
determine whether T cell derived MMP-9 is present in the primary murine splenic CD4+ 
and CD8+ T cells of the C57BL/6 mouse strain. T cells were isolated from C57BL/6 mice 
and cultured in the presence or absence of soluble anti-CD3 Ab (0.5μg/ml) for 24 hours. 
Anti-CD3 is polyclonal agonistic antibody that binds the epsilon chain of the T cell 
47 
receptor to mimic antigen-MHC complex ligation, thereby inducing T cell activation and 
proliferation. MMP-9 mRNA and protein expression was measured in the cell lysates and  
conditioned media of activated CD4+ and CD8+ T cells by means of real-time PCR and 
substrate zymography, respectively. 
 As shown in [figure 5], there were detectable levels of MMP9 mRNA expression 
in unstimulated CD4+ [figure 5A] and CD8+ [figure 5B] T cells. Interestingly, following 
anti-CD3 Ab stimulation, an increase in MMP9 mRNA expression was detected in CD8+ 
T cells [figure 5B] but not in CD4+ T cells [figure 5A]. To determine if there was a 
correlation with MMP9 expression at the protein level, MMP9 expression was measured 
in the cell lysates and conditioned media of activated CD4+ and CD8+ T cells. As shown 
in [figure 5C], lysate from unstimulated CD4+ T cells display a prominent band which 
corresponds to pro-MMP9 (105kDa). T cell lysates from activated (anti-CD3 Ab 
stimulated) CD4+ T cells reveal a faint band again corresponding to pro-MMP9. 
Conditioned media from the activated cell culture supernatant revealed two bands, one 
corresponding to pro-MMP9 and a band below at approximately 95kDa, corresponding to 
the conversion of pro MMP9 to the active form [figure 5C].  
 Observation of unstimulated CD8+ T cell lysate also reveals a prominent band 
representing pro-MMP9 [figure 5C]. Cell lysate from activated CD8+ T cells reveal a 
faint band representing pro-MMP9, whereas conditioned media from the activated cell 
culture supernatant revealed two bands, again corresponding to the pro- and active form 
of MMP9 [figure 5C]. As expected, media from unstimulated cells displays no MMP-9 
expression. All the gelatinolytic activities were blocked by the addition of 1,10 
phenanthroline, which inhibits MMP activity, to ensure that the activity seen is 
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Figure 5. Differential MMP9 mRNA and protein expression in CD4+ and CD8+ T 
cells 
Pure splenic A) CD4+ and B) CD8+ T cells were isolated from C57BL/6 mice. T cells were plated at 
2x106/well in a 24 well plate in the presence of anti-CD3 Ab (1μg/ml) for 24 hours. RNA was 
isolated, cDNA synthesizes and mRNA expression levels were measured by real-time quantitative 
PCR. Data were normalized to β-actin. A and B are data are representative of two separate 
experiments performed in triplicate. C) Gelatin zymogram analysis of CD4+ and CD8+ T cell lysates 
and supernatant. Data representative of four separate experiments.  
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gelatinolytic (data not shown). These data confirm that T cell derived pro- and active 
MMP-9 is expressed in murine CD4+ and CD8+ T cells. 
 
B. Broad-spectrum MMP inhibition abrogates alloantigen- and anti-CD3 Ab 
induced T cell proliferation 
 Our laboratory recently reported that blocking MMPs in vivo using a broad-
spectrum MMP inhibitor, COL-3, a chemically modified tetracycline, abrogated 
alloantigen-induced T cell proliferation in a rat model of lung transplantation, suggesting 
a role for MMPs in T cell activation (106). To address this question, we utilized mixed 
leukocyte reactions to determine if murine splenic T cells treated with broad-spectrum 
MMP inhibitors (1,10 phenanthroline or COL-3) were able to respond to alloantigen 
stimulation. Dendritic cells (antigen presenting cells) isolated from C57BL/6 mice were 
co-cultured at varying ratios (0.01 and 0.075) in the presence of allogeneic T cells from 
Balb/c mice with the addition of varying concentrations of 1,10 phenanthroline (0.001-
0.1μM). As anticipated, untreated T cells proliferated in response to alloantigen stimulus 
at both ratios [figure 6A]. As shown in figure 6A, treatment with a very low 
concentration (0.001μM) of 1.10 phenanthroline showed proliferative responses similar 
to those seen in untreated cells (white bar). In contrast, compared to untreated cells, 
treatment with 0.01μM (striped bar) and 0.1μM (shaded bar) of 1,10 phenanthroline 
completely abrogated the alloantigen-induced proliferative responses.  
 To further examine the effects of MMP inhibition on T cells specifically, T cell 
proliferation assays were utilized, in which, T cells were treated for 6 hours with 1,10 
phenanthroline followed by stimulation with soluble anti-CD3 Ab.  
 50 
 
  
Figure 6. Broad spectrum MMP inhibition by 1,10 phenanthroline (0.001-0.1μM) 
reduced alloantigen and anti-CD3 induced T cell proliferation 
Pure splenic CD4+ T cells were isolated from Balb/c or C57BL/6 mice. A) CD4+ Balb/c T cells were 
treated with varying concentrations of 1,10 phenanthroline (0.001-0.1μM) and cocultured with 
allogeneic (C57BL/6) dendritic cells at various ratios (0.01-0.15:1 DC:T cell). B) CD4+ T cells 
isolated from C57BL/6 mice were treated with varying concentrations of 1,10 phenanthroline (0.001-
0.1μM). Cells were then washed in RPMI and plated at 3x105/well in a 96 well plate in the presence of 
anti-CD3 Ab (0.5μg/ml). 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the 
culture. T cell proliferation was measured by the amount of 3H thymidine incorporation. These data 
are representative of the mean ± SD of one of three separate experiments performed in triplicate. 
*p<0.001 compared to anti-CD3 Ab stimulated untreated T cells. (n=3)  
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As shown in [figure 6B], untreated anti-CD3 Ab stimulated cells exhibited a normal 
proliferative response. Similar to the results shown in the mixed leukocyte reaction 
above, T cells treated with1,10 phenanthroline [figure 6B] exhibited a significant 
decrease in proliferation at 0.01μM and 0.1μM (p<0.001). It is worth nothing that testing 
a concentration between 0.001 and 0.01 such as 0.005 may provide more accurate dose-
dependent examination of 1,10 phenanthroline. To examine the effects of COL-3 on 
alloantigen stimulation, mixed leukocyte reactions were performed as above. Dendritic 
cells (antigen presenting cells) were isolated from C57BL/6 mice and co-cultured at 
varying ratios (0.01 and 0.075) in the presence of allogeneic T cells from Balb/c mice 
with the addition of varying concentrations of COL-3 (1-100μM).  
 Observation of COL-3 treatment revealed a significant decrease in alloantigen-
induced proliferation in response to 100μM treatment of COL-3 (p<0.001), as compared 
to untreated cells, [figure 7A]. Likewise, examination of COL-3 treated T cells [figure 
7B] in T cell proliferation assays reveals a dose-dependent decrease in proliferative 
ability as the concentration of COL-3 increases from 1μM to 100μM (p<0.001). 
Collectively, these data demonstrate that broad-spectrum MMP inhibition abrogates 
alloantigen-induced and anti-CD3 Ab-induced T cell proliferation, thereby confirming 
the in vivo data from the rat lung transplant model (106), suggesting an important role for 
MMPs in T cell activation. 
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Figure 7. Broad spectrum MMP inhibition by COL-3 (1-100μM) reduced 
alloantigen and anti-CD3 induced T cell proliferation 
Pure splenic CD4+ T cells were isolated from Balb/c or C57BL/6 mice. A) CD4+ Balb/c T cells were 
treated with varying concentrations of 1,10 phenanthroline (1-100μM) and cocultured with allogeneic 
(C57BL/6) dendritic cells at various ratios (0.01-0.15:1 DC:T cell). B) CD4+ T cells isolated from 
C57BL/6 mice were treated with varying concentrations of COL-3 (1-100μM). Cells were then 
washed in RPMI and plated at 3x105/well in a 96 well plate in the presence of anti-CD3 Ab 
(0.5μg/ml). 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the culture. T cell 
proliferation was measured by the amount of 3H thymidine incorporation. These data are 
representative of the mean ± SD of one of three separate experiments performed in triplicate. 
*p<0.001 compared to anti-CD3 Ab stimulated untreated T cells. (n=3) 
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C. Anti-CD3 Ab- induced T cell proliferation is abrogated following specific MMP9 
inhibition 
 Many studies have used broad-spectrum MMP inhibitors (MMPIs) to prevent 
MMP activity. Many of the earlier reports studying the role of MMPs in various disease 
states have used broad-spectrum MMP inhibitors (MMPIs), such as COL-3. These 
inhibitors are designed to chelate the active-site zinc ions. However, they have also been 
shown to be problematic due to their lack of specificity and their effects on other non-
related signaling events. One such study reported that COL-3 inhibits the activity of 
protein kinase C (PKC) in mast cells, suggesting that COL-3 functions as more than just 
an MMPI and can negatively affect cell growth and differentiation (107). To circumvent 
these limitations, a MMP2 and MMP9 (gelatinase) specific mechanism-based inhibitor, 
SB3CT, was utilized, which irreversibly inhibits MMP9 by permanently blocking the 
cysteine switch interaction (47). That is, the inhibitor prevents activation by blocking the 
disruption of the cysteine residue (thiol group) interaction with the Zn2+ ion. As shown in 
figure 4, the thiirane sulfur group of the inhibitor first coordinates with the zinc in the 
active site of the MMP. The coordinated thiirane is then predisposes the inhibitor to 
nucleophilic attack by the glutamate located in the active site of the MMP. This 
mechanistic series of events leads to covalent modification and the loss of activity.  
 With the previous data implicating the importance of MMP inhibition in T cell 
activation, it was first important to determine if SB3CT inhibited MMP9 expression in 
CD4+ and CD8+ T cells. To accomplish this, CD4+ and CD8+ T cells were isolated from 
wild-type C57BL/6 mice were treated with 10µM of SB3CT for 6 hour, washed and then 
cultured in the presence of soluble anti-CD3 Ab for 72 hours. Cells were then collected 
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and processed for gene analysis by means of real-time PCR. SB3CT treated CD4+ T cells 
[figure 8A] and CD8+ T cells [figure 8B] exhibited fewer MMP9 gene transcripts as 
compared to vehicle treated cells. To assess enzymatic activity, CD8+ T cells were treated 
with 10μM of SB3CT for 6 hours, washed and then cultured in the presence of soluble 
anti-CD3 Ab for 24 hours. Cell lysates and conditioned media were collected and 
analyzed by substrate zymography. As shown in figure 8C, pro and active MMP9 is 
expressed in untreated CD8+ T cell lysate. Six hour treatment of SB3CT decreases the 
expression of active MMP9, while not decreasing pro-MMP9 expression. Following 
stimulation with anti-CD3 Ab, pro- and active MMP9 expression is diminished. 
Supernatant from SB3CT treated CD8+ T cells displayed a decrease in pro-MMP9 
expression, although some active MMP9 is still present. These data demonstrate that 
SB3CT inhibits MMP9 mRNA expression, as well as, pro- and active MMP9 protein 
expression.   
 Next, we wanted to determine whether specific MMP inhibition by means of  
SB3CT, would affect T cell activation in a similar manner as was shown following broad 
spectrum treatment with COL-3. To explore this, mixed leukocyte reactions were 
utilized. Dendritic cells (antigen presenting cells) isolated from C57BL/6 mice were co-
cultured at varying ratios (0.01, 0.075 and 0.15) in the presence of allogeneic T cells from 
Balb/c mice with the addition of varying concentrations of SB3CT (1-10µM) for 72 
hours. As expected, untreated T cells proliferated in response to alloantigen stimulus at 
all three ratios [figure 9A]. As shown in figure 9A, 0.01μM (striped bar) and 1 μM 
(shaded bar) of SB3CT showed proliferative responses similar to those seen in untreated  
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Figure 8. MMP9 specific inhibition by SB3CT treatment abrogates MMP9 
expression in CD4+ and CD8+ T cells 
A) Pure splenic CD4+ and B) CD8+ T cells were isolated from wild-type C57BL/6 mice. Cells were 
treated with 10μM of SB3CT or VCtl for 6 hours, then plated at 2x106/tube in 3ml tissue culture tubes 
in the presence of anti-CD3 Ab (0.5μg/ml) for 24 hours. MMP9 mRNA expression levels were 
measured by real-time quantitative PCR. These data are representative of two separate experiments 
performed in triplicate (n=2) C) Gelatin zymogram analysis of CD8 T cell lysates and supernatant. 
n=1  
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Figure 9. MMP9 specific inhibition by SB-3CT (1-30μM) reduced alloantigen and 
anti-CD3 induced T cell proliferation 
Pure splenic CD4+ and CD8+ T cells were isolated from Balb/c or C57BL/6 mice. A) CD4+ Balb/c T 
cells were treated with varying concentrations of SB3CT (0.01-10μM) or vehicle (VCtl) and 
cocultured with allogeneic (C57BL/6) dendritic cells at various ratios (0.01-0.15:1 DC:T cell). B) 
C57BL/6 CD4+ T cells or C) CD8+ T cells were treated with varying concentrations of SB3CT (5-
30μM) or VCtl for 6 hours. Cells were then washed in RPMI and plated at 3x105/well in a 96 well 
plate in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. 18 hours prior to harvest, 3H thymidine 
(0.5μCi/well) was added to the culture. T cell proliferation was measured by the amount of 3H 
thymidine incorporation. These data are representative of the mean ± SD of one of three separate 
experiments performed in triplicate. *p<0.001 compared to anti-CD3 Ab stimulated untreated T cells. 
(n=3) 
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cells (white bar). Strikingly, treatment of cells with 10µM of SB3CT (black bar) 
completely abrogated T cell proliferation.  
 To next investigate T cells specifically, CD4+ and CD8+ T cells were isolated 
from wild-type C57BL/6 mice and treated with varying concentrations of SB3CT (5-
20μM) for 6 hour, washed and then cultured in the presence of soluble anti-CD3 Ab for  
72 hours. Notably, SB3CT treated CD4+ [figure 9B] and CD8+ [figure 9C] T cells 
exhibited a dose-dependent decrease in proliferative ability in response to anti-CD3 Ab 
stimulation, as compared to vehicle treated cells. These data corroborate the previous data 
shown with broad-spectrum MMPIs and further suggest that specific gelatinolytic MMP 
inhibition significantly abrogates T cell activation.  
 
D. SB3CT does not induce cell death or anergy in CD4+ or CD8+ T cells 
 It is well known that the activation of T cells via ligation of the T cell receptor 
(TCR) induces a myriad of signaling events, including an increase in intracellular 
calcium that leads to the nuclear translocation of NFAT (nuclear factor of activated T 
cells) which activates the transcription of many pleiotropic genes, such as IL-2 and the 
IL-2 receptor (CD25). The data raise thus far the possibility that the decrease in T cell 
activation may be due to cell death or anergy. Trypan blue exclusion along with annexin 
V and propidium iodide (PI) staining, used to detect early cell death revealed that cell 
viability was greater than 90 percent following treatment with SB3CT, suggesting that 
the decrease in proliferative ability is not due to cells death [figure 10]. To assess whether 
or not SB3CT treatment induces T cell anergy, T cell proliferation assays were utilized, 
in which exogenous IL-2 was added to vehicle or SB3CT treated T cells cultured in the 
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Figure 10. Cell viability of SB3CT treated CD4+ T cells 
Pure splenic CD4+ T cells were isolated from wild-type C57BL/6 mice. Cells were treated with 10μM 
of vehicle or SB3CT for 6 hours. Cells were collected and stained with annexin V and propidium 
iodide (PI). Cells were analyzed by flow cytometry. These data are representative of the mean ± SD of 
one of two separate experiments (n=2).  
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Figure 11. Exogenous IL-2 partially rescues anti-CD3 induced T cell proliferation in 
response to SB3CT treatment 
Pure splenic CD4+ and CD8+ T cells were isolated from C57BL/6 mice. A) CD4+ T cells or B) CD8+ T 
cells were treated with varying concentrations of SB3CT (5-30μM) or VCtl for 6 hours. Cells were 
then washed in RPMI and plated at 3x105/well in a 96 well plate in the presence of anti-CD3 Ab 
(0.5μg/ml) with 20U of IL-2 for 72 hours. 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was 
added to the culture. T cell proliferation was measured by the amount of 3H thymidine incorporation. 
These data are representative of the mean ± SD of one of three separate experiments performed in 
triplicate. #p<0.05, *p<0.001 compared to anti-CD3 Ab stimulated untreated T cells. (n=3)  
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presence of soluble anti-CD3 Ab. As shown in [figure 11A] (CD4+ T cells) and [figure 
11B] (CD8+ T cells), the addition of IL-2 induced partial recovery of the proliferative 
response in CD4+ and CD8+ T cells treated with 5μM of SB3CT, and increased the 
overall proliferative counts in all treatment groups as compared to the data shown in 
figure 9 (SB3CT + anti-CD3 Ab in the absence of exogenous IL-2). These data suggest 
that although partial recovery of T cell proliferation was shown in response to exogenous 
IL-2, the question of anergy remains unknown. This data does however reinforce that the 
cells are not undergoing cell death due to their ability to respond to IL-2 treatment. 
 One other possibility that may be responsible for the lack of a proliferative 
response may be that the drug (SB3CT) was not fully washed from the cells and therefore 
was still present in the supernatant. To investigate this possibility, T cell proliferation 
assays were performed, in which, CD4+ T cells were treated with varying concentrations 
of SB3CT (10µM-1mM) for 6 hours. The cells were then washed and cultured for 48 
hours. Following the 48 hour period, cell supernatants were collected and transferred to 
freshly plated CD4+ T cells. These cells were cultured for 72 hours in the presence of 
soluble anti-CD3. As shown in figure 12, fresh T cells that were given cell supernatant 
from the 10µM SB3CT treatment group display a proliferative trend similar to that seen 
in untreated cells. 10-fold and 100 fold higher concentrations of supernatant completely 
abrogated T cell proliferation. These results confirm that at 10µM treatment, SB3CT is 
effectively washed from the cells and does not remain in the media. This is of importance 
because 10μM SB3CT is the concentration that was used in the majority of the 
experiments performed. Additionally, these data ensure that in later experiments in which  
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Figure 12. Cell Supernatant from T cells treated with 10µM SB3CT does not alter 
proliferation when added to fresh untreated T cells  
Pure splenic CD8+ T cells were treated with varying concentrations of SB3CT (5-30μM) for 6 hours. 
Cells were then washed in RPMI and plated at 3x105/well in a 96 well plate in the presence of anti-
CD3 Ab (0.5μg/ml) for 72 hours. Cell supernatants were then added to freshly isolated T cells cultured 
in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. 18 hours prior to harvest, 3H thymidine 
(0.5μCi/well) was added to the culture. T cell proliferation was measured by the amount of 3H 
thymidine incorporation. These data are representative of the mean ± SD of one experiment performed 
in quadruplicate. (n=1) 
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untreated T cells are co-cultured in the presence of SB3CT treated T cells, the effects that 
are observed will not be due to residual SB3CT in the media. 
 
E. Anti-CD3 Ab- induced proliferation is diminished in MMP9 deficient  CD4+ and  
 CD8+ T cells  
 With the continual advancement of mouse models and the development of MMP 
genetically deficient mice, we next examined the proliferative capacity of MMP deficient 
T cells by means of T cell proliferation assays. CD4+ and CD8+ T cells were isolated 
from MMP2, MMP9 and MMP2/9 deficient C57BL/6 mice and their corresponding wild-
type littermates and cultured in the presence of soluble anti-CD3 Ab for 72 hours. As 
compared to wild-type T cells, MMP2 deficient T cells only exhibited a 20% decrease in 
proliferation [figure 13A]. Examination of MMP2/9 deficient T cells displayed a 40% 
decrease in proliferation [figure 13B]. Interestingly, MMP9 deficient cells displayed an 
80% decrease in proliferative ability [figure 14A] (p<0.001). 
 Since the most pronounced decrease in T cell proliferation was seen following 
MMP9 deficiency, we also examined the proliferative ability of MMP9 deficient CD8+   
T cells. CD8+ T cells from MMP9 deficient mice and their wild-type littermates were 
again cultured in the presence of soluble anti-CD3 Ab just as in previous experiments. 
Surprisingly, the results revealed a significant decrease in T cell proliferation similar to 
that seen in CD4+ T cells [figure 14B] (p<0.001). These results confirm our previous 
findings and emphasize a key role of MMP9 in the process of T cell activation.  
 In addition to the anti-CD3-TCR ligation, there is a second co-stimulatory signal 
that occurs via interaction between the B7 family members, B7.1 or B7.2, on the antigen- 
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Figure 13. MMP2 and MMP2/9 deficient CD4+ T cells display altered proliferative 
ability 
CD4+ T cells were isolated from wild-type and A) MMP2 or B) MMP2/9 deficient mice. Cells were 
plated at 3x105/well in a 96 well plate in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. 18 
hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the culture. T cell proliferation was 
measured by the amount of 3H thymidine incorporation. These data are representative of the mean ± 
SD of one of three separate experiments performed in triplicate. (n=3) *P=0.02,**p<0.001 compared 
to wild-type T cells.  
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Figure 14. MMP deficient CD4+ and CD8+ T cells display impaired proliferative 
ability 
A) CD4+ and B) CD8+ T cells were isolated from wild-type and MMP9 deficient mice. Cells were 
plated at 3x105/well in a 96 well plate in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. 18 
hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the culture. T cell proliferation was 
measured by the amount of 3H thymidine incorporation. These data are representative of the mean ± 
SD of one of three separate experiments performed in triplicate. *p<0.001 compared to wild-type T 
cells. (n=3) 
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presenting cells and CD28 on the T cell. CD28 is a 44-kd subunit found on the surface of 
most CD4+ cells and 70% of CD8+ cells. Anti-CD28 monoclonal antibodies can 
substitute for the B7 ligand to stimulate CD28 on the T cell and provide a strong 
stimulatory signal. With this understanding, we to determine if co-stimulation with anti-
CD3/anti-CD28 Abs would alter the proliferation pattern of CD8+ T cells from MMP9 
deficient mice or following SB3CT treatment. To address the effects of co-stimulation on 
MMP9 deficient T cells, CD8+ T cells were isolated from MMP9 deficient C57BL/6 mice 
and their corresponding wild-type littermates and cultured in the presence of soluble anti-
CD3/anti-CD28 Abs for 72 hours. In the presence of co-stimulation T cell proliferation is 
increased in MMP9 deficient cells, as compared to wild-type co-stimulated cells [figure 
15A]. As shown previously, in the presence of anti-CD3 Ab and absence of anti-CD28 
Ab stimulation, MMP9 deficient T cells are abrogated, as compared to wild-type cells. 
These results demonstrate that anti-CD28 Ab co-stimulation is able to rescue the 
proliferative ability of MMP9 deficient CD8+ T cells.  
 To examine the effects of co-stimulation on SB3CT treated T cells, CD8+ T cells 
were isolated from wild-type C57BL/6 mice and treated with varying concentrations of 
SB3CT (1-25μM) for 6 hour, washed and then cultured in the presence of soluble anti-
CD3/anti-CD28 Abs for 72 hours. As displayed in figure 15B, there was a dose-
dependent decrease in T cell proliferation even in the presence of anti-CD3/anti-CD28 
Abs. These results are similar to those previously shown above in response to stimulation 
with anti-CD3 alone (figure 11B), demonstrating that anti-CD28 Ab co-stimulation does 
not rescue T cell proliferation following SB3CT treatment.  
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Figure 15. MMP9 deficient or SB3CT treated CD8+ T cell proliferative ability 
following anti-CD3/CD28 Ab stimulation  
A) CD8+ T cells were isolated from wild-type and MMP9 deficient mice. B) Wild-type CD8+ T cells 
were treated with varying concentrations of SB3CT (1-25μM). A and B) Cells were plated at 
3x105/well in a 96 well plate in the presence of anti-CD3 Ab or anti-CD3/anti-CD28 Ab (0.5μg/ml) 
for 72 hours. 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to the culture. T cell 
proliferation was measured by the amount of 3H thymidine incorporation. These data are 
representative of the mean ± SD of one of three separate experiments performed in triplicate. *p<0.01, 
**P<0.001 compared to the corresponding vehicle treatment group. (n=3) 
67 
 Based in the results above, MMP9 deficient T cells may be anergic, due to the 
fact that they can be rescued in response to the addition of anti-CD28 Ab, in the presence 
of anti-CD3 Ab. However, this is not the case in T cells treated with SB3CT. This implies 
that inhibition of MMP9 by gene deletion may alter T cell activation in a different 
manner than that observed by pharmacological inhibition. Since MMP9 deficient T cells 
positively responded to the addition of anti-CD28 Ab, this suggests that CD28 signaling 
is intact in the T cells in the absence of MMP9. However, in SB3CT treated T cells, the 
addition of anti-CD28 Ab did not rescue the proliferative response. In addition to the 
ability of SB3CT to decrease MMP9 gene transcripts, this pharmacological inhibitor may 
also interfere with the activating action of anti-CD28 Ab by preventing the CD28-anti-
CD28 Ab interaction, thereby inhibiting CD28 function and proliferation.  
 Although the TCR and CD28 are independent signaling components, they share 
many redundant downstream signaling pathways important in T cell activation. 
Consequently, it is very difficult to discriminate the effects of the two independent 
signaling components. Previous studies have identified the PI3K/AKT pathway and NF-
B as the most relevant CD28 biochemical targets. Further investigation is needed to 
clarify the co-stimulatory differences seen between MMP9 deficient and SB3CT treated 
T cells. Our data thus far does however, does imply that MMP9 inhibition by means of 
SB3CT or gene deletion, is likely to affect cell signaling events downstream of TCR 
ligation. We next investigated how MMP9 may be acting to regulate T cell activation and 
signaling events. 
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Chapter 2. T cell signaling events altered in response to matrix metalloproteinase 
inhibition 
A. Anti-CD3 Ab-induced calcium flux is elevated in MMP9 deficient CD4+ and 
CD8+ T cells in calcium-free media 
 It is well known that immediately following T cell receptor activation, there is an 
up-regulation of a multitude of events including the induction of specific protein tyrosine 
kinases, activation of protein kinase C and an increase in intracellular calcium flux (108, 
109) [figure 16]. This calcium flux can occur following the interaction of inositol 1, 4, 5-
triphosphate (IP3) with its receptor, thereby stimulating the release of intracellular 
calcium from the endoplasmic reticulum (ER) and/or as a result of calcium channels 
opening, thereby allowing an influx of exogenous calcium into the cell.  
 With the results thus far suggesting a clear role for MMP9 in T cell activation, 
and with the understanding of the necessity of calcium in the regulation of T cell 
signaling, we subsequently examined the effect of MMP9 inhibition on intracellular 
calcium release from the ER. As diagramed in figure 17, CD4+ and CD8+ T cells from 
MMP9 deficient C57BL/6 mice and wild-type littermates were plated in calcium-free 
assay buffer and loaded with fluoro-4 dye. Cells were then stimulated with 10µg of 
soluble anti-CD3 Ab and calcium flux was measured in real time for 300 seconds. 
Unexpectedly, CD4+ MMP9 deficient T cells exhibited a greater degree of intracellular 
calcium influx as compared to wild-type T cells [figure 18A]. CD8+ T cells revealed a 
similar trend, with MMP deficient T cells also displaying a greater degree of intracellular 
calcium flux than was seen in the wild-type cells [figure 18B]. Since the experiments 
were performed in calcium-free media, the increase in intracellular calcium flux 
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Figure 17. Diagram of calcium flux Assay  
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Figure 18. Anti-CD3 induced calcium flux is enhanced in MMP9 deficient T cells in 
the presence of calcium-free/divalent ion-reduced media 
Pure splenic A) CD4+ and B) CD8+ T cells were isolated from wild-type and MMP9 deficient mice. 
Cells were then plated at 1.25 x 105 /well in a 96-well plate in calcium-free/divalent ion-reduced 
media and loaded with Fluo-4 dye for 30 minutes at 37°C, followed by a 30 minute incubation at room 
temperature. Cells were then stimulated with 10μg of soluble anti-CD3 Ab and fluorescence read in 
real time (0-300sec). These data are representative of the mean ± SD of one of three separate 
experiments performed in triplicate (n=3).  
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observed, occurred as a result of calcium release from the ER. Taken together, these 
results may suggest that MMP9 deficient T cells may release more calcium as a 
compensatory mechanism to overcome their impaired activation. It is worth noting that 
the calcium-free media contained trace amount of other divalent ions that were capable of 
reacting with the fluoro-4 dye. This corresponds to the slight increase in calcium flux 
seen in the corresponding graphs following the initial spike of calcium flux, which 
corresponds to the release of calcium from the ER. 
 
B. MMP9 specific inhibition by SB3CT enhanced anti-CD3 Ab-induced calcium flux 
in calcium-free media 
 Since SB3CT treated CD8+ T cells seem to display the most dramatic changes in 
calcium influx, we next examined whether SB3CT treatment affected anti-CD3 Ab-
induced calcium influx in calcium-free media. CD8+ T cells were again isolated from 
wild-type C57BL/6 mice and treated with 10μM of SB3CT or the corresponding vehicle 
control for 6 hours. Cells were then washed and plated in calcium-free media, loaded 
with fluoro-4 dye and stimulated with 10μg anti-CD3 Ab and measured in real time for 
300 seconds. Similar to the results shown in CD8+ MMP9 deficient T cells stimulated 
with anti-CD3 Ab in calcium-free media, SB3CT treatment increases the amount of free 
intracellular calcium [figure 19], which is most likely due to the release of calcium from 
the ER.  
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C. MMP9 specific inhibition by SB3CT enhanced anti-CD3 Ab-induced calcium  
 influx in calcium containing media                                                                                                            
 To further examine the significance of MMP inhibition on anti-CD3 Ab-induced 
calcium flux, we next wanted to determine if the presence of exogenous calcium in the 
media would alter the influx of calcium following SB3CT treatment. Our hypothesis is 
that the presence of calcium in the media will cause an increase in calcium influx due to 
the influx of exogenous calcium from the media. CD4+ and CD8+ T cells were again 
isolated from wild-type C57BL/6 mice and treated with 10μM of SB3CT or the 
corresponding vehicle control for 6 hours. Cells were then washed and plated in calcium-
free media, loaded with fluoro-4 dye and stimulated with 10μg anti-CD3 Ab and 
measured in real time for 300 seconds. As predicted, there was a dramatic influx of 
exogenous calcium in CD8+ SB3CT treated cells following anti-CD3 Ab stimulation 
[figure 20].  
 Furthermore, the overall fluorescence was two-fold higher than that seen in 
calcium-free media. In the presence of calcium, the graph depicts a very pronounced 
release from the ER (large drop in the graph), followed by the initiation of the store 
operated calcium entry (SOCE), causing the influx of calcium into the cell. This trend in 
calcium influx is known based on thapsigargin, which raises the cytosolic calcium 
concentration by blocking the ability of the cell to pump calcium into the sarcoplasmic 
and endoplasmic reticula which causes these stores to become depleted. Store-depletion 
can secondarily activate plasma membrane calcium channels, allowing an influx of 
calcium into the cytosol. Taken together, these results demonstrate that SB3CT treatment  
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Figure 19. Anti-CD3 Ab-induced calcium flux is up-regulated in SB3CT treated 
CD8+ T cells in calcium-free/divalent ion-reduced media 
Pure splenic CD8+ T cells isolated from wild-type C57BL/6 mice were treated with 10μM of 
SB3CT or VCtl for 6 hours. Cells were then plated at 1.25 x 105 /well in a 96-well plate in 
calcium-free/divalent ion-reduced media and loaded with Fluo-4 dye for 30 minutes at 37°C, 
followed by a 30 minute incubation at room temperature. Cells were then stimulated with 10μg of 
soluble anti-CD3 Ab and fluorescence read in real time (0-300sec). These data are representative 
of the mean ± SD of one of three separate experiments performed in triplicate (n=3).  
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Figure 20. Anti-CD3 Ab-induced calcium flux is up-regulated in SB3CT treated 
CD8+ T cells in calcium-containing media 
Pure splenic CD8+ T cells isolated from wild-type C57BL/6 mice were treated with 10μM of SB3CT 
or VCtl for 6 hours. Cells were then plated at 1.25 x 105 /well in a 96-well plate in calcium-containing 
media and loaded with Fluo-4 dye for 30 minutes at 37°C, followed by a 30 minute incubation at room 
temperature. Cells were then stimulated with 10μg of soluble anti-CD3 Ab and fluorescence read in 
real time (0-300sec). These data are representative of the mean ± SD of one of three separate 
experiments performed in triplicate (n=3).  
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or MMP9 deficiency enhanced anti-CD3 Ab- induced calcium flux following T cell 
activation. 
 As a result of the calcium data demonstrating that MMP absence or inhibition  
enhances calcium signaling, it may be beneficial to observe other downstream pathways 
involved in calcium signaling, such as MEK1/2. Since intracellular calcium flux is 
elevated, analysis of the MEK1/2 pathway may provide further evidence that other T cell 
pathways are functional and aid in pinpointing potential intracellular MMP targets. 
MEK1/2 is activated by a wide variety of growth factors and cytokines and also by 
membrane depolarization and calcium influx (110). It is also worth noting that another 
interesting experiment to perform would be to examine MMP9 deficient T cells 
stimulated with anti-CD3 Ab in the presence of calcium.  
 
D. MMP9 inhibition by SB3CT does not prevent MEK1/2 activity in T cells 
 MEK1 and MEK2, also called MAPK or Erk kinases, are dual-specificity protein 
kinases that function in a mitogen activated protein kinase cascade [figure 21] that 
regulates cell growth and differentiation (110). Activation of MEK1 and MEK2 occurs 
through phosphorylation by Raf-like molecules of two serine residues at positions 217 
and 221, located in the activation loop. MEK1/2 is activated by a wide variety of growth 
factors and cytokines and also by membrane depolarization and calcium influx (110). 
Since calcium flux was altered in T cells, we were interested in examining another 
pathway present in T cell signaling to determine if this pathway is altered in response to 
MMP inhibition by SB3CT. To explore this, CD8+ T cells were isolated from wild-type  
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Figure 22. Total and phosphorylated MEK1/2 protein levels are maintained in 
SB3CT or vehicle treated CD8+ T cells  
CD8+ T cells were isolated from wild-type C57BL/6 mice and treated with 10μM of SB3CT or the 
corresponding vehicle control for 6 hours. Cells were then washed and cultured in the presence of 
soluble anti-CD3 Ab for varying time-points (5-60 minutes). The cells were then fixed and MEK1/2 
total and phosphorylated protein levels were measured. 0 min = non-stimulated group (n=1) 
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C57BL/6 mice and treated with 10μM of SB3CT or the corresponding vehicle control for 
6 hours. Cells were then washed and cultured in the presence of soluble anti-CD3 Ab for 
varying time-points (5-60 minutes). The cells were then fixed and MEK1/2 total and 
phosphorylated protein levels were measured. As shown in figure 22A, following 
treatment with SB3CT or vehicle, total MEK1/2 protein levels remain relatively low and 
consistent between 5-30 minutes. At 60 minutes however, there was a significant increase 
in protein expression. It is interesting to note that although there was a dramatic increase 
in expression,  this increase is seen in both the vehicle group as well as in the SB3CT 
treated group.  
 These data suggest that MEK1/2 total protein is unaltered following MMP9 
inhibition by SB3CT. Analysis of phosphorylated MEK1/2, [figure 22B] revealed a 
similar trend, showing that the levels of phosphorylated MEK1/2 were unaltered in the 
presence of SB3CT. Collectively, these data suggest that MEK1/2 protein functions 
properly in T cell signaling, even following MMP9 inhibition by SB3CT. This data may 
also imply that MMP9 may be either acting independently or downstream of the MAPK 
pathway, which may further suggest a potential intracellular target. 
 
E. Ionomycin-induced calcium flux is unaltered between wild-type and MMP9 
deficient CD4+ and CD8+ T cells in calcium-free media 
 T cells may also be activated when the transmembrane signaling process has been 
bypassed by treatment with pharmacological agents such as ionomycin, which can 
elevate intracellular calcium levels. To determine whether ionomycin, a calcium 
ionophore that shuttles calcium across the cell membrane, induces an increase in  
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Figure 23. No change in ionomycin-induced calcium flux between wild-type 
andMMP9 deficient T cells in the presence of calcium-free /divalent ion-reduced 
media 
Pure splenic A) CD4+ and B) CD8+ T cells were isolated from wild-type and MMP9 deficient mice. 
Cells were then plated at 1.25 x 105 /well in a 96-well plate in calcium-free/ divalent ion-reduced 
media and loaded with Fluo-4 dye for 30 minutes at 37°C, followed by a 30 minute incubation at room 
temperature. Cells were then stimulated with 10μM ionomycin and read in real time (0-300sec). These 
data are representative of the mean ± SD of one of three separate experiments performed in triplicate 
(n=3). 
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intracellular calcium release from the ER, similar to that seen following anti-CD3 Ab 
simulation, CD4+ and CD8+ T cells from MMP9 deficient C57BL/6 mice and wild-type 
littermates were plated in calcium-free assay buffer and loaded with fluoro-4 dye. Cells 
were then stimulated with 10µM of ionomycin and calcium flux was measured in real 
time for 300 seconds. Interestingly, there is no difference in ionomycin-induced calcium 
influx between CD4+ [figure 23A] or CD8+ [figure 23B] MMP9 deficient T cells and 
their wild-type littermates. Both cell groups equally produce an influx of intracellular 
calcium. These results suggest that in the absence of exogenous calcium from the media, 
ionomycin may be able to transverse the cell membrane and nonspecifically stimulate the 
release of calcium from the inside the cell, either from the ER or other intracellular 
components that contain calcium, such as the mitochondria. With regard to MMP9, it 
appears that intracellular calcium release from the ER is not affected by the absence of 
MMP9 following stimulation with ionomycin.   
 
F. Ionomycin-induced calcium flux is abrogated in MMP9 deficient CD4+ and CD8+ 
T cells in calcium containing media 
 Since calcium flux also involves the influx of exogenous calcium via calcium 
channels, following the release from the ER, we next wanted to determine if calcium 
channel function was altered in ionomycin-induced calcium influx in MMP9 deficient T 
cells. To study the influx of exogenous calcium, CD4+ and CD8+ wild-type and MMP9 
deficient T cells were plated in calcium containing media and loaded with fluoro-4 dye. 
As in the previous experiments, cells were again stimulated with 10µM of ionomycin and 
calcium flux was measured in real time for 300 seconds. As shown in figure 24A, 
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Figure 24. Ionomycin-induced calcium flux is abrogated in MMP9 deficient T cells 
in the presence of calcium-containing media 
Pure splenic A) CD4+ and B) CD8+ T cells were isolated from wild-type and MMP9 deficient mice. 
Cells were then plated at 1.25 x 105 /well in a 96-well plate in calcium containing media and loaded 
with Fluo-4 dye for 30 minutes at 37°C, followed by a 30 minute incubation at room temperature. 
Cells were then stimulated with 10μM ionomycin and read in real time (0-300sec). These data are 
representative of the mean ± SD of one of three separate experiments performed in triplicate (n=3). 
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exogenous calcium influx in CD4+ MMP9 deficient T cells was significantly impaired, 
when compared to wild-type cells. Observations of CD8+ MMP9 deficient T cells [figure 
24B] also revealed impairment of ionomycin-induced calcium influx, although to a lesser 
extent than that seen in CD4+ MMP9 deficient T cells. These data displayed differing 
results than those seen following anti-CD3 Ab TCR stimulation and suggest that MMP9 
also plays a role in ionomycin-induced exogenous calcium influx. In the absence of 
MMP9, ionomycin-induced calcium influx is impaired; suggesting that inhibition of 
normal MMP9 function within T cells impairs calcium channel function or alters 
membrane permeability. 
 
G. MMP-9 specific inhibition by SB3CT reduced ionomycin-induced calcium influx 
in a dose-dependent manner in CD4+ and CD8+ T cells in calcium containing 
media 
 Since MMP9 deficient T cells exhibited a defect in ionomycin-induced exogenous 
calcium signaling, we wanted to determine if inhibition of MMP9 by SB3CT would also 
affect ionomycin-induced calcium influx in a similar manner. To answer this question, 
calcium influx assays were performed, in which CD4+ and CD8+ T cells were isolated 
from wild-type C57BL/6 mice and treated with varying concentrations of SB3CT (5-
20μM) or the corresponding vehicle control for 6 hours. Cells were then washed and 
plated in calcium containing media, loaded with fluoro-4 dye and stimulated with 10μM 
ionomycin and measured in real time for 300 seconds. As shown in figure 25A, 5μM and 
10µM treatment of SB3CT [figure 25B] only slightly reduced calcium influx in CD4+ T  
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Figure 25. Ionomycin-induced calcium flux is down-regulated in SB3CT treated 
CD4+ T cells in calcium containing media  
Pure splenic CD4+ T cells isolated from wild-type C57BL/6 mice were treated with varying 
concentrations of SB3CT (5-20μM) or VCtl for 6 hours. Cells were then plated at 1.25 x 105 /well in a 
96-well plate and loaded with Fluo-4 dye for 30 minutes at 37°C, followed by a 30 minute incubation 
at room temperature. Cells were then stimulated with 10μM of ionomycin and read in real time (0-
300sec). These data are representative of the mean ± SD of one of three separate experiments 
performed in triplicate (n=3).  
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Figure 26. Ionomycin-induced calcium flux is significantly down-regulated in 
SB3CT treated CD8+ T cells in calcium containing media  
Pure splenic CD8+ T cells isolated from wild-type C57BL/6 mice were treated with varying 
concentrations of SB3CT (5-20μM) or VCtl for 6 hours. Cells were then plated at 1.25 x 105 /well in a 
96-well plate in calcium containing media and loaded with Fluo-4 dye for 30 minutes at 37°C, 
followed by a 30 minute incubation at room temperature. Cells were then stimulated with 10μM of 
ionomycin and read in real time (0-300sec). These data are representative of the mean ± SD of one of 
three separate experiments performed in triplicate (n=3).  
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cells. Increasing the concentration of SB3CT to 20µM [figure 25C] yielded a more 
pronounced reduction in calcium flux. 
Interestingly, in examining CD8+ T cells, treatment with SB3CT induced a dose-
dependent decrease in exogenous calcium influx [figure 26]. Five micromolar of SB3CT 
[figure 26A] caused a slight reduction in calcium influx. However, increasing the 
concentration of SB3CT to 10μM [figure 26B] produced a 50% decrease in calcium 
influx, whereas 20μM of SB3CT [figure 26C] completely abrogated the influx of  
exogenous calcium. Collectively, these data not only confirm those shown in the MMP9 
deficient T cells, but also imply that in the absence or inhibition of functional MMP9, T 
cells exhibit significant alterations in calcium signaling. Following anti-CD3 Ab 
stimulation of the TCR, in the absence of exogenous calcium, intracellular calcium 
release from the ER was shown to be more pronounced. Additionally, in the presence of 
exogenous calcium similar results were seen, with the absence or inhibition of MMP9 
leading to an increased influx of calcium. On the other hand, following ionomycin 
stimulation, calcium influx is either unaltered, as was shown in the absence of exogenous 
calcium, or abrogated, as was seen in the presence of exogenous calcium.  
 These data highlight the complexity of MMP9s role in T cell signaling events 
involved in activation and suggest that MMP9 may function differently in calcium 
signaling depending on the stimulus the T cell receives (TCR = antiCD3 v.s. non-specific 
= ionomycin). These differences may be due to the nature of the stimulus. Ionomycin is a 
lipid-soluble ionophore that acts as a mobile carrier of divalent cations across cell 
membranes. Treatment of cells with 10μM of ionomycin is sufficient to increase the 
permeability of the plasma membrane. Anti-CD3 Ab, is a polyclonal antibody that ligates 
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the TCR leading to receptor-mediated signaling events leading to calcium flux. Therefore 
the differences seen in calcium flux in T cells in response to the absence or inhibition of 
MMP9 reflect the differences in the T cells ability to response to different stimuli 
depending on the mode of action. 
 
H. MMP2 and MMP9 deficiency or inhibition by SB3CT alters CD25 and NFATc1  
 mRNA expression 
 It has been well established that NFAT is critical for T cell activation (111). 
NFAT is involved in promoting the transcription of IL-2Rα (CD25) and IL-2 expression 
following stimulation of the TCR [figure 27]. It has been reported that in T lymphocytes 
from NF-ATp-deficient mice, the expression of CD25 is severely impaired, causing 
delayed IL-2 receptor expression after T cell anti-CD3 Ab stimulation (112). These 
results highlight the importance of the NFAT-CD25 relationship. With this understanding 
and the results thus far showing a definite defect in T cell activation in response to the 
absence or inhibition of MMP9, we next examined the effect of SB3CT on NFAT mRNA 
expression. Since the data thus far show that CD4+ and CD8+ T cells respond similarly to 
treatment with SB3CT, CD4+ T cells were used in the next set of studies.  
 CD4+ T cells were isolated and treated with varying concentrations of SB3CT (5-
20μM) for 6 hours. Following treatment, CD4+ T cells were washed and cultured in the 
presence of soluble anti-CD3 Ab for 24 hours. MMP9 deficient CD4+ T cells were 
cultured in the presence or absence of soluble anti-CD3 Ab for 72 hours. Cells were then 
collected and analyzed by means of real-time PCR. Strikingly, SB3CT treatment 
abrogated NFATc1 expression in a dose-dependent manner, as compared to vehicle 
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Figure 28. SB3CT treatment and MMP2 and MMP9 deficiency abrogate NFATc1 
mRNA expression in CD4+ T cells 
Pure splenic CD4 T cells were isolated from wild-type and MMP9 deficient mice. A) CD4+ T cells 
were treated with varying concentrations of SB3CT (5-20μM) or VCtl for 6 hours. B) MMP2-/- and 
MMP9-/- CD4+ T cells and A were plated at 2x106/tube in 3ml tissue culture tubes in the presence of 
anti-CD3 Ab (0.5μg/ml) for 24 or 72 hours. Cells were then collected and NFATc1 mRNA expression 
levels were measured by real-time quantitative PCR. These data are representative of the mean ± SD 
of three separate experiments performed in triplicate. *p<0.001 compared to corresponding vehicle 
treatment group (in panel A) or Wt + anti-CD3 treated T cells (in panel B). (n=3) 
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treatment [figure 28A]. In accordance with this data, examination of MMP9 deficient 
CD4+ T cells also displayed a significant defect in their ability to express NFATc1 levels 
following stimulation, as compared to wild-type T cells [figure 28B]. However, 
examination of MMP2 deficient CD4+ T cells revealed that although NFATc1 levels 
were significantly less than that seen in wild-type T cells, levels were comparable in the  
presence or absence of anti-CD3 Ab [figure 28B]. NFAT translocation to the nucleus is 
required for efficient transcription of many genes, such as IL-2 and IL-2Rα. The 
interaction of IL-2 with its high affinity membrane receptor IL-2Rα (CD25) plays a key 
role in T cell activation. This process requires proper synthesis and expression of CD25, 
to which IL-2 can bind, leading to the cascade of events required for suitable activation.  
 With the finding that NFAT expression is altered in response to specific MMP9 
inhibition or its complete absence, we wanted to determine if this alteration would affect 
the expression of CD25, which is dependent on NFAT transcriptional expression (113). 
Based on this fact, we would expect CD25 expression to be decreased in response to the 
decrease in NFAT gene expression. To address this, wild-type CD4+ T cells were again 
treated with varying concentrations of SB3CT (5-20μM) or the corresponding vehicle 
control for 6 hours. Following treatment, CD4+ T cells were washed and cultured in the 
presence of soluble anti-CD3 Ab for 24 hours. Cells were then collected and analyzed by 
means of real-time PCR. As shown in figure 29A, the mRNA expression level of CD25 
in vehicle-treated cells following anti-CD3 Ab stimulation is similar to that observed in 
untreated cells stimulated with anti-CD3 Ab. This trend remains even as the 
concentration of vehicle treatment increases from 5-20μM. Interestingly, increasing the 
concentration of SB3CT treatment caused a decrease in CD25 mRNA expression in a  
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Figure 29. SB3CT treatment and MMP9 deficiency abrogate CD25 mRNA 
expression in CD4+ T cells 
Pure splenic CD4 T cells were isolated from wild-type and MMP9 deficient mice. A) CD4+ T cells 
were treated with varying concentrations of SB3CT (5-20μM) or VCtl for 6 hours. B) MMP2-/- and 
MMP9-/- CD4+ T cells and A) were plated at 2x106/tube in 3ml tissue culture tubes in the presence of 
anti-CD3 Ab (0.5μg/ml) for 24 or 72 hours. Cells were then collected and CD25 mRNA expression 
levels were measured by real-time quantitative PCR. These data are representative of the mean ± SD 
of three separate experiments performed in triplicate. *p<0.05, **p<0.01, ***p<0.001 compared to 
corresponding vehicle treatment group (in panel A) or Wild-type + anti-CD3 treated T cells (in panel 
B). (n=3) 
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dose-dependent manner [figure 29A]. These results were further confirmed upon 
examination of MMP9 deficient CD4+ T cells. In figure 29B, as compared to the elevated 
levels of CD25 seen in stimulated wild-type cells, CD25 expression is impaired in MMP9 
deficient T cells.  
 Additionally, examination of MMP2 deficient T cells also revealed diminished 
CD25 expression levels, although not as dramatic. These data point to the importance of 
MMP9 in regulating NFAT and CD25 expression, thereby affecting proper T cell 
activation. Taken together, these results further highlight the role of MMP9 in T cell 
activation. The decrease seen in NFAT and CD25 expression, both of which are regulated 
intracellularly, in response to MMP9 inhibition or absence suggests that MMPs may 
regulate T cell activation by targeting an intracellular substrate that affects NFAT and 
CD25 expression, thereby preventing proper T cell activation. 
 
I. MMP9 inhibition does not induce regulatory T cell function 
 Studies have shown that regulatory T cells (Tregs) are unable to proliferate or 
produce IL-2 following anti-CD3 Ab stimulation. However, Tregs are capable of 
suppressing proliferative responses and cytokine production by effector T cells (114). It 
has been reported that following TCR stimulation, nuclear NFAT expression in Tregs 
remains low, whereas in T helper cells nuclear NFAT levels increase. Inhibition of NFAT 
induction has been described as a hallmark of Tregs. Analysis of forkhead transcription 
factor ( Foxp3), a specific molecular marker of Tregs, revealed high mRNA and protein 
expression in Treg cells and low expression in naive T cells (115). Studies have shown 
that Foxp3 antagonizes NFAT function by competition for DNA binding sites and acting 
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as a transcriptional repressor. It has also been proposed that Foxp3 is induced in a variety 
of cell types as a general mechanism of negative immune regulation by repressing 
production of inflammatory cytokines (115). 
 To determine if MMP9 deficient or SB3CT treated T cells exhibited other Treg 
characteristics, we examined Foxp3 expression. CD4+ T cells were isolated from wild-
type and MMP9 deficient mice and cells were cultured in the presence or absence of 
soluble anti-CD3 Ab for 72 hours. Cells were then analyzed by means of real-time PCR. 
Surprisingly, as shown in figure 30A, foxp3 transcript levels were significantly increased 
in MMP9 deficient CD4+ T cells, as compared to MMP2 deficient and wild-type T cells. 
 We also examined SB3CT treatment on foxp3 expression in CD4+ T cells to 
determine if MMP9 inhibition by SB3CT would yield results similar to those seen in 
MMP9 deficient T cells. CD4+ T cells were isolated and treated with varying 
concentrations of SB3CT (5-20μM) for 6 hours. Following treatment, CD4+ T cells were 
washed and cultured in the presence of soluble anti-CD3 Ab for 24 hours. As shown in 
figure 30C, foxp3 transcript levels were significantly increased following 20μM 
treatment of SB3CT, as compared to vehicle treated cells. During this observation, we 
also measured the expression of interleukin 10 (IL-10), being that it is a suppressive 
cytokine predominantly secreted by CD4+ T cells along with a few others. IL-10 has 
important suppressive functions on immune responses and is involved in the maintenance 
of tolerance and blocks activation of cytokine synthesis by Th1 cells. MMP9 deficient 
CD4+ T cells and their wild-type control cells were cultured in the presence or absence of 
soluble anti-CD3 Ab for 72 hours. Cell culture supernatants were collected and protein  
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Figure 30. Foxp3 and IL-10 expression is elevated in MMP9 deficient and SB3CT 
treated CD4+ T cells 
Pure splenic CD4+ T cells were isolated from wild-type and MMP2 and MMP9 deficient mice. A) 
Cells were plated in a 96 well plate in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. Cells 
were collected and foxp3 gene expression was measured by quantitative real-time PCR. B) Culture 
supernatants were collected and assayed for IL-10 using a Cytometric Bead Array (CBA). The beads 
were washed and analyzed by flow cytometry. C) CD4+ T cells were treated with varying 
concentrations of SB3CT (5-20μM) or VCtl for 6 hours. Cells were collected and foxp3 mRNA levels 
were measured by real-time quantitative PCR. These data are representative of the mean ± SD of one 
of three separate experiments performed in triplicate (n=3).  
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expression was analyzed by cytokine bead array. Interestingly, as shown in figure 30B, 
IL-10 protein expression is significantly elevated in anti-CD3 Ab stimulated MMP2 and 
MMP9 deficient T cells, suggesting that MMP inhibition may induce cells to exhibit a 
suppressive nature. 
 We next wanted to determine if inhibition of MMP9 induces regulatory T cell 
function, thereby causing a suppressive effect, leading to the decrease in T cell 
proliferation. To address this concept, suppressor assays [figure 31A] were utilized in 
which, CD4+25- T cells were treated for 6 hours with 10μM of SB3CT or the vehicle 
control. These cells were then co-cultured at varying ratios (1:1, 2:1, 4:1, 6:1 treated: 
untreated) with untreated CD4+25- T cells in the presence of irradiated antigen presenting 
cells (APCs). Seventy-two hours later we measured the ability of SB3CT treated T cells 
to inhibit/suppress the proliferative capacity of untreated CD4+25- T cells. As shown in 
figure 31B, SB3CT treatment at each ratio (1:1-6:1 treated: untreated) inhibited T cell 
proliferation by 50%. However, as the ratio of SB3CT treated cells increased, T cell 
proliferation also increased, suggesting that SB3CT treatment does not induce regulatory 
T cell function. For this to be the case, we would have expected to see that as the number 
of SB3CT treated cells increased there should have been a significantly larger decrease in 
T cell proliferation. 
 Likewise, when CD4+25+ T cells [figure 32A] were treated with SB3CT and co-
cultured at varying ratios (.5:1 and 1:1 treated:untreated) with untreated CD4+25- T cells 
in the presence of irradiated APCs, it was found that CD4+25+ T cells retained their 
suppressive function [figure 32B]. Worth noting however is that, SB3CT treated 
CD4+25+ T cells displayed somewhat altered suppressive ability, requiring more treated 
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Figure 31. SB3CT treatment does not induce suppressor T cell function 
A) Diagram of suppressor assay. B) Pure splenic CD4+ T cells were isolated from C57BL/6 mice. 
CD4+25- T cells were treated with 10μM of SB3CT or VCtl for 6 hours. Cells were then washed in 
RPMI and plated at varying ratios (1-6:1 treated CD4+25-:fresh CD4+25-) in a 96 well plate in the 
presence of anti-CD3 (0.5μg/ml). 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to 
the culture. T cell proliferation was measured by the amount of 3H thymidine incorporation. These 
data are representative of the mean ± SD of one of three separate experiments performed in triplicate 
(n=3). *p<0.01, **p<0.001 as compared to vehicle in each ratio.  
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Figure 32. SB3CT treatment does not induce regulatory T cell function 
A) Diagram of regulatory T cell assay B) Pure splenic CD4+ T cells were isolated from C57BL/6 
mice. CD4+25+ T cells were treated with 10μM of SB3CT or VCtl for 6 hours. Cells were then washed 
in RPMI and plated at varying ratios (.5-1:1 treated CD4+25+:fresh CD4+25-) in a 96 well plate in the 
presence of anti-CD3 (0.5μg/ml). 18 hours prior to harvest, 3H thymidine (0.5μCi/well) was added to 
the culture. T cell proliferation was measured by the amount of 3H thymidine incorporation. These 
data are representative of the mean ± SD of one of three separate experiments performed in triplicate 
(n=3). *p<0.01, **p<0.001 as compared to vehicle in each ratio.  
 98 
cells to exhibit their suppressive nature [figure 32B]. The reasoning behind the increase 
in foxp3 and IL-10 levels remains unclear. Taken together, these data suggest that MMP9 
inhibition does not induce a mechanism of regulatory T cell function. These data do 
however suggest MMP9 involvement in foxp3 and IL-10 expression. 
 
J. Production of IL-2, TNF-α and IFN-γ in MMP9 deficient CD4+ and CD8+ T cells 
 In an effort to further understand how MMP9 regulates intracellular T cell 
signaling, we sought to examine the effects of MMP9 deficiency on T cell cytokine gene 
and protein expression. Three cytokines of interest were chosen, IL-2, TNF-α and IFN-γ. 
IL-2 is produced primarily by antigen activated T cells, and as such it is known to 
stimulate proliferation in T cells. Therefore changes seen in T cell proliferation may be 
due to changes in the production of IL-2. IL-2 has also been shown to be a potent inducer 
of IFN-γ gene expression in T cells (116). TNF-α is a major pro-inflammatory cytokine, 
that can exert multiple stimulatory activities on activated T cells. TNF-α enhances 
expression of IL-2 receptors and synergizes with IL-2 with respect to both stimulation of 
T cell proliferation and production of IFN-γ (117). IFN-γ is the hallmark cytokine of Th1 
cells and is expressed in CD8+ T cell (118). 
 To examine the effects of MMP9 deficiency on T cell cytokine gene production, 
mRNA expression levels for IL-2, TNF-α and IFN-γ in MMP9 deficient CD4+ and CD8+ 
T cells and their wild-type littermates were measured by means of real-time PCR. CD4+ 
and CD8+ T cells were cultured in the presence of soluble anti-CD3 Ab for 72 hours. Cell 
pellets were then collected and processed for real-time PCR and the supernatants were 
collected and analyzed by means of cytokine bead array. Gene expression levels in CD4+ 
99 
 
Figure 33. Cytokine gene profile of IL-2, 
TNF-α and IFN-γ in MMP9 deficient 
CD4+ T cells  
Pure splenic CD4+ T cells were isolated from wild-
type and MMP9 deficient mice. Cells were plated 
at 2x106/tube in 3ml tissue culture tubes in the 
presence or absence of anti-CD3 Ab (0.5μg/ml) 
for72 hours. Cells were collected and IL-2, TNFα, 
and IFN-γ were measured by real-time quantitative 
PCR. These graphs are representative of one of 
three separate experiments performed in triplicate 
(n=3). *p<0.001 as compared to stimulated wild-
type cells.   
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Figure 34. Cytokine protein profile of 
IL-2, TNF-α and IFN-γ in MMP9 
deficient CD4+ T cells  
Pure splenic CD4+ T cells were isolated from 
wild-type and MMP9 deficient mice. Cells were 
plated at 2x106/tube in 3ml tissue culture tubes 
in the presence or absence of anti-CD3 Ab 
(0.5μg/ml) for72 hours. Culture supernatants 
were collected and assayed using a Cytometric 
Bead Array (CBA). Fifty microliters of 
supernatant from each sample was added to 
50μl of cytokine capture beads and incubated at 
room temperature for 2 hours. The beads were 
washed and analyzed by flow cytometry. These 
graphs are representative of one of two separate 
experiments performed in triplicate (n=3). 
*p<0.01, **p<0.001, ***p<0.0001 as compared 
to stimulated wild-type cells. 
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MMP9 deficient T cells displayed a significant decrease in IL-2, with a dramatic increase 
in TNF-α and IFN-γ, as compared to wild-type CD4+ T cells [figure 33A-C]. Strikingly, 
supernatants from CD4+ MMP9 deficient T cells, as compared to wild-type, showed 
significantly lower levels of IL-2 [figure 34A], TNF-α [figure 34B] and IFN-γ [figure 
34C] protein expression, with IL-2 and TNF-α displaying a 50% decrease and IFN-γ 
displaying an 80-90% decrease. The discrepancy in the mRNA and protein expression 
levels of TNF-α and IFN-γ remain unclear. Increasing the replicates in the sample size 
may clarify this discrepancy. 
 Examination of mRNA levels in CD8+ MMP9 deficient T cells revealed 
significantly diminished levels of IL-2, IFN-γ, and to a lesser extent, although still 
pronounced, TNF-α [figure 35A-C]. In addition, supernatants from CD8+ MMP9 
deficient T cells showed diminished levels of TNF-α [figure 36A] and IFN-γ [figure 36B] 
protein expression very similar to those seen in the CD4+ T MMP9 deficient T cells (due 
to limited sample size, IL-2 data was not assessed). These results indicate that T cells 
deficient in MMP9 exhibit altered cytokine production at the mRNA and protein levels. If 
we combine these results with the previous observation that IL-10 and foxp3 expression 
were elevated and that NFAT and CD25 expression were diminished in the absence of 
MMP9, then these findings suggest that although MMP inhibition does not induce Treg 
function, these cells exhibit regulatory T cell characteristics in response to the absence of 
MMP9. These data may suggest a role of foxp3 in inhibiting NFAT and repressing 
cytokine expression as is seen in Tregs. 
 It has been previously reported that in addition to the alterations in cytokine 
expression, MMP9 deficient mice display alterations in chemokine expression (95).  
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Figure 35. Cytokine gene profile of 
IL-2, TNF-α and IFN-γ in MMP9 
deficient CD8+ T cells  
Pure splenic CD8+ T cells were isolated from 
wild-type and MMP9 deficient mice. Cells 
were plated at 2x106/tube in 3ml tissue 
culture tubes in the presence or absence of 
anti-CD3 Ab (0.5μg/ml) for72 hours. Cells 
were collected and IL-2, TNFα, and IFN-γ 
were measured by real-time quantitative PCR. 
These graphs are representative of one of 
three separate experiments performed in 
triplicate (n=3). *p<0.01, **p<0.0001 as 
compared to stimulated wild-type cells. 
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Figure 36. Cytokine protein profile of TNF-α and IFN-γ in MMP9 deficient CD8+ T 
cells  
Pure splenic CD8+ T cells were isolated from wild-type and MMP9 deficient mice. Cells were plated 
at 2x106/tube in 3ml tissue culture tubes in the presence or absence of anti-CD3 Ab (0.5μg/ml) for 72 
hours. Culture supernatants were collected and assayed using a Cytometric Bead Array (CBA). Fifty 
microliters of supernatant from each sample was added to 50μl of cytokine capture beads and 
incubated at room temperature for 2 hours. The beads were washed and analyzed by flow cytometry. 
These graphs are representative of one of two separate experiments performed in triplicate (n=2).  
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Figure 37. MCP-1 expression is elevated in MMP9 deficient CD4+ T cells  
Pure splenic CD4+ T cells were isolated from wild-type and MMP9 deficient mice. Cells were plated 
at 2x106/tube in 3ml tissue culture tubes in the presence or absence of anti-CD3 Ab (0.5μg/ml) for 72 
hours. Culture supernatants were collected and assayed using a Cytometric Bead Array (CBA). Fifty 
microliters of supernatant from each sample was added to 50μl of cytokine capture beads and 
incubated at room temperature for 2 hours. The beads were washed and analyzed by flow cytometry. 
This graph is representative of one experiments performed in triplicate (n=1)  
105 
Campbell et al. reported an increase in MCP-1, MCP-5 and RANTES (95). To determine 
if these changes were present in our studies, we examined the expression of MCP-1 from 
MMP9 deficient T cell supernatant. Our preliminary data also revealed an increase in 
MCP-1 protein expression in MMP9 deficient T cells following stimulation with anti-
CD3 Ab [figure 37]. Although it is not clear, what importance MCP-1 plays in our 
studies, the increase in MCP-1 may be due to the T cell trying to compensate for the 
defect in T cell activation. Since MCP-1 is a chemokine important in guiding cellular 
infiltration or trafficking, its up-regulation in MMP9 deficient T cells may aid in their 
cellular migration. 
 
K. Production of IL-2, TNF-α, and IFN-γ are reduced in SB3CT treated CD4+ and 
CD8+ T cells 
 To determine the effects of MMP9 inhibition by SB3CT on T cell cytokine 
production and identify any correlation with MMP9 deficiency, mRNA and protein 
expression levels of IL-2, TNF-α and IFN-γ were measured by means of real-time PCR 
and a cytokine bead array, respectively. Wild-type CD4+ T cells were treated with 
SB3CT or the corresponding vehicle control for 6 hours, followed by stimulation with 
soluble anti-CD3 Ab for varying time points (1-12 hours). The cell pellets were collected 
and processed for real-time PCR and the supernatants were collected and analyzed by 
means of a cytokine bead array. In figure 38, vehicle treated CD4+ T cells exhibit 
increasing levels of IL-2 [figure 38A], TNF-α [figure 38B] and IFN-γ [figure 38C] 
mRNA expression in relation to time. In response to SB3CT treatment however, mRNA 
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Figure 38. Cytokine mRNA profile 
of IL-2, TNF-α and IFN-γ 
expression in SB3CT treated CD4+ 
T cells  
Pure splenic CD4+ T cells were isolated 
from C57BL/6 mice and treated with 
10μM of SB3CT or VCtl for 6 hours. 
Cells were then washed in RPMI and 
plated at 2x106/tube in 3ml tissue culture 
tubes in the presence of anti-CD3 Ab 
(0.5μg/ml) for 1-12 hours. Cells were 
collected and IL-2, TNFα and IFN-γ 
mRNA levels were measured by real-time 
quantitative PCR. These graphs are 
representative of one of three separate 
experiments performed in triplicate (n=3). 
*p>0.01, **p>0.001 as compared to the 
corresponding vehicle treated group. 
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Figure 39. Cytokine protein profile of 
TNF-α and IFN-γ in SB3CT treated 
CD4+ T cells  
Pure splenic CD8+ T cells were isolated 
from C57BL/6 mice and treated with 10μM 
of SB3CT or VCtl for 6 hours. Cells were 
then washed in RPMI and plated at 
2x106/tube in 3ml tissue culture tubes in 
the presence of anti-CD3 Ab (0.5μg/ml) for 
1-12 hours. Culture supernatants were 
collected and assayed using a Cytometric 
Bead Array (CBA). Fifty microliters of 
supernatant from each sample was added to 
50μl of A) IL-2, B) TNF-α or C) IFN-γ 
cytokine capture beads and incubated at 
room temperature for 2 hours. The beads 
were washed and analyzed by flow 
cytometry. These graphs are representative 
of one of two separate experiments 
performed in triplicate two experiments 
(n=2). 
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Figure 40. Cytokine gene 
and protein expression 
of IL-2, TNF-α and IFN-
γ are reduced in SB3CT 
treated CD8+ T cells  
Pure splenic CD8+ T cells 
were isolated from C57BL/6 
mice and treated with 10μM 
of SB3CT or VCtl for 6 hours. 
Cells were then washed in 
RPMI and plated at 
2x106/tube in 3ml tissue 
culture tubes in the presence 
of anti-CD3 Ab (0.5μg/ml) for 
1-6 or 1-12 hours. Cells were 
collected and A) IL-2 and B) 
IFN-γ mRNA expression 
levels were measured by real-
time quantitative PCR. 
Culture supernatants were 
collected and assayed using a 
Cytometric Bead Array 
(CBA). Fifty microliters of 
supernatant from each sample 
was added to 50μl of C) TNF-
α cytokine capture beads and 
incubated at room temperature 
for 2 hours. The beads were 
washed and analyzed by flow 
cytometry. These graphs are 
representative of one of two 
separate experiments 
performed in triplicate two 
experiments (n=2).  
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Figure 41. Cytokine protein production of TNF-α and IFN-γ are reduced in SB3CT 
treated CD8+ T cells  
Pure splenic CD8+ T cells were isolated from C57BL/6 mice. Cells were treated with 10μM of SB3CT 
or Vehicle (VCtl) for 6 hours. Cells were then washed three times in RPMI and plated at 2x106/tube in 
3ml tissue culture tubes in the presence of anti-CD3 Ab (0.5μg/ml) for 72 hours. Culture supernatants 
were collected and assayed using a Cytometric Bead Array (CBA). Fifty microliters of supernatant 
from each sample was added to 50μl of A) TNF-α and B) IFN-γ cytokine capture beads and incubated 
at room temperature for 2 hours. The beads were washed and analyzed by flow cytometry. These 
graphs are representative of two experiments (n=2).  
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levels are dramatically lower, even with the slight increase in IL-2, TNF-α and IFN-γ 
mRNA expression over time. 
 Observation of protein expression reveals significantly lower levels of all three 
cytokines in SB3CT treated CD4+ T cells over the 12 hour period, as compared to protein 
levels produced from vehicle treated cells [figure 39A-C]. In contrast, examination of 
vehicle or SB3CT treated CD8+ T cells revealed variable mRNA expression levels. There 
does not seem to be a distinct trend in the expression levels over time. IL-2 expression 
appears to peak at 4 hours and then decrease over time, with not much distinction 
between vehicle or SB3CT treatment [figure 40A]. IFN-γ mRNA expression in SB3CT 
treated CD8+ T cells appears to plateau over the duration of time, while vehicle treated 
cells display a slight decrease in expression from 4 to 24 hours [figure 40B]. Due to the 
limited sample size, TNF-α mRNA expression was not assessed. In examining protein 
expression, TNF-α protein expression appears to be similar between the vehicle and 
SB3CT treated T cells until 12 hours, when expression in SB3CT treated cells seems to 
decline as vehicle treated cells continues to rise [figure 40C] (due to sample size, IL-2 
and IFN-γ expression was not assessed). When cell supernatants were analyzed 72 hours 
after stimulation, TNF-α [figure 41A] and IFN-γ [figure 41B] protein expression were 
still reduced. Taken together, these data confirm that inhibition of T cell derived MMP9 
by SB3CT alters cytokine production at the mRNA and protein levels. 
 
L. MMP9 deficiency alters CD4+ and CD8+ T cell phenotypes  
 To further characterize the role of T cell derived MMP9, the cell phenotype of 
MMP9 sufficient T cells, as well as MMP9 deficient T cells were assessed by means of 
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flow cytometry. A panel of seven cell surface markers were chosen, because their 
expression is elevated following T cell activation and, as such are T cell activation 
markers. CD45RO is an isoform of the transmembrane tyrosine phosphatase CD45, 
present on CD4+ effector cells. CD45 regulates the threshold of T cell antigen receptor 
(TCR) signaling through dephosphorylation of protein tyrosine kinases (119). CD69 is 
the earliest inducible cell surface glycoprotein acquired during lymphoid activation, and 
is involved in lymphocyte proliferation (120). CD25 is the alpha chain of the IL-2 
receptor and is a type I transmembrane protein present on activated T cells (121). CD40L 
is a membrane glycoprotein and differentiation antigen expressed on the surface of T-
cells, that co-stimulates proliferation of activated T-cells, accompanied by the production 
of IFN-γ, TNF-α, and IL-2 (122). CD44 is a cell-surface glycoprotein involved in cell-
cell interactions, cell adhesion and migration along with T cell activation (123). CTLA-4 
is a member of the immunoglobulin super-family, which is expressed on the surface of T 
cells and transmits an inhibitory signal to T cells (124). Intracellular CTLA4 is also found 
in regulatory T cells and may be important to their function. CD62L is a cell adhesion 
molecule found on leukocytes (125).  
 CD4+ and CD8+ T cells isolated from wild-type and MMP9 deficient C57BL/6 
mice were cultured in the presence or absence of soluble anti-CD3 Ab for 24 hours. Cells 
were then collected and stained for CD45RO-FITC, CD69-FITC, CD25-PE, CD40L-PE, 
CD44-PE, CTLA-4-PE and CD62L-APC. Analysis of wild-type CD4+ T cells revealed 
increased surface expression levels of CD25, CD69, CD62L, and CD44. CTLA-4 and 
CD40L were also expressed, although at lower levels, while CD45RO expression was 
significantly diminished [figure 42]. In comparison, analysis of CD4+ T cells from 
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MMP9 deficient T cells revealed increased surface expression levels of CD62L, CTLA-4 
and CD45RO. CD44 and CD40L were expressed as well, although at lower levels. CD25, 
CD69 and CD40L expression levels were all significantly diminished [figure 42]. These 
data show that as compared to wild-type CD4+ T cells, MMP9 deficient CD4+ T cells 
have significantly lower levels of cell surface CD25 and CD69, while expressing higher 
levels of CD45RO and CTLA-4 [figure 42].  
 Analysis of cell surface expression in wild-type CD8+ T cells [figure 42] revealed 
increased levels of CD25, CD62L and CD69, although, CD25 levels were somewhat 
lower than that seen in wild-type CD4+ T cells. Additionally, CD40L, CD44 and CTLA-4 
were expressed although the percent expression was less than or equal to 20%. CD45RO 
was also expressed at very low levels, not exceeding 5%. Analysis of MMP9 deficient 
CD8+ T cells as compared to wild-type CD8+ T cells revealed extremely low expression 
levels of CD69, CD25, CD62L. CD45RO and CD44 surface expression levels remained 
the same as in wild-type cells. Interestingly, CTLA-4 and CD40L surface expression 
exhibited slight elevation as compared to wild-type cells [figure 42]. Taken together, 
these data demonstrate that CD4+ and CD8+ T cells display differential cell surface 
expression in the absence of MMP9.  
 
M. MMP9 inhibition by SB3CT alters CD4 and CD8 T cell phenotypes  
 In continuation of the phenotypic analysis of T cells in response to MMP 
inhibition, we next wanted to determine the phenotype of T cells treated with SB3CT 
and compare the results to those seen in the MMP9 deficient T cells. Since CD25 and 
CD69 were significantly diminished in the MMP9 deficient CD4+ and CD8+ T cells, we  
113 
          
 114 
chose to analyze the surface expression of these two markers in T cells following MMP9 
inhibition by SB3CT. CD4+ T cells were isolated from wild-type C57BL/6 mice and 
treated with varying concentrations of SB3CT (5-20μM) or the corresponding vehicle 
control for 6 hours. Following treatment, CD4+ T cells were washed and cultured in the 
presence or absence of soluble anti-CD3 Ab for 24 hours. Cells were then collected and 
stained for CD69-FITC and CD25-PE. In the absence of anti-CD3 Ab stimulation, cell 
surface expression levels of CD69 and CD25 were minimal (data not shown). 
 Analysis of stimulated vehicle-treated CD4+ T cells revealed enhanced CD69 
surface expression, which remained elevated as the concentration of vehicle-treatment 
increased from 5-20µM [figure 43A]. Interestingly, SB3CT-treatment also displayed an 
increase in CD69 expression, similar to that seen in vehicle-treated cells [figure 43B]. As 
the concentration of SB3CT increased, however, there was a slight decrease in CD69 
expression. Analysis of CD25 surface expression on vehicle-treated cells revealed a slight 
decrease in CD25 expression as the concentration of vehicle-treatment increased from 5-
20µM [figure 44A].  Comparatively, SB3CT treated cells displayed a significant dose-
dependent decrease in CD25 surface expression as the concentration of SB3CT increased 
[figure 44B]. Taken together, these data demonstrate a significant defect in CD25 surface 
expression thereby confirming results previously shown in MMP9 deficient T cells. 
These data also strengthen the gene expression data, again confirming MMP9s 
involvement in regulating CD25 expression, thereby affecting T cell activation and 
function. 
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Figure 43. Phenotypic analysis of CD69 on SB3CT treated CD4+ T cells  
Pure splenic CD4+ T cells were isolated from wild-type C57BL/6 mice. Cells were treated with 
varying concentrations of SB3CT (5-10μM). Cells were then plated in a 96 well plate in the presence 
of anti-CD3 Ab (0.5μg/ml) for 24 hours. Cells were collected and surface expression of CD69 was 
analyzed by flow cytometry. These data are representative of the mean ± SD of one of two separate 
experiments performed in triplicate (n=2).  
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Figure 44. Phenotypic analysis of CD25 on SB3CT treated CD4+ T cells  
Pure splenic CD4+ T cells were isolated from wild-type C57BL/6 mice. Cells were treated with 
varying concentrations of SB3CT (5-10μM). Cells were then plated in a 96 well plate in the presence 
of anti-CD3 Ab (0.5μg/ml) for 24 hours. Cells were collected and surface expression of CD25 was 
analyzed by flow cytometry. These data are representative of the mean ± SD of one of two separate 
experiments performed in triplicate (n=2).  
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Chapter 3. MMP inhibition in vivo: Model of antigen-specific T cell mediated lung 
injury 
A. Murine model of antigen-specific CD8+ effector T cell mediated lung injury 
 To investigate the role of MMP inhibition in vivo, we utilized a CC10-OVA 
model of airway hyperresponsiveness. Our data has demonstrated that CD8+ T cells 
express significantly elevated levels of MMP9 following anti-CD3 Ab activation. 
Therefore, studying an in vivo CD8+ T cell dependent model of lung injury will allow us 
to investigate the role of T cell derived MMP9 in mediating antigen-specific T cell 
activation in a physiological environment in vivo. Medoff et al. created this model, which 
was adapted by Shilling et al., such that transgenic mice only express chicken ovalbumin 
(126) in the lung as a result of ligation of the OVA gene behind the promoter for Clara 
cell secretory protein (CC10) (127). Since CC10 is specifically expressed by Clara cells, 
which make up 50-60% of the conducting airways of the lung in mice, this model allows 
us to specifically assess OVA-induced airway hypersensitivity in the lung (126). To 
induce lung injury, CD8+ T cells are isolated from OT-1 transgenic mice, which have a 
TCR specific for the OVA peptide SIINFEKL bound to the class I MHC H-2Kb (128). 
This murine model provides a means for us to examine the role of antigen-specific T cell 
mediated lung injury, similar to that seen in lung transplant rejection and bronchiolitis 
obliterans syndrome (44).  
 
B. MMP9 inhibition by SB3CT abrogates antigen-specific T cell proliferation 
 To examine the role of MMP inhibition on antigen-specific T cell mediated lung 
injury in vivo, we first wanted to determine whether specific MMP inhibition by SB3CT 
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would affect antigen-specific T cell proliferative function. To answer this question, 
antigen-specific T cell proliferation assays [figure 45] were utilized. Antigen-specific 
CD4+ and CD8+ T cells from OT-II and OT-1 transgenic C57BL/6 mice, respectively, 
were treated with varying concentrations of SB3CT (5-20μM) for 6 hours and cultured in 
the presence of OT-II (ova peptide) or OT-I (SIINFEKL peptide) pulsed antigen-
presenting cells, respectively. As shown in figure 46A, untreated or vehicle treated OT-II 
transgenic CD4+ T cells proliferated in response to OT-II pulsed antigen presenting cells. 
Interestingly, SB3CT treatment of OT-II transgenic CD4+ T cells completely abrogated 
the proliferative response to OT-II pulsed antigen presenting cells. Examination of CD8+ 
T cells from OT-I transgenic mice revealed a similar trend. OT-I transgenic CD8+ T cells 
treated with SB3CT significantly decreased T cell proliferation in a dose-dependent 
manner in response to OT-I-pulsed antigen presenting cells, compared to vehicle 
treatment [figure 46B]. These data suggest that specific MMP inhibition can also 
abrogates T cell proliferation in an antigen-specific manner. Since anti-CD3 Ab is not a 
physiological stimulus of cells, we wanted to assess the effects of MMP inhibition on T 
cell activation in an in vivo model, which allows us to study MMP regulated T cell 
activation under physiological conditions.  
 
C. Adoptive transfer of SB3CT treated OT-1 CD8+ T cells 
 To determine whether MMP inhibition had an effect on antigen-specific T cell 
mediated lung injury in vivo, CD8+ T cells were isolated from OT-1 transgenic mice and 
treated with 10μM of SB3CT or the corresponding vehicle control for 6 hours [figure 47]. 
The cells were then cultured in vitro for 5 days in the presence of IL-2, IL-12, 
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Figure 45. Schematic diagram of antigen specific (OT-I and OT-II) T cell 
proliferation  
OT-II Tg CD4+ T cells were isolated from OT-I Tg mice. OT-II T cells proliferate in response to 
residues 323-339 of ovalbumin. OT-I Tg CD8+ T cells were isolated from OT-I Tg mice. OT-I T cells 
proliferate in response to residues 257-264 of ovalbumin.  
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Figure 46. SB3CT treated antigen-specific T cells (OT-I and OT-II) display 
impairment in proliferative ability 
Pure splenic CD4+ and CD8+ T cells were isolated from OTII transgenic and OTI transgenic C57BL/6 
mice, respectively. A) OTII Tg CD4+ T cells were treated with 20μM SB3CT or VCtl for 6 hours, and 
B) OTI Tg CD8+ T cells were treated with varying concentrations of SB-3CT (5-20μM) or VCtl. Cells 
were then washed three times in RPMI and plated at 1x105/well in a 96 well plate in the presence of 
OVA-pulsed antigen presenting cells (APCs) for 72 hours. 18 hours prior to harvest, 3H thymidine 
(0.5μCi/well) was added to the culture. T cell proliferation was measured by the amount of 3H 
thymidine incorporation. These data are representative of the mean ± SD *P<0.001 of one of two 
separate experiments performed in triplicate (n=2). *p<0.001, **p<0.0001 as compared to stimulated 
wild-type cells. 
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Figure 47. Schematic diagram of adoptive transfer of SB3CT treated OT-I CD8+ T 
cells into CC10-OVA mice   
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anti-CD28 Ab, OVA peptide, and irradiated antigen presenting cells to generate effector 
CD8+ lymphocytes. The cultured OT-1 CD8+ T cells were then intratrachelly transferred 
into the lungs of CC10-OVA transgenic or non-transgenic wild-type C57BL/6 mice. 
Analysis of total cell accumulation in bronchoalveolar lavage 7 days after adoptive 
transfer into wild type mice revealed similar low cell accumulation between the SB3CT 
treated (MMPI) and vehicle groups [figure 48A]. Additionally, total cell accumulation in 
the BAL of CC10-OVA transgenic mice 7 days after adoptive transfer displayed similar 
cell numbers between the SB3CT treated and vehicle groups [figure 48A] (not 
statistically significant). As expected, total cell accumulation was significantly higher in 
the BAL from CC10-OVA transgenic mice, as compared to wild-type mice, due to T cell 
mediated antigen specificity.  
 Within this animal model, neutrophilic alveolitis is determined by neutrophil 
accumulation in the BAL, quantified by the percentage of GR1+ staining (126). Analysis 
of flow cytometry revealed a significantly higher percentage of neutrophilic accumulation 
in the CC10-OVA transgenic mice, as compared to the non-transgenic wild-type mice 
following adoptive transfer [figure 48B]. Strikingly, the mice that received SB3CT 
treated OT-1 cells displayed a significant decrease in neutrophilic accumulation, as 
compared to the mice that received vehicle-treated OT-1 cells [figure 48B] (p<0.01). The 
OT-1 transgenic mice were on a Thy1.1+ background, providing a means of tracking the 
transferred cells in the CC10-OVA mice, which were on a Thy1.2+ background. We next 
wanted to determine if there was a difference in the accumulation of CD8+ Thy1.1+ T 
cells in the lung between the two CC10-OVA treated groups (vehicle or SB3CT). 
Interestingly, analysis of the lung revealed a significant impairment of SB3CT treated 
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Figure 48. SB3CT treated OT-1 cells dampen neutrophilic accumulation in the BAL 
SB3CT or vehicle treated OT-1 CD8+ T cells were cultured for 5 days in vitro then adoptively 
transferred in the CC10-OVA transgenic (CC10) or non-transgenic (B6) wild-type C57BL/6 mice. 
Seven days after adoptive transfer, BAL fluid from the CC10-OVA or non-transgenic mice was 
analyzed and total cells present in the BAL were quantitated and neutrophils were stained with GR1 
and analyzed by means of flow cytometry. B6 vehicle or MMPI = vehicle or SB3CT treated OT-I 
cells into wild-type C57BL/6 mice, respectively. CC10 vehicle or MMPI = vehicle or SB3CT treated 
OT-I cells into CC10-OVA transgenic mice, respectively. *p<0.005 as compared to stimulated wild-
type cells. n=10 
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CD8+ Thy1.1+ T cells to accumulate in the lung compared with vehicle-treated CD8+ 
Thy1.1+ T cells (p<0.01) [figure 49A]. Moreover, analysis of CD25 cell surface 
expression revealed that of the SB3CT treated CD8+ Thy1.1+ T cells that accumulated in 
the lung, these cells displayed a lower percentage of CD25 expression (~30%) [figure 
49B] and mean fluorescence intensity (MFI) as compared to vehicle-treated CD8+ 
Thy1.1+ T cells, which were ~50% CD25+ and displayed a higher MFI (p<0.01) [figure 
49C].  
 In the BAL fluid, adoptive transfer of OT-I vehicle treated T cells showed an 
increase in neutrophilic presence, whereas OT-1 SB3CT treated T cells showed a 
decrease. We hypothesized that this could in part be due to an up-regulation of 
interleukin 8 (IL-8), known as KC in mice. MMP9 can cleave IL-8 at its N-terminus, 
causing an increase its chemotactic activity for neutrophils. If MMP9 is inhibited, then 
this should prevent the cleavage and activation of IL-8, thereby reducing neutrophilic 
migration or infiltration. Using an KC elisa assay to measure the presence of active IL-8, 
we unexpectedly discovered that KC levels were not different between the vehicle and 
SB3CT treatment groups [figure 50]. These data suggest that the changes in neutrophilic 
recruitment may be IL-8 independent.  
 Histological analysis of the lung demonstrated varying degrees of perivascular 
and peribronchial inflammation among the groups. Due to the variability in the histology 
between mice, we did not achieve statistical significance when comparing the groups. 
However, the CC10-OVA mice that received vehicle-treated OT-1 CD8+ T cells 
exhibited severe inflammation, with cells migrating into the vessel wall and lumen 
causing severe vessel occlusion (arrows point to cellular occlusion) [figure 51]. 
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Strikingly, although some of the CC10-OVA mice that received SB3CT treated OT-1 
CD8+ T cells displayed varying degrees of inflammation, the degree of inflammation was 
significantly dampened. As shown in figure 51, SB3CT treated OT-1 CD8+ T cells did 
not induce perivascular or perinuclear infiltration following intrapulmonary adoptive 
transfer into CC10-OVA mice, although there was some cellular accumulation around the 
vessels (arrows point to the clear vessel lumen). Taken together, these results demonstrate 
that inhibition of T cell derived MMPs leads to a decrease in the percentage of CD8+ 
Thy1.1+ cells residing in the lung, along with a decrease in CD25 surface expression. 
These data clearly demonstrate a role for MMP9 in mediating antigen specific T cell 
driven lung injury. This injury is then dampened by inhibition of T cell- derived MMPs, 
which lessening T cell activation, thereby providing a protective response. 
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Figure 49. SB3CT treated OT-1 cells abrogated CD8+Thy1.1+ T cell accumulation in 
the lung 
Activated OT-1 CD8+ T cells were adoptively transferred in the CC10-OVA transgenic or non-
transgenic wild-type C57BL/6 mice. CD8+ Thy1.1+ T cells were isolated from the lung mice following 
the adoptive transfer of SB3CT or vehicle treated cells. The CD8+ Thy1.1+ T cells were stained with 
CD25 and analyzed by means of flow cytometry. *p<0.01 as compared to stimulated wild-type cells. 
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Figure 50. IL-8 (KC) expression in the BAL fluid of vehicle or SB3CT treated OT-1 
T cells adoptively transferred into the lungs of CC10 mice  
CD8+ T cells were isolated from OT-1 transgenic mice and were treated with 10μM of SB3CT or the 
corresponding vehicle control for 6 hours. The cells were then washed and cultured in vitro for 5 days 
in the presence of IL-2, IL-12, anti-CD28, OVA peptide, and irradiated antigen presenting cells to 
generate effector CD8+ lymphocytes. The cultured OT-1 CD8+ T cells were then adoptively 
transferred in the CC10-OVA transgenic or non-transgenic wild-type C57BL/6 mice. BAL fluid was 
collected and assayed for IL-8 expression by elisa. n=8 per group p value=0.04  
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Figure 51. Murine model of antigen-specific CD8+ effector T cell mediated lung 
injury 
CD8+ T cells were isolated from OT-1 transgenic mice and were treated with 10μM of SB3CT or the 
corresponding vehicle control for 6 hours. The cells were then washed and cultured in vitro for 5 days 
in the presence of IL-2, IL-12, anti-CD28, OVA peptide, and irradiated antigen presenting cells to 
generate effector CD8+ lymphocytes. The cultured OT-1 CD8+ T cells were then adoptively 
transferred in the CC10-OVA transgenic or non-transgenic wild-type C57BL/6 mice. Histology of the 
lung was evaluated by H&E staining 20X. In vehicle panels, arrows indicate areas of mononuclear 
cellular infiltrate, along with neutrophilic infiltration. In SB3CT panels, arrows indicate areas that are 
void of infiltration. n=8 per group 
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IV. DISCUSSION 
A. Summary 
 Previous reports have demonstrated the importance of MMP in a variety of T cell 
mediated pulmonary diseases (44, 51). Although many studies have addressed functional 
aspects of MMPs, such as their involvement in the process of matrix remodeling, cell 
migration and the processing of other non-matrix substrates, the role of MMPs in 
regulating T cell activation has not been investigated and therefore remains unknown. 
The results presented herein demonstrate that MMPs, specifically MMP9 has a functional 
role in the regulation of T cell activation.  
 In chapter 1, the effects of MMP inhibition on T cells (CD4+ and CD8+) were 
examined from a functional standpoint. We first identified the presence of MMP9 within 
these cells and then assess their functional response to broad spectrum MMP inhibition 
by assessing their proliferative ability. We reported that broad spectrum MMP inhibition, 
by treatment with 1,10 phenanthroline and COL-3, abrogated alloantigen- and anti-CD3 
Ab-induced T cell proliferative responses. We then continued our studies by assessing the 
effects of a specific MMP2/MMP9 inhibitor (SB3CT) and discovered that along with 
abrogating T cell proliferative responses, this pharmacological inhibitor down-regulated 
MMP9 expression at the level of transcription. Further assessment of SB3CT treated cells 
revealed that neither IL-2 nor anti-CD3/anti-CD28 Ab co-stimulation was able to fully 
rescue the proliferative responses. The functional proliferative studies with SB3CT were 
then confirmed using T cells (CD4+ and CD8+) from MMP2, MMP2/9 and MMP9 
deficient mice. We reported that T cells from MMP9 deficient mice displayed the greatest 
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decrease in proliferation and chose to focus our studies on the effects of MMP9 in T cell 
activation.  
 In chapter 2, the effects of MMP inhibition on intracellular T cell signaling events 
were examined. Our observation began with the evaluation of calcium signaling, since it 
is an intracellular event proximal to the TCR. We reported that in response to MMP 
inhibition (SB3CT) or in the absence of MMP9 (MMP9 deficient mice), T cells (CD4+ 
and CD8+) displayed elevated levels of intracellular calcium release from the ER, as well 
as, influx of exogenous calcium from the media, following anti-CD3 Ab stimulation. 
After observing the effects of calcium signaling following specific TCR mediated T cell 
activation by anti-CD3 Ab, we next examined the effects of non-specific T cell activation 
on calcium signaling. We reported that following non-specific stimulation, with a phorbol 
ester (ionomycin), T cells (CD4+ and CD8+) displayed varying levels of intracellular 
calcium flux in response to MMP inhibition by (SB3CT) or MMP9 deficiency.  
 Upon further examination of intracellular signaling events, we reported that 
MEK1/2 total and phosphorylated protein expression were unaffected in response to 
MMP inhibition. Our investigation continued downstream, where we examined changes 
in the expression of genes involved in T cell activation. Following MMP inhibition or 
MMP9 deficiency, NFATc1 and CD25 gene expression were down-regulated. 
Additionally, we found that foxp3 gene expression and IL-10 protein expression levels 
were elevated, suggesting regulatory T cell function. However, upon further investigation 
through T cell suppressor assays, we reported that MMP inhibition did not induce 
regulatory T cell function. Moreover, analysis of IL-2, TNF-α and IFN-γ cytokine gene 
and protein expression revealed an overall trend of down-regulation in response to 
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MMP9 deficiency and MMP9 inhibition. Phenotypic analysis of T cells in response to 
MMP9 deficiency or MMP9 inhibition, revealed changes in cell surface activation 
marker expression when compared to T cells from wild-type mice.  
 In chapter 3, we examine the effects of MMP inhibition in vivo, in a model of 
antigen-specific T cell (OT-I) mediated lung injury. We first assess the functional 
response of antigen-specific T cells (OT-I and OT-II) by examining their proliferative 
ability in response to MMP inhibition (SB3CT). We reported that SB3CT abrogated the 
proliferative ability of antigen-specific OT-I (CD8+) and OT-II (CD4+) T cells to respond 
to their corresponding antigen-pulsed APCs. Following this observation, OT-I SB3CT 
treated T cells, were intratracheally transferred into the lungs of CC10-OVA mice, which 
express ovalbumin in their lungs. We reported that the number of total cells is the BAL 
was decreased, and that the percentage of GR1+ cells (neutrophils) were significantly 
reduced. Additionally, in response to MMP9 inhibition, the percentage of CD8+ Thy1.1+ 
T cells in the lung of CC10-OVA mice was decreased. Further analysis of CD25 surface 
expression on CD8+ Thy1.1+ T cells in the lung revealed a dramatic decrease in CD25 
surface expression. Histological analysis of lung sections collected from the lungs of 
CC10-OVA mice, provide further evidence that MMP9 inhibition decreased the degree of 
inflammation within the lung. These results supported the hypothesis that MMP 
inhibition significantly impaired the degree of neutrophilic alveolitis, thereby dampening 
T cell mediated lung injury. Collectively, these data clearly indicate a role for T cell 
derived MMP9 in the process of T cell activation and in mediating T cell induced lung 
injury. These findings will be discussed in more detail below.
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B. MMP9 expression in T cells  
 There have been many reports showing the presence of T cell-derived MMP9 
following treatment with various stimuli or in abnormal disease states. Human 
recombinant IL-2 has been shown to up-regulate MMP9 activity in human peripheral 
blood T cells (105, 129). Additionally, 12-O-tetradecanoylphorbol 13-acetate (TPA), has 
been shown to induce MMP9 activity in primary human T cells (130), as well as in a 
human T-lymphoma cell line (HSB) (131). T cell-derived MMP9 expression has also 
been shown to be up-regulated in a mammary tumor-bearing mouse model. In this model 
CD4+ and CD8+ T cells both in the periphery (in the spleen) and within the tumor 
microenvironment expressed high levels of MMP9 (132). Although, these and other 
studies have confirmed that T cells can express MMPs in humans and mice, the role of 
MMPs, specifically MMP9, in regulating T cell activation remains unknown.  
 In the current studies, we demonstrated that MMP9 is expressed in murine splenic 
CD4+ and CD8+ T cells by protein and mRNA transcript levels. Interestingly, following 
stimulation with anti-CD3 Ab, there seems to be a diverging effect in mRNA expression 
[figure 5]. In CD4+ T cells, MMP9 expression is decreased following anti-CD3 Ab 
stimulation whereas in CD8+ T cells, MMP9 expression levels are significantly elevated. 
This alteration in gene expression may be due to the different T cell subsets being 
analyzed. CD4+ T cells are T helper cells, known to “help” in the immune system by 
activating and directing other immune cells. In contrast, CD8+ T cells are cytotoxic T 
cells known to “kill” by exhibiting cytotoxic effects on other cells within the immune 
system. Since CD8+ T cells have the ability to secrete perforin, a cytolytic protein and 
granzyme B, a serine protease, it is possible that these cells are predisposed to the 
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induction of MMP9 expression more readily, being that MMP9 itself is a protease. 
Although the changes in mRNA expression are drastically divergent, observation of 
protein levels reveal similar expression patterns between CD4+ and CD8+ T cells.  
 
C. SB3CT regulates MMP9 expression at the transcriptional level  
 Many of the earlier reports studying the role of MMPs in various disease states 
have used broad-spectrum or global MMPIs, such as batimastat, doxycycline and 
chemically modified tetracyclines (COL-3), to name a few. These inhibitors function to 
non-selectively inhibit MMPs by binding to the active site zinc and secondarily to the 
inactive calcium ion site, causing conformational changes and loss of enzymatic activity. 
We reported that global MMPIs 1,10 phenanthroline and COL-3 both displayed 
significant reductions in T cell proliferation in response to alloantigen induced or anti-
CD3 Ab-induced stimulation. Global MMPIs non-specifically inhibit MMP activity by 
functioning as metal chelators (divalent ions). The lack of specificity makes studying 
individual MMPs challenging. For example, Sandler et al. reported that COL-3 inhibits 
the activity of protein kinase C (PKC) in mast cells, suggesting that COL-3 functions as 
more than just an MMPI and can negatively affect cell growth and differentiation (107), 
thus making it difficult to elucidate the role of MMP9 specifically in T cell activation.  
 To circumvent these limitations we utilized MMP deficient mice and SB3CT. 
SB3CT is a mechanism based specific inhibitor that irreversibly inhibits MMP2 and 
MMP9 by permanently blocking the cysteine switch interaction. Many studies have 
demonstrated that SB3CT blocks MMP2 and MMP9 activity (133-135). Since SB3CT 
inhibits MMP2 and MMP9, many of the studies presented herein were paralleled by data 
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from MMP2, MMP/9 and MMP9 deficient mice to allow for comparison of the effects of 
MMP2 deficiency on some of the events involved in T cell activation, including the 
proliferative responses.  
 In our study of specific MMP inhibition, we examined MMP9 expression in T 
cells following SB3CT treatment. Unexpectedly, the results demonstrated that SB3CT 
significantly inhibited the mRNA transcript levels of MMP9. These results suggest that 
SB3CT functions not only in the catalytic site, but also functions to block MMP9 
transcript levels, which in turn will block translation and protein activity. The ability of 
MMP inhibitors to inhibit mRNA transcript levels is supported by a report showing that 
COL-3 and doxycycline, two broad spectrum MMPIs, markedly decreased MMP2 
mRNA levels in human skin keratinocytes as early as 6 hours which was further 
decreased 24 hours later (136). Similarly, this report concluded that doxycycline and the 
chemically modified tetracyclines, in addition to inhibiting MMP activity, also reduced 
the enzyme expression at the transcriptional level (136). In their studies, it is possible that 
binding of cations by those broad spectrum MMPIs may result in derangement of some 
transcriptional and posttranscriptional steps. For example, RNA polymerases require 
Mg2+ or Mn2+ for their activity. If the MMPIs chelate divalent ions necessary for 
polymerase activity, then this would inhibit transcription. In our case however, this is not 
a likely phenomenon because SB3CT does not function as a chelator, it is a mechanism-
based inhibitor of MMP2 and MMP9 by binding to the catalytic site of the enzyme.  
 In our studies, it could be that translational inhibition of some factors necessary 
for MMP9 transcription may result in gene down-regulation. The MMP9 promoter 
contains binding sites for transcription factors AP-1, NF-κB, SP1, AP-2 and Ets (PEA3) 
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(137). AP-1 and NF- κB have been shown to play important regulatory roles in T cell 
proliferation (4). SB3CT may also be decreasing the levels of intracellular zinc, which 
can then lead to the down-regulation of AP-1 (c-fos/c-jun heterodimer) binding to the 
AP-1 binding site in the MMP9 promoter, causing the down-regulation of MMP9 gene 
expression. This is to say, MMP9 gene expression may be regulated by its direct cleavage 
of a nuclear target or indirect induction of a nuclear target. Further studies are needed to 
elucidate whether SB3CT is acting on the MMP9 promoter, thereby causing a decrease in 
transcriptional activation. Also, examination of other AP-1 or NFAT target genes in 
response to SB3CT treatment, would provide insight into the relationship of these genes 
and the MMP9 promoter. 
 
D. T cell proliferation assays and T cell alloreactivity 
 In assessing the effects of MMP9 on T cells from a functional perspective, we 
found that anti-CD3 Ab-induced T cell proliferation was significantly decreased in CD4+ 
and CD8+ T cells in response to SB3CT treatment (figure 9). Additionally, this anti-
proliferative response was not rescued by the addition of exogenous IL-2. This provided 
evidence that SB3CT treated T cells were not anergic. Moreover, the proliferative 
response was still abrogated in response to anti-CD3/anti-CD28 co-stimulation; further 
negating the idea of SB3CT treated T cells exhibiting anergy. Comparison of MMP 
deficient T cells demonstrated that MMP9 deficient T cells displayed the greatest 
reduction in proliferative capacity (figure 14) as compared to MMP2 and MMP2/9 
deficient T cells (figure 13). 
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 Interestingly, treatment of MMP9 deficient T cells with anti-CD3/anti-CD28 Ab 
co-stimulation fully rescued the proliferative response and even elevated it (figure 15A). 
These results suggested that although SB3CT treated cells were not anergic, MMP9 
deficient T cells may exhibit cell anergy. This could be further confirmed by performing 
a T cell proliferation experiment with the addition of exogenous IL-2. If proliferation is 
rescued, then this would provide further confirmation that MMP9 deficient T cells exhibit 
T cell anergy.  
 Another potential explanation for the lack of proliferation seen in SB3CT treated 
T cells following anti-CD3/anti-CD28 Ab co-stimulation, is that SB3CT could be 
blocking the CD28 receptor, preventing proper stimulation. Since MMP9 deficient T 
cells exhibit normal CD28 receptor signaling, we can assess whether or not SB3CT 
blocks CD28 expression experimentally by utilizing these cells in T cell proliferation 
assays. If MMP9 deficient T cells are treated with SB3CT, co-stimulated with anti-
CD3/anti-CD28 Ab and the proliferative response is not rescued, then this would confirm 
an additional role for SB3CT in regulating T cell activation.  
 Recently, reports have begun to show a functional role of MMPs in allograft 
rejection and their role in T cell alloreactivity. For example, Fernandez et al. reported in a 
tracheal allograft obstructive airway disease (OAD) model, that increased intragraft 
expression and activity of MMP2 and MMP9 correlated with OAD development, and 
host mice that lacked MMP-9 expression did not develop OAD when transplanted with 
wild-type tracheas, which correlated with significantly lower levels of CD4+ and CD8+ T 
cells (97). They also reported that alloreactivity was enhanced in MMP9 deficient bulk T 
cells stimulated with allogeneic BALB/c DCs.  
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 In our studies however, we reported that MMP9 deficiency significantly 
abrogated T cell activation/ proliferation and that MMP2 deficiency only partially 
reduced T cell proliferative ability. One reason for these dissimilar results, may be due to 
the fact that in the study above, they used bulk T cells (CD3+) in the presence of 
allogeneic DCs, thereby inducing non-specific (CD4+ and CD8+ T cell subsets) T cell 
activation. In contrast, our studies consisted of culturing MMP9 deficient CD4+ and 
CD8+ T cells separately in the presence of anti-CD3 Ab, allowing us to individually 
examine how these two cell populations function in the process of T cell activation. Our 
results indicated that T cell-derived MMP9 plays a more significant role in T cell 
activation than does MMP2. It has been reported that T cells and macrophages are 
important to the development of OAD (138, 139), as studies have shown that mice with a 
genetic T cell deficiency, such as severe combined immunodeficient (SCID) mice or 
recombinase activating gene 1-deficient (RAG-/-) do not develop OAD (140). These 
studies provide strong evidence that T cells are important in the development of OAD 
and suggest that T cell derived MMP9 may play an important role in this development.  
 In another study using a mouse model of cardiac allograft rejection to study the 
role of MMP2 and MMP9 in the pathogenesis of cardiac allograft rejection, Campbell et 
al. reported that rejection was inhibited in MMP2 deficient host mice, and exacerbated in 
MMP9 deficient host mice (95). They suggest that the protective effects seen in MMP2 
deficient mice were due to an inhibition of mononuclear cellular infiltration into the 
allograft, resulting in lower levels of collagen deposition and tissue remodeling. 
Examination of T cell alloreactivity revealed that MMP2 deficient T cells displayed an 
innate defect in their alloresponsive capacity. These data demonstrate that the absence of 
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a T cell-derived MMP can alter T cell alloreactivity, which is in essence effecting T cell 
activation. Taken together, these two studies demonstrate that MMP2 and MMP9 play 
different roles in the process of activation and expansion of alloreactive T cells during the 
process of cardiac allograft rejection or OAD. These data highlight the complexity of 
MMPs in immune responses, and suggest that prevention of T cell derived MMPs can 
result in decreased T cell activation, which provides protective effects in response to a 
variety of pathogenic states.  
 
E. Calcium signaling is up-regulated as a compensatory mechanism 
 It is well known that immediately following T cell receptor activation, there is an 
initiation of signaling pathways that leads to the up-regulation of a myriad of events 
including the induction of specific protein tyrosine kinases, activation of protein kinase C 
and an increase in calcium flux. This influx of intracellular calcium then allows for the 
activation of calcineurin, which in turn dephosphorylates NFAT, allowing for its nuclear 
translocation. With our finding that T cell activation was altered in response to MMP 
inhibition, we investigated events proximal to the TCR that may be altered in response to 
MMP inhibition. We reported that in response to MMP inhibition (SB3CT) or the 
absence of MMP (MMP9 deficient mice), CD4+ and CD8+ T cells displayed elevated 
levels of calcium release from the ER following anti-CD3 Ab stimulation. The 
experiments were performed in calcium-free, divalent ion reduced media, ensuring that 
any intracellular calcium flux seen was in fact due to release from the ER.  
 Since the calcium signaling pathway also involves an influx of exogenous 
calcium via calcium channels, we wanted to determine if MMP inhibition or MMP 
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deficiency would affect exogenous calcium influx. Since the patterns of calcium flux 
were similar between the CD4+ and CD8+ T cells, we chose to examine only CD8+ T 
cells in this experiment. To ensure that we were able to measure the influx of exogenous 
calcium, these experiments were performed in calcium containing media (cRPMI). 
Interestingly, we reported that in response to MMP inhibition, CD8+ T cells displayed 
elevated levels of intracellular calcium, corresponding to release from the ER as well as 
an influx of exogenous calcium from calcium containing media following anti-CD3 Ab 
stimulation. Moreover, the arbitrary units used to measure calcium flux, were doubled in 
the experiments that contained calcium in the media as compared to the experiments that 
were only measuring calcium release from the ER. This is to be expected as exogenous 
influx of calcium would increase overall intracellular calcium influx. These findings 
suggested that in response to MMP9 inhibition or MMP9 deficiency the increase in 
calcium influx may be the T cell’s way of trying to compensate for the lack of effective 
activation. MMP9 may function as a tonic down-regulator of calcium mediated events.  
 Although these results suggest that anti-CD3 Ab mediated stimulation of the TCR 
was able to induce proximal T cell activation in response to MMP9 inhibition or MMP9 
deficiency, this may not be the case. There may be other altered signaling events 
occurring upstream of calcium that are involved. A report by Denny et al. examined the 
ability of Fyn (a members of the Src family of tyrosine kinases) to mediate TCR signal 
transduction in an Lck-deficient T-cell line (JCaM1). Interestingly, Fyn in the absence of 
Lck was able to induce tyrosine phosphorylation of the TCR and recruitment of the ZAP-
70 kinase, but the activation of ZAP-70 was defective (141). The SLP-76 adapter protein 
was inducibly tyrosine phosphorylated, and both the Ras-mitogen-activated protein kinase 
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and the phosphatidylinositol 4,5-biphosphate signaling pathways were activated. TCR 
stimulation of JCaM1/Fyn cells also induced the expression of the CD69 activation 
marker and the influx of calcium, while displaying reduced proliferative ability, NFAT 
activation and IL-2 production. Additionally, they reported that the induction of AP-1 
DNA binding activity in JCaM1/Fyn cells was defective (141). These results display 
some similarities with our studies (table 1) and suggest that alterations in signaling events 
upstream of calcium signaling may also account for changes seen downstream, such as 
proliferation and IL-2 production.   
 
Table 2. Comparison of data compilation from wild-type and MMP9 
inhibition/deficiency 
 
 To further investigate MMP9’s role in calcium flux, we examined the effects of 
ionomycin on calcium signaling in SB3CT treated or MMP9 deficient T cells. Ionomycin 
is a calcium ionophore responsible for shuttling calcium across the plasma membrane and 
the release of calcium from any other intracellular sources (such as the mitochondria). 
Following ionomycin stimulation, there was no change in calcium release from the ER as 
compared to wild-type cells in CD4+ and CD8+ MMP9 deficient T cells in calcium-free 
media. However, in the presence of calcium, as compared to wild-type T cells, CD4+ and 
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CD8+ MMP9 deficient T cells displayed significant decreases in calcium flux following 
ionomycin stimulation. In the presence of calcium, the influx typically corresponds to the 
release from the ER and the influx of exogenous calcium. Additionally, following 
treatment with SB3CT, intracellular calcium flux decreased in a dose-dependent manner 
in CD4+ and CD8+ T cells, corresponding to the flux of ER release and exogenous 
calcium influx. These data suggesting that MMP9 inhibition or its absence effects the 
ability of ionomycin to transverse the membrane, thereby decreasing calcium influx or 
that there is a defect in SOCE that cannot be stimulated by ionomycin treatment. Further 
studies are needed to elucidate the effects seen following ionomycin stimulation. 
 
F. CD25 and NFAT expression and the AP-1 binding site 
 Following TCR ligation, there is an up-regulation of signaling events, leading to 
the nuclear translocation of NFAT. We reported that following SB3CT treatment, NFAT 
gene expression was abrogated, which is likely due to the defect in MMP9 gene 
transcription. Similar results were observed in MMP9 deficient T cells. Due to the 
importance of NFAT as a transcription factor involved in T cell activation, it is likely that 
alteration of NFAT expression alters the expression of other downstream genes that rely 
on NFAT translocation for their proper function. Of these genes, IL-2Rα (CD25) and L-2 
are two pleiotropic genes dependent on NFAT expression for their function.  
 CD25 induction is controlled at the transcriptional level and its promoter activity 
is rapidly induced by TCR-mediated signals and many transcription factors, one of which 
is AP-1 (112). AP-1 has been shown to play a role in CD25 transcription, in addition to 
its formerly established role for the transactivation of the IL-2 gene. Leonard et al. 
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suggests that diminished levels of AP-1 correspond to diminished levels of CD25 
expression which in turn decreases IL-2 responsiveness, thereby promoting T cell anergy 
(142, 143). In the current studies, we observed a decrease in CD25 mRNA (figure 29) 
and surface expression (figure 41 and 43) in MMP9 deficient and SB3CT treated CD4+ or 
CD8+ T cells. Moreover, when exogenous IL-2 was added to the cultures of SB3CT 
treated CD4+ and CD8+ T cells, T cell proliferation exhibited partial recovery (figure 11). 
 Taken together, these findings strongly suggest that MMP inhibition down-
regulates NFAT activation, possibly by repressing NFAT transcription, which in turn 
decreases CD25 and IL-2 expression. The decrease in CD25 expression means that less 
CD25 will be present on the cell surface, which will limit the number of receptors 
available to bind IL-2 and induce proliferation, thereby abrogating T cell activation. This 
explains why the addition of exogenous IL-2 did not recover the proliferative response. 
An effort was made to examine NFATc1 protein expression and nuclear localization. We 
probed for nuclear and cytoplasmic NFAT with 3 different NFAT antibodies from three 
different companies. Our attempts were unsuccessful. Although we cannot rule out an 
extracellular mechanism responsible for these alterations in T cell activation, these data 
strongly suggest that MMPs are regulating T cell activation by an intracellular 
mechanism. 
 
G. Regulatory T cell function, Foxp3 and IL-10 expression and regulation of IL-2  
 and IFN-γ  
 We reported that MMP inhibition by SB3CT did not induce regulatory T cell 
function. We did find however, that foxp3 expression was elevated in SB3CT treated and 
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MMP9 deficient T cells. Regulatory T cells are considered to be anergic in that they do 
not produce IL-2 or IFN-γ. In T cells that have adopted the Treg lineage, the inability to 
produce IL-2 and IFN-γ, seems to be a consequence of transcriptional repression by 
foxp3. Foxp3 binds to the regulatory regions of endogenous IL-2 and IFN-γ loci in Tregs 
and inhibits the activation induced IL-2 and IFN-γ production. Foxp3 is known to 
constitutively occupy the promoters of genes that are constitutively expressed in Tregs 
such as CTLA-4, CD25, and GITR. Following TCR ligation however, foxp3 can bind to 
the IL-2 promoter (144, 145). This can occur when NFAT cooperates with foxp3 for 
binding to composite NFAT-forkhead elements in the antigen receptor response element 
(ARRE)-2 region of the IL-2 promoter. Under traditional activation conditions, NFAT 
binds to the ARRE-2 site of the IL-2 promoter to a composite NFAT-AP-1 element. In 
Tregs, foxp3 inhibits AP-1 DNA binding and takes its place with NFAT at the ARRE-2 
site (15, 146). In our studies, foxp3 may be actively repressing IL-2 and IFN-γ gene 
expression following TCR ligation in response to MMP inhibition, thereby causing a 
decrease in T cell activation. Since IL-10 is a characteristic immunosuppressive cytokine 
secreted by Tregs and Tr1 suppressive cells, we assessed IL-10 protein expression in 
MMP9 deficient T cells. We found that IL-10 was elevated in MMP9 deficient T cells 
following stimulation with anti-CD3 Ab. This may suggest that the absence of MMP2 or 
MMP9, leads to the development of a new IL-10 secreting T cell subset that exhibits 
regulatory T cell characteristics but not regulatory T cell function. 
 Although we have confirmed that MMP9 inhibition did not induce regulatory T 
cell function, we did report that Treg function was altered in response to MMP9 
inhibition. These cells were still suppressive, but to a lesser extent, requiring more Tregs 
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to induce the same suppressive effects as in untreated Tregs. One possible explanation for 
this finding is that SB3CT inhibited MMP9 transcriptional expression. If this expression 
is a necessary function for normal T cell activation, then it is possible that in Tregs, this 
transcriptional inhibition led to a decrease in Treg suppressive function. Another 
possibility is that SB3CT may bind to another substrate present in the cell that is similar 
in structure to an MMP active site and required for Treg function, causing a decrease in 
the overall suppressive function. Overall, although the exact mechanism of how MMPs 
are regulating T cell activation and function is not well understood, these data still 
demonstrate that T cell derived MMPs play an important role in T cell activation and 
function. Future studies are necessary to more specifically elucidate the regulation of 
MMP9 in T cell activation in terms of identifying a potential new T cell subset. 
 
H. Cytokine/Chemokine gene changes in response to MMP9 inhibition 
 Observation of cytokine/chemokine production in the cardiac allograft rejection 
model, as well as the OAD model both display abnormal cytokine/chemokine production 
in the MMP9 deficient recipients (95, 97). Our studies also displayed changes in cytokine 
production in MMP9 deficient T cells, specifically a reduction in IL-2 and IFN-γ and to a 
lesser extent, TNF-α at the mRNA and protein levels. With our previous discussion of 
NFAT and the changes that occur in response to MMP inhibition, it is likely that the 
decrease seen in IL-2, IFN-γ and TNF-α are due to the decrease in NFAT expression 
affecting the expression of other downstream genes.  
 In a heterotopic mouse airway model of OB, Neuringer et al. reported an up-
regulation of IL-2, IFN-γ (Th1 cytokines) and IL-10 (Th2 cytokine) and CD8+ cytotoxic 
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T cell granzyme B gene expression during the early (cellular) phase of allograft rejection 
(weeks 2-4), in addition to significant T cell infiltration into the allografts (140). These 
results demonstrated a strong up-regulation of Th1 cytokines, which has also been shown 
in orthotopic and heterotopic rodent lung transplant models. In orthotopic rat lung 
models, which develop features of acute rejection, IL-2 and IFN-γ gene expression are 
elevated in allografts compared with isografts (147). Similar to mouse models, 
heterotopic rat trachea models mimic OB, and exhibit increased CD25, IL-2, and IFN-γ 
gene expression in allografts (148). Taken together, these reports demonstrate that Th1 
cytokine gene is strongly associated with rejection in many rodent lung allografts. 
Therefore, our data demonstrating that T cell-derived MMP9 inhibition or deficiency 
abrogates Th1 cytokine gene expression, support the idea that inhibition of Th1 cytokine 
expression may protect against T cell mediated injury, including the infiltration seen in 
early rejection.  
 
I. MMP9 preferentially expressed by TH1 versus TH2 cells  
 Th1 and Th2 subsets are distinguished by their characteristic production of 
divergent cytokine profiles. Th1 cells secrete IFN-γ, IL-2 and TNF-α. While Th2 cells 
secrete IL-4, IL-5, IL-10 and IL-13. The data presented herein showed that IL-2, TNF-α 
and IFN-γ production were all down-regulated in MMP9 deficient CD4+ T cells 
following anti-CD3 Ab stimulation. Additionally, in figure 30B, IL-10 protein expression 
was significantly elevated in MMP9 deficient T cells following anti-CD3 Ab stimulation. 
It is still not clear why IL-10 levels were elevated, although we can speculate that it is in 
an effort to exert a suppressive effect. These results show that the absence of MMP9 
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abrogates the production of Th1 producing cytokines and suggests that MMP9 may play 
an important role in Th1 cell skewing and possibly in preventing Th2 cell skewing. In 
support of this idea, Abraham et al. reported that Th1 in comparison to Th2 cells, from 
both human (healthy subjects and multiple sclerosis (MS) patients) as well as from 
murine origin, secrete higher levels of MMP-9 following anti-CD3/anti-CD28 Ab co-
stimulation (149). Taken together, these results suggest a link between MMP9 and Th1 
cell skewing and imply that inhibition of Th1 cell derived MMP9 may regulate Th1 
mediated diseases. 
 Further investigation suggests that STAT proteins may play a role in this Th1 cell 
skewing process. STATs are a family of transcription factors that regulate a broad range 
of cellular processes, such as T cell differentiation and proliferation. Of the STAT 
proteins, STAT4 has been implicated in the induction of CD4+ Th1 T cells. It has been 
reported that STAT4 deficient mice display impairment in the production of IFN- , 
cellular proliferation and Th1 cell differentiation (150). In MMP9 deficient CD4+ T cells 
we reported that IFN-γ mRNA and protein production were reduced, which is similar to 
that seen in STAT4 deficient mice. Taken together, these results suggest a potential link 
between MMPs and STAT4 induction. 
 In CD4+ T cells, T-bet is rapidly and specifically induced in developing Th1 but 
not Th2 cells. T-bet functions as a master regulator of Th1 cell differentiation (151). 
Some studies have suggested that a regulatory circuit involving IFNγR signaling via 
STAT1 maintains high-level T-bet expression in developing Th1 cells (152, 153). 
However, the main role of T-bet regulation is known to be STAT4 dependent. In MMP9 
deficient mice, we reported that T-bet expression is elevated, while IFN-γ mRNA and 
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protein expression is abrogated. Conversely, it has been reported that CD4+ T cells 
isolated from T-bet-deficient mice failed to produce IFNγ in response to either anti-
CD3/anti-CD28 Ab or PMA/ionomycin stimulation. One potential hypothesis for these 
disparaging results is that in response to MMP9 deficiency, the T cells are desperately 
trying to overcome the lack of proper activation and as such, are inducing expression of 
STAT4, which is up-regulating the expression of T-bet. MMP9 may also function at the 
junction between T-bet signal and IFN-γ production. Another hypothesis may be that 
STAT4 is not essential in T-bet induction. This idea has been reported in a study 
demonstrating that STAT4 was not required for T-bet induction and that it was not 
required to aid T-bet in inducing Th1 identity (154), suggesting that T-bet is upstream of 
the STAT4 pathway. Further studies are needed to clearly define a role for MMP9 in T-
bet signaling. 
 
J. Murine model of antigen-specific T cell mediated lung injury 
 To investigate the role of MMP inhibition in vivo, we utilized a CC10-OVA 
model of airway hyperresponsiveness. Our reasoning behind choosing this model was 
due to the fact that our data demonstrated that MMP9 gene expression was significantly 
elevated in activated CD8+ T cells. Additionally, because anti-CD3 Ab is not a 
physiological T cell stimulus, we wanted to study MMP regulation of T cell activation 
under physiological conditions. This directed our focus to study a CD8+ T cell dependent 
disease. We first assessed the functional response of antigen-specific T cells (OT-I and 
OT-II) by examining their proliferative ability in response to MMP inhibition (SB3CT). 
The findings that SB3CT abrogated the proliferative ability of antigen-specific OT-I and 
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OT-II T cells, provided proof that SB3CT could reduce antigen specific proliferation and 
allowed us to move forward in our model. Following adoptive transfer of OT-I MMP 
inhibitor treated T cells, we reported that the number of total cells in the BAL was 
decreased, and that the percentage of GR1+ cells (neutrophils) were significantly reduced. 
These results were exactly what we expected, which demonstrate that MMP inhibition 
decreases cellular infiltration. 
 Since the animal model was set up to allow us to discriminate between the OT-1 
adoptively transferred cells (Thy1.1) and host CC10 cells (Thy1.2), we were able to track 
the OT-1 transferred cells and determine their localization. In response to MMP9 
inhibition, there was a significant decrease in the percentage of CD8+ Thy1.1+ T cells in 
the lung of CC10-OVA mice, suggesting that MMP inhibition effects T cell migration, 
likely by decreasing their activation. Further analysis of CD25 surface expression on 
CD8+ Thy1.1+ T cells in the lung revealed a dramatic decrease in CD25 surface 
expression. These results are similar to our previous data demonstrating a significant 
decrease in CD25 mRNA and cell surface expression in response to MMP inhibition. 
This may also provide more of an explanation of the lack of neutrophilic infiltration into 
the BAL and lung. If T cells are non-reactive to the OVA present in the lung as a result of 
MMP inhibition, then there is no major increase in inflammation, which negates the need 
for neutrophilic infiltration. This suggests that T cells are mediating this inflammation 
and that MMPs are regulating the T cells’ reactivity. 
 Additionally, we hypothesized that the decrease in neutrophilic migration was in 
part due to the decrease in the neutrophil chemotactic property of IL-8. MMP9 can cleave 
IL-8 at its N-terminus, causing an increase in its chemotactic activity for neutrophils. 
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Therefore, if MMP9 is inhibited by SB3CT, then this should prevent the cleavage of IL-
8, thereby decreasing IL-8 chemotactic activity for neutrophils, preventing neutrophil 
infiltration. Unfortunately, this hypothesis was disproven with results demonstrating no 
significant changes in IL-8 expression in the BAL of OVA-CC10 mice adoptively 
transferred with vehicle treated or SB3CT treated OT-I T cells. 
 Histological analysis of lung sections collected from the lungs of CC10-OVA 
mice demonstrated varying degrees of perivascular and perinuclear infiltrates. Following 
the transfer of vehicle-treated OT-1 cells, mononuclear cellular infiltrate was 
significantly increased, demonstrating the induction of T cell mediated lung injury. This 
infiltrate lead to severe occlusion of airway vessels. Following the adoptive transfer of 
SB3CT treated OT-1 cells, the mononuclear cellular infiltration was minimal, suggesting 
that MMP9 inhibition dampened the degree of inflammation within the lung, thus 
significantly impairing the degree of T cell mediated lung injury. These results suggest 
that it would be beneficial to examine the expression of chemokines being that they are 
important in cell infiltration and trafficking in tissues. We found in our preliminary data 
that MCP-1 expression was elevated in MMP9 deficient CD4+ T cells following 
stimulation with anti-CD3 Ab [figure 51]. Other chemokines such as RANTES would 
also be of interest. It would also be useful to perform lung function studies, thus allowing 
us to obtain more physiological evidence of the beneficial effect of SB3CT treatment in 
abrogating T cell mediated lung injury.
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K. Potential intracellular role for MMP9    
 Although we cannot say with absolute certainty that MMP9 intracellularly 
regulates T cell activation, our results strongly indicate that MMP9 plays a definite role 
in T cell activation and are suggestive that this role is intracellular by regulation 
/modulation of mRNA and protein expression under normal homeostatic conditions. In 
this regard, Kwan et al., reported the presence of an active form of MMP2 within the 
nucleus of cardiac myocytes, suggesting a possible biological role for MMPs in the 
nucleus (99). Si-Tayeb et al. reported the presence of an active form of MMP3 in the 
nucleus of a human hepatocellular carcinoma cell line (HepG2) and hepatocellular 
carcinoma patient samples, and identified a nuclear localization signal (100). These 
studies clearly demonstrate an intracellular role for MMPs.  
 Proteolytic processing of inflammatory mediators in vitro has provided important 
functional information about the possible biochemical behavior of molecules as sites of 
inflammation, however little is known about the relevant in vivo substrates of MMPs, 
particularly MMP2 and MMP9. As mentioned earlier, new proteomic studies are 
beginning to elucidate potential intracellular substrates for MMP2 and MMP9 (36). 
Further studies aimed to better define the intracellular signaling mechanisms responsible 
for the regulation of MMP9 in T cell activation under homeostatic conditions may 
provide useful for understanding how these cells function normally and how regulation of 
T cells early in the process of lung disease may provide a novel therapeutic to arbitrate T 
cell mediated lung disease. 
 Towards this, VDIPEN, a peptide fragment of aggrecan (the interglobular 
domain) has been identified that is specific for MMP9 cleavage, along with 5 other 
151 
MMPs (MMP-1, -2, -3, -7 and -8) (155). An antibody has been designed that specifically 
recognizes this cleavage site. This antibody has been identified for its uses in studying 
MMP destruction of articular cartilage in immune inflammatory arthritic disease 
(155).We were interested in using this antibody in hopes of identifying potential 
intracellular MMP cleavage sites that may provide information to potential intracellular 
MMP2 and MMP9 substrates. This would provide valuable information as to identifying 
a new functional intracellular role for MMPs in T cell activation.
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V. CONCLUSIONS 
 
 In normal T cell activation, ligation of the TCR by anti-CD3 Ab stimulates a 
myriad of signaling events leading to the production of inositol 1, 4, 5-triphosphate (IP3). 
IP3 is then able to bind to its receptor, stimulating the release of intracellular calcium 
from the endoplasmic reticulum (ER). This leads to store operated calcium entry (SOCE) 
as a result of calcium channels opening, thereby allowing an influx of exogenous calcium 
into the cell. This increase in calcium influx allows for activation of the serine/threonine 
phosphatase, calcineurin. Activated calcineurin dephosphorylates NFAT allowing for its 
nuclear translocation. NFAT expression in turn activates the expression of other 
pleiotropic genes such as CD25 and IL-2. CD25 is then expressed on the surface of the T 
cell, which in turn, can bind IL-2. This interaction of CD25 and IL-2 leads proper T cell 
activation and proliferation.  
 In our study of T cell activation, we discovered that MMP9 inhibition by SB3CT 
or absence by MMP9 deficiency altered proper T cell activation. We found that upon 
ligation of the TCR with anti-CD3 Ab, there was an increase in intracellular calcium 
released from the ER. Moreover, SOCE was increased as demonstrated by the influx of 
exogenous calcium. In contrast, NFAT expression was down-regulated, which also 
corresponded with the down regulation of CD25 and IL-2 expression. Cell surface CD25 
expression was also down-regulated. Additionally, Foxp3 and IL-10 expression levels 
were increased, which is characteristic of regulatory T cell and suppressor T cell 
function. However, functional T cell suppressor studies ruled out the induction of a 
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regulatory T cell. These results support the hypothesis that MMP9 regulates T cell 
activation.
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Figure 52. Schematic diagram of differences in T cell activation in response to MMP 
inhibition (SB3CT) or absence (MMP9 deficiency) 
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VI. FUTURE STUDIES 
 
 The discovery that matrix metalloproteinases, particularly MMP9, regulates T cell 
activation and that the potential regulatory targets may be intracellular are novel findings. 
There are however, a number of future studies that are needed to further elucidate the 
exact mechanism of action by which this regulation is occurring. One of the studies that 
would provide further evidence of MMPs regulatory role in vivo, would be to revisit the 
CC10-OVA airway-hyperresponsiveness model. To confirm our report that MMP 
inhibition by SB3CT dampened the T cell mediated lung injury, it would be interesting to 
adoptively transfer MMP9 deficient T cells into the airway of CC10-OVA mice, to 
determine if MMP9 deficiency further dampens airway hyperresponsiveness. One caveat 
to this approach is that in order to adoptively transfer antigen-specific MMP9 deficient T 
cells, OT-1 transgenic mice would need to be crossed with MMP9 deficient mice to 
provide a mouse that is OT-1 specific and MMP9 deficient. If these mice are created, 
then they will also provide another platform in which to study antigen-specific, MMP 
deficient T cell mediated events. These studies would shed light on T cell mediated 
disease under physiological conditions and allow for the study of a specific set of T cells 
that only respond to a particular antigen. This model could be used to study T cell 
mediated disease in any organ system. 
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In trying to identify intracellular MMP2 and MMP9 targets, it would be 
interesting to generate a mouse model of asthma, which is a T cell mediated lung disease 
and determine if any of the newly identified in vivo substrates (Ym1, S100A8 and 
S100A9) are expressed in T cells under inflammatory conditions. Additionally, VDIPEN 
could also be used to identify any MMP cleavage sites. If any of these proteins or 
cleavage sites are found to be present, then this would provide evidence of MMP2 and/or 
MMP9 activity in a T cell and support our hypothesis of T cell derived MMPs working 
inside the cell to regulate cellular signals, which can result in alterations in activation 
patterns. These substrates can be identified by performing quantitative RT-PCR to 
identify gene expression, or western blotting to identify protein expression. 
 Another aspect of this project that requires further investigation is the calcium 
signaling cascade in response to MMP inhibition. Identification of intracellular potential 
targets responsible for the increase in intracellular calcium signaling and consistent 
decrease in T cell activation would help us understand where MMPs could be acting 
inside the cell to regulate this pathway. Further experiments are also needed to elucidate 
the mechanism or mechanisms responsible for the differences in calcium flux between 
TCR mediated activation and non-specific, ionomycin-induced T cell activation. During 
our calcium assays, it was discovered that the assay buffer we were using contained 
traces of divalent ions, such as Mg2+ and Cu2+. These divalent ions prevented us from 
demonstrating the traditional calcium curve that is seen due to the fact that the divalent 
ions present in the media are quenched by the dye and therefore display some 
fluorescence. It would also be useful to repeat some of the calcium studies using an assay 
buffer that contains no divalent ions that interact with fluor-4 dye, which is used to 
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measure calcium flux. Collectively, the most important next step in this project would be 
to identify an intracellular MMP2 and MMP9 substrate in T cells responsible for T cell 
activation, thus proving the hypothesis that MMPs regulate T cell activation by an 
intracellular mechanism. 
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